var title_f20_0_20480="Medial plica of the knee MRI";
var content_f20_0_20480=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F79326&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F79326&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Magnetic resonance imaging of medial plica of the knee explaining dry tap",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 279px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    An axial T2 weighted image through the midportion of the patella shows a prominent medial plica (arrow). Placement of a needle from the medial approach in such a patient could result in the plica behaving as a valve, preventing the aspiration of fluid despite the presence of a moderate effusion.",
"    <div class=\"footnotes\">",
"     M: medial; L: lateral.",
"    </div>",
"    <div class=\"reference\">",
"     From: Hayes CW, Conway WF. Magnetic resonance imaging of miscellaneous knee disorders. In: Magnetic Resonance Imaging and Computerized Tomography of the Musculoskeletal System: A Text-Atlas, Bloem JI, Sartoris DJ (Eds), Williams &amp; Wilkins, Baltimore 1992.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_0_20480=[""].join("\n");
var outline_f20_0_20480=null;
var title_f20_0_20481="Port wine stain midline demarcation";
var content_f20_0_20481=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F83601&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F83601&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Port wine stain in an infant",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_0_20481=[""].join("\n");
var outline_f20_0_20481=null;
var title_f20_0_20482="Ultrasound urethral diverticulum";
var content_f20_0_20482=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F82806&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F82806&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 521px\">",
"   <div class=\"ttl\">",
"    Transvaginal sonography of a urethral diverticlum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 501px; height: 344px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Transvaginal sonographic image shows the cystic space of a diverticulum (white arrow) immediately adjacent to a thick-walled urethra (yellow arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Dr. Deborah Levine",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_0_20482=[""].join("\n");
var outline_f20_0_20482=null;
var title_f20_0_20483="Cowpox lesion";
var content_f20_0_20483=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F53156&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F53156&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cowpox lesion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 356px; height: 281px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The lesion on the right fifth finger. The black central eschar with surrounding oedema and erythema was associated with ascending lymphangitis and regional lymphadenitis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Lawn SD, Planche T, Riley P, et al. A Black necrotic ulcer. Lancet 2003; 361:1518. Copyright &copy; 2003 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_0_20483=[""].join("\n");
var outline_f20_0_20483=null;
var title_f20_0_20484="Methazolamide: Patient drug information";
var content_f20_0_20484=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Methazolamide: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/43/41652?source=see_link\">",
"     see \"Methazolamide: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F10415504\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Neptazane&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F194139\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Methazolamide&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10023763\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10023765\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691860",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat glaucoma.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10023764\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702489",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to methazolamide or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701385",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a sulfa (sulfonamide) allergy, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2835999",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Acidic blood problem, kidney disease, liver disease, low potassium levels, low sodium levels, or poor adrenal function.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10023769\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697300",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have lung disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698504",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your eye pressure checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697788",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get sunburned more easily. Avoid sun, sunlamps, and tanning beds. Use sunscreen and wear clothing and eyewear that protects you from the sun.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10023770\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696432",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bad taste in your mouth. This most often goes back to normal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10023772\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698988",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Numbness or tingling in your hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10023767\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10023768\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10023773\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10023774\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10853 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-61.234.146.186-99C72D4C66-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_0_20484=[""].join("\n");
var outline_f20_0_20484=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10415504\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194139\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023763\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023765\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023764\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023769\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023770\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023772\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023767\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023768\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023773\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023774\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?40/43/41652?source=related_link\">",
"      Methazolamide: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_0_20485="Amiodarone pneumonitis CT";
var content_f20_0_20485=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F58121&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F58121&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Amiodarone pulmonary toxicity",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 343px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Computed tomographic scan obtained without intravenous contrast reveals a high-attenuation right upper lobe consolidation (upper panel). Images from the upper abdomen (lower panel) demonstrate increased attenuation of the liver parenchyma. The attenuation of this lesion is the result of iodine deposition from chronic amiodarone therapy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_0_20485=[""].join("\n");
var outline_f20_0_20485=null;
var title_f20_0_20486="Tubulointerstitial nephritis and uveitis (TINU syndrome)";
var content_f20_0_20486=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Tubulointerstitial nephritis and uveitis (TINU syndrome)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/0/20486/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/0/20486/contributors\">",
"     Geoffrey Lee, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/0/20486/contributors\">",
"     Akhtar Ashfaq, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/0/20486/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/0/20486/contributors\">",
"     Gary C Curhan, MD, ScD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/0/20486/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/0/20486/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/0/20486/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 8, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A unique subset of patients with interstitial nephritis has the TINU syndrome (tubulointerstitial nephritis and uveitis). First described in 1975 [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20486/abstract/1\">",
"     1",
"    </a>",
"    ], more than 150 cases have now been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20486/abstract/2\">",
"     2",
"    </a>",
"    ]. The majority of cases have been documented in the ophthalmology and pediatric nephrology literature via case reports and small descriptive series.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The underlying mechanisms for TINU are not well understood. Limited data suggest that modified C-reactive protein, (mCRP), an autoantigen common to both the uvea and renal tubular cells, may be involved in the pathogenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20486/abstract/3\">",
"     3",
"    </a>",
"    ]. In a study of 97 patients with various renal disorders and 40 healthy controls, the prevalence of IgG antibodies directed against mCRP was significantly higher among nine patients with TINU syndrome (100 percent) than among those with Sjogren&rsquo;s associated interstitial nephritis (29 percent), drug induced interstitial nephritis (36 percent), glomerulonephritis (5 percent), and healthy controls (0 percent).",
"   </p>",
"   <p>",
"    The inflammation in TINU syndrome is thought to be T-lymphocyte driven based upon the histologic findings. In contrast, immune cells in patients with TINU syndrome have a paradoxical suppression of cytokine production and a decrease in peripheral immune response as demonstrated by anergy to skin testing. This paradox is not unique to TINU, as the presence of increased tissue inflammation with concomitant suppression of peripheral immunity is also seen in patients with sarcoidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20486/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RISK FACTORS AND ASSOCIATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;No identifiable risk factors have been found in at least 50 percent of cases. In some instances, prior infection or the use of specific drugs (antibiotics to treat upper respiratory infections and NSAIDs) have been implicated [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20486/abstract/6\">",
"     6",
"    </a>",
"    ]. The Chinese herb, \"goreisan,\" has been associated in a case report [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20486/abstract/7\">",
"     7",
"    </a>",
"    ]. Although causality is unclear, concurrent Chlamydia and Epstein-Barr virus infections have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20486/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. TINU syndrome has also been reported in patients with autoimmune diseases like hypoparathyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20486/abstract/10\">",
"     10",
"    </a>",
"    ], hyperthyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20486/abstract/11\">",
"     11",
"    </a>",
"    ], IgG4-related autoimmune disease [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20486/abstract/12\">",
"     12",
"    </a>",
"    ], and rheumatoid arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20486/abstract/10,13\">",
"     10,13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with TINU are adolescents and young women, with a median age of 15 years [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20486/abstract/14\">",
"     14",
"    </a>",
"    ]. It has also been reported in adults and the elderly [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20486/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Overall, there is a 3:1 female to male predominance; however, in cases reported since 1990, there is only 2:1 female predominance [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20486/abstract/6\">",
"     6",
"    </a>",
"    ], with no particular racial affinity.",
"   </p>",
"   <p>",
"    Although sporadically reported [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20486/abstract/17-19\">",
"     17-19",
"    </a>",
"    ], there has been no definitive identified familial, genetic, or geographic clustering. In the past, various HLA types have also been ascribed without inter-series consistency. Subsequently, however, a strong association was noted with HLA-DQA1*01, HLA-DQB1*05, and HLA-DQB1*01 in a series of eighteen patients [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20486/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL AND LABORATORY MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to uveitis and interstitial nephritis, TINU may be associated with systemic findings including, fever, weight loss, fatigue, malaise, anorexia, asthenia, abdominal and flank pain, arthralgias, myalgias, headache, polyuria",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    nocturia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Uveitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with uveitis present with eye pain or redness; it is typically bilateral, although unilateral or alternating uveitis can be observed. This can also be accompanied by photophobia and decreased visual acuity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/16/23817?source=see_link\">",
"     \"Uveitis: Etiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Since the uveitis is predominantly anterior, the majority of clinical findings include anterior chamber cells and flare, conjunctival injection, keratic precipitates, and dry eyes [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20486/abstract/21\">",
"     21",
"    </a>",
"    ]. Posterior uveitis can also be seen, resulting in vitreous humor cells, chorioretinitis, intraretinal hemorrhages, retinal vascular sheathing, cotton wool spots, dilated retinal vessels, arteriovenous nicking and retinal edema [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20486/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The uveitis has been observed to occur two months before, concurrently, and up to fourteen months after the onset of the interstitial nephritis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20486/abstract/6\">",
"     6",
"    </a>",
"    ]. The majority of cases present after the onset of renal disease.",
"   </p>",
"   <p>",
"    In about 20 percent of patients with uveitis, intraocular complications have been noted. These include posterior synechiae, optic disc swelling, cystoid macular edema, chorioretinal scar formation, cataracts, and glaucoma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Renal manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal manifestations with TINU syndrome are typical for acute interstitial nephritis. These may include flank pain, sterile pyuria, hematuria, proteinuria (usually subnephrotic range), renal insufficiency, and acute renal failure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/34/22058?source=see_link\">",
"     \"Urinalysis in the diagnosis of kidney disease\"",
"    </a>",
"    .) Multiple proximal and distal tubular defects can be commonly seen, resulting in aminoaciduria, glucosuria, phosphaturia, and acidification defects [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20486/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/32/10759?source=see_link\">",
"     \"Overview of renal tubular acidosis\"",
"    </a>",
"    .) Renal sonography can demonstrate marked swelling of the kidneys.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Laboratory findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no specific serum markers or laboratory findings that are unique to patients with TINU. Laboratory findings may include eosinophilia, anemia, slightly abnormal liver function tests, and an elevated ESR. Associations of TINU with a variety of serologic markers in the absence of their correspondent disease have been reported. Thus, the disorder has been associated with antineutrophil cytoplasmic antibody (ANCA) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20486/abstract/24\">",
"     24",
"    </a>",
"    ], antinuclear antibody (ANA), an autoantibody directed against renal tubular cells [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20486/abstract/25\">",
"     25",
"    </a>",
"    ], rheumatoid factor (RF), and hypocomplementemia [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20486/abstract/26\">",
"     26",
"    </a>",
"    ]. In addition, antibodies that react to both tubular and uveal cells have been identified in the serum of a patient with TINU syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20486/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Elevations have been found in serum levels of beta-2 microglobulin and Krebs Von Den Lunge-6 (KL-6), a glycoprotein found in lung tissue of normal individuals as well as in the distal renal tubules of patients with TINU syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20486/abstract/27\">",
"     27",
"    </a>",
"    ]. Although the data are limited, measurement of KL-6 may provide a basis to differentiate other causes of tubulointerstitial nephritis and uveitis from TINU syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     DIAGNOSIS AND HISTOLOGIC FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The definitive diagnosis of TINU syndrome is nonspecific and is suggested by the combination of uveitis and renal involvement, with renal biopsy consistent with acute interstitial nephritis. On light microscopy, typical biopsy findings include tubulointerstitial edema and infiltration of inflammatory cells composed mainly of mononuclear cells, such as lymphocytes, plasma cells, and histiocytes. Eosinophils and noncaseating granulomas are frequently seen, with neutrophils also being observed [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20486/abstract/28\">",
"     28",
"    </a>",
"    ]. Glomerular and vascular structures are generally preserved. Findings with immunofluorescence and electron microscopy are also nonspecific.",
"   </p>",
"   <p>",
"    Bone marrow and lymph node granulomas can be present as well, representing the systemic nature of the disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis for interstitial nephritis occurring in association with ocular findings is broad. Thus, the following disorders should be considered in this setting:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Sarcoidosis",
"     </li>",
"     <li>",
"      Sj&ouml;gren's syndrome",
"     </li>",
"     <li>",
"      Systemic lupus erythematosus",
"     </li>",
"     <li>",
"      Wegener's granulomatosis",
"     </li>",
"     <li>",
"      Beh&ccedil;et&rsquo;s disease",
"     </li>",
"     <li>",
"      Infectious diseases, such as tuberculosis, brucellosis, toxoplasmosis, histoplasmosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Many of these disorders may present with additional ocular findings that are distinct from uveitis as well as evidence of other organ involvement, thereby helping suggest the correct diagnosis.",
"   </p>",
"   <p>",
"    However, sarcoidosis and Sj&ouml;gren's syndrome share similar findings with TINU, making accurate diagnosis difficult in the absence of characteristic involvement of other organs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/12/20677?source=see_link\">",
"     \"Renal disease in Sj&ouml;gren's syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/31/40438?source=see_link\">",
"     \"Renal disease in sarcoidosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/25/21914?source=see_link\">",
"     \"Clinical manifestations and diagnosis of sarcoidosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/22/18794?source=see_link\">",
"     \"Classification and diagnosis of Sj&ouml;gren's syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     MANAGEMENT AND PROGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Renal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal disease in patients with TINU is usually self-limited and, in most patients, can be expected to spontaneously resolve [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20486/abstract/29\">",
"     29",
"    </a>",
"    ]. In a series of 10 patients, eight of whom had creatinine clearances of less than 70",
"    <span class=\"nowrap\">",
"     mL/min/1.73m2,",
"    </span>",
"    renal function returned to normal levels within one year in all patients [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20486/abstract/29\">",
"     29",
"    </a>",
"    ]. Although seven were administered systemic steroids for uveitis, renal function recovery was independent of such therapy or the relapse of eye disease.",
"   </p>",
"   <p>",
"    Patients with progressive renal insufficiency are typically treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    at a dose of 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day (typically between 40 to 60",
"    <span class=\"nowrap\">",
"     mg/day).",
"    </span>",
"    Therapy is given for three to six months (with the duration of therapy dependent upon the response), and then slowly tapered. Most patients recover normal renal function. This regimen is similar to (but more prolonged than) therapy in acute interstitial nephritis. However, relapses are more likely to occur in TINU syndrome because of the potential immunological basis of the disease and the lack of a possible culprit agent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/28/34245?source=see_link\">",
"     \"Treatment of acute interstitial nephritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     Mycophenolate",
"    </a>",
"    mofetil has been used in a limited number of patients with acute interstitial nephritis and in one reported patient with TINU for the treatment of progressive renal insufficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20486/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/28/34245?source=see_link\">",
"     \"Treatment of acute interstitial nephritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The prognosis is dependent upon the degree of tubulointerstitial fibrosis. Although a few have required renal replacement therapy, even these patients can expect to only temporarily require dialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20486/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Uveitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical and systemic corticosteroids have been used for uveitis with success. However, recurrences and relapses of uveitis are common; infrequently, steroid-sparing immunosuppressive agents, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil are needed. The optimal management of the patient with uveitis requires early referral to and management by an ophthalmologist. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/10/10407?source=see_link\">",
"     \"Uveitis: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      TINU syndrome is defined by the combination of tubulointerstitial nephritis and uveitis. First described in 1975, most cases have been documented via case reports and small descriptive series. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The pathogenesis of TINU syndrome is unknown. Limited evidence suggests that an autoantigen to modified C-reactive protein (mCRP) may underlie the pathogenesis of the disease. Delayed-type hypersensitivity and suppressed cell-mediated immunity, with a predominance of T-lymphocytes, likely also play a significant role. Proliferation and activation of T-lymphocytes by IL-2 has been implicated. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Possible risk factors include prior infection or the use of specific drugs (antibiotics and NSAIDs). The Chinese herb, \"goreisan,\" and concurrent Chlamydia and Epstein-Barr virus infections have been associated in case reports. TINU syndrome has also been reported in patients with autoimmune diseases like hypoparathyroidism, hyperthyroidism, IgG4-related autoimmune disease, and rheumatoid arthritis. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Risk factors and associations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most patients with TINU are adolescents and young women, although it has been reported in adults and the elderly. There is a female to male predominance with no particular racial affinity. There may be an association with HLA-DQA1*01, HLA-DQB1*05, and HLA-DQB1*01. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      TINU may be associated with systemic findings including fever, weight loss, fatigue, malaise, anorexia, asthenia, abdominal and flank pain, arthralgias, myalgias, headache, polyuria",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      nocturia. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Renal manifestations include flank pain, sterile pyuria, hematuria, proteinuria (usually subnephrotic range), renal insufficiency, and acute renal failure. Proximal and distal tubular defects can be seen, resulting in aminoaciduria, glucosuria, phosphaturia, and acidification defects. Renal sonography may demonstrate marked swelling of the kidneys. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Renal manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with uveitis usually present with bilateral eye pain or redness accompanied by photophobia and decreased visual acuity, usually after the onset of renal disease. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Uveitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Laboratory findings include eosinophilia, anemia, slightly abnormal liver function tests, and an elevated ESR. TINU syndrome has been associated with antineutrophil cytoplasmic antibody (ANCA), antinuclear antibody (ANA), an autoantibody directed against renal tubular cells, rheumatoid factor (RF), and hypocomplementemia. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Laboratory findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of TINU syndrome is suggested by the combination of uveitis and renal involvement, with renal biopsy consistent with acute interstitial nephritis. The differential diagnosis includes sarcoidosis, Sj&ouml;gren's syndrome, systemic lupus erythematosus, Wegener's granulomatosis, Beh&ccedil;et&rsquo;s disease, and infectious diseases, such as tuberculosis, brucellosis, toxoplasmosis, and histoplasmosis. The distinction of TINU syndrome from sarcoidosis and Sj&ouml;gren's syndrome is particularly difficult. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Renal disease in patients with TINU is usually self-limited. Patients with progressive renal insufficiency are typically treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      at a dose of 1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day (typically between 40 to 60",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      for three to six months (with the duration of therapy dependent upon the response), and then slowly tapered. The optimal management of the patient with uveitis requires early referral to and management by an ophthalmologist. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Management and prognosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Uveitis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/10/10407?source=see_link\">",
"       \"Uveitis: Treatment\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20486/abstract/1\">",
"      Dobrin RS, Vernier RL, Fish AL. Acute eosinophilic interstitial nephritis and renal failure with bone marrow-lymph node granulomas and anterior uveitis. A new syndrome. Am J Med 1975; 59:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20486/abstract/2\">",
"      Abed L, Merouani A, Haddad E, et al. Presence of autoantibodies against tubular and uveal cells in a patient with tubulointerstitial nephritis and uveitis (TINU) syndrome. Nephrol Dial Transplant 2008; 23:1452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20486/abstract/3\">",
"      Tan Y, Yu F, Qu Z, et al. Modified C-reactive protein might be a target autoantigen of TINU syndrome. Clin J Am Soc Nephrol 2011; 6:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20486/abstract/4\">",
"      Gafter U, Kalechman Y, Zevin D, et al. Tubulointerstitial nephritis and uveitis: association with suppressed cellular immunity. Nephrol Dial Transplant 1993; 8:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20486/abstract/5\">",
"      Yoshioka K, Takemura T, Kanasaki M, et al. Acute interstitial nephritis and uveitis syndrome: activated immune cell infiltration in the kidney. Pediatr Nephrol 1991; 5:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20486/abstract/6\">",
"      Mandeville JT, Levinson RD, Holland GN. The tubulointerstitial nephritis and uveitis syndrome. Surv Ophthalmol 2001; 46:195.",
"     </a>",
"    </li>",
"    <li>",
"     Suzuki, H, Yoshioka, K, Miyano, M, et al. Tubulointerstitial nephritis and uveitis (TINU) syndrome caused by the Chinese herb \"Goreisan\". Clin Exp Nephrol 2008 [Epub ahead of print].",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20486/abstract/8\">",
"      Stupp R, Mihatsch MJ, Matter L, Streuli RA. Acute tubulo-interstitial nephritis with uveitis (TINU syndrome) in a patient with serologic evidence for Chlamydia infection. Klin Wochenschr 1990; 68:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20486/abstract/9\">",
"      Grefer J, Santer R, Ankermann T, et al. Tubulointerstitial nephritis and uveitis in association with Epstein-Barr virus infection. Pediatr Nephrol 1999; 13:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20486/abstract/10\">",
"      Catalano C, Harris PE, Enia G, et al. Acute interstitial nephritis associated with uveitis and primary hypoparathyroidism. Am J Kidney Dis 1989; 14:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20486/abstract/11\">",
"      Paul E, Van Why S, Carpenter TO. Hyperthyroidism: a novel feature of the tubulointerstitial nephritis and uveitis syndrome. Pediatrics 1999; 104:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20486/abstract/12\">",
"      Yoneda K, Murata K, Katayama K, et al. Tubulointerstitial nephritis associated with IgG4-related autoimmune disease. Am J Kidney Dis 2007; 50:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20486/abstract/13\">",
"      Iida H, Terada Y, Nishino A, et al. Acute interstitial nephritis with bone marrow granulomas and uveitis. Nephron 1985; 40:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20486/abstract/14\">",
"      Sessa A, Meroni M, Battini G, et al. Acute renal failure due to idiopathic tubulo-intestinal nephritis and uveitis: \"TINU syndrome\". Case report and review of the literature. J Nephrol 2000; 13:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20486/abstract/15\">",
"      Cacoub P, Deray G, Le Hoang P, et al. Idiopathic acute interstitial nephritis associated with anterior uveitis in adults. Clin Nephrol 1989; 31:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20486/abstract/16\">",
"      Salu P, Stempels N, Vanden Houte K, Verbeelen D. Acute tubulointerstitial nephritis and uveitis syndrome in the elderly. Br J Ophthalmol 1990; 74:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20486/abstract/17\">",
"      Gianviti A, Greco M, Barsotti P, Rizzoni G. Acute tubulointerstitial nephritis occurring with 1-year lapse in identical twins. Pediatr Nephrol 1994; 8:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20486/abstract/18\">",
"      Howarth L, Gilbert RD, Bass P, Deshpande PV. Tubulointerstitial nephritis and uveitis in monozygotic twin boys. Pediatr Nephrol 2004; 19:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20486/abstract/19\">",
"      Dusek J, Urbanova I, Stejskal J, et al. Tubulointerstitial nephritis and uveitis syndrome in a mother and her son. Pediatr Nephrol 2008; 23:2091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20486/abstract/20\">",
"      Levinson RD, Park MS, Rikkers SM, et al. Strong associations between specific HLA-DQ and HLA-DR alleles and the tubulointerstitial nephritis and uveitis syndrome. Invest Ophthalmol Vis Sci 2003; 44:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20486/abstract/21\">",
"      Rosenbaum JT. Bilateral anterior uveitis and interstitial nephritis. Am J Ophthalmol 1988; 105:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20486/abstract/22\">",
"      Igarashi T, Kawato H, Kamoshita S, et al. Acute tubulointerstitial nephritis with uveitis syndrome presenting as multiple tubular dysfunction including Fanconi's syndrome. Pediatr Nephrol 1992; 6:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20486/abstract/23\">",
"      Koike K, Lida S, Usui M, et al. Adult-onset acute tubulointerstitial nephritis and uveitis with Fanconi syndrome. Case report and review of the literature. Clin Nephrol 2007; 67:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20486/abstract/24\">",
"      Simon AH, Alves-Filho G, Ribeiro-Alves MA. Acute tubulointerstitial nephritis and uveitis with antineutrophil cytoplasmic antibody. Am J Kidney Dis 1996; 28:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20486/abstract/25\">",
"      Wakaki H, Sakamoto H, Awazu M. Tubulointerstitial nephritis and uveitis syndrome with autoantibody directed to renal tubular cells. Pediatrics 2001; 107:1443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20486/abstract/26\">",
"      Conz PA, Milan M, Bragantini L, et al. TINU syndrome associated with reduced complement levels. Nephron 2001; 89:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20486/abstract/27\">",
"      Kase S, Kitaichi N, Namba K, et al. Elevation of serum Krebs von den Lunge-6 levels in patients with tubulointerstitial nephritis and uveitis syndrome. Am J Kidney Dis 2006; 48:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20486/abstract/28\">",
"      Joss N, Morris S, Young B, Geddes C. Granulomatous interstitial nephritis. Clin J Am Soc Nephrol 2007; 2:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20486/abstract/29\">",
"      Takemura T, Okada M, Hino S, et al. Course and outcome of tubulointerstitial nephritis and uveitis syndrome. Am J Kidney Dis 1999; 34:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20486/abstract/30\">",
"      Neilson EG, Farris AB. Case records of the Massachusetts General Hospital. Case 21-2009. A 61-year-old woman with abdominal pain, weight loss, and renal failure. N Engl J Med 2009; 361:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20486/abstract/31\">",
"      Preddie DC, Markowitz GS, Radhakrishnan J, et al. Mycophenolate mofetil for the treatment of interstitial nephritis. Clin J Am Soc Nephrol 2006; 1:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20486/abstract/32\">",
"      van Leusen R, Assmann KJ. Acute tubulo-interstitial nephritis with uveitis and favourable outcome after five months of continuous ambulatory peritoneal dialysis (CAPD). Neth J Med 1988; 33:133.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7189 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.72.76.133-1E93B43961-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_0_20486=[""].join("\n");
var outline_f20_0_20486=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RISK FACTORS AND ASSOCIATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL AND LABORATORY MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Uveitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Renal manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Laboratory findings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      DIAGNOSIS AND HISTOLOGIC FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      MANAGEMENT AND PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Renal disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Uveitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/22/18794?source=related_link\">",
"      Classification and diagnosis of Sj&ouml;gren's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/25/21914?source=related_link\">",
"      Clinical manifestations and diagnosis of sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/32/10759?source=related_link\">",
"      Overview of renal tubular acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/12/20677?source=related_link\">",
"      Renal disease in Sj&ouml;gren's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/31/40438?source=related_link\">",
"      Renal disease in sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/28/34245?source=related_link\">",
"      Treatment of acute interstitial nephritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/34/22058?source=related_link\">",
"      Urinalysis in the diagnosis of kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/16/23817?source=related_link\">",
"      Uveitis: Etiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/10/10407?source=related_link\">",
"      Uveitis: Treatment",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_0_20487="Pregnancy after cardiac transplantation";
var content_f20_0_20487=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pregnancy after cardiac transplantation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/0/20487/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/0/20487/contributors\">",
"     Michael R Foley, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/0/20487/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/0/20487/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/0/20487/contributors\">",
"     Sharon A Hunt, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/0/20487/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/0/20487/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/0/20487/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnancy after cardiac transplantation has generally been discouraged by most heart transplantation centers. The potential risks to the prospective mother and concerns regarding maternal longevity and possible teratogenic effects from immunosuppressive drugs have been the primary reasons for this recommendation. However, a more optimistic view of pregnancy outcomes in cardiac transplant recipients is evolving [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20487/abstract/1-5\">",
"     1-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The first woman to become pregnant after a heart transplant was reported in 1988 [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20487/abstract/6\">",
"     6",
"    </a>",
"    ]; a few dozen of these pregnancies have been described subsequently [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20487/abstract/1\">",
"     1",
"    </a>",
"    ]. The number of female heart transplant recipients of childbearing age has escalated due to both an overall increase in heart transplantation in adults and to an aging pediatric heart transplant population.",
"   </p>",
"   <p>",
"    The maternal and fetal risks associated with pregnancy after cardiac transplantation and recommendations for management of these patients during pregnancy will be reviewed here. The indications and complications of cardiac transplantation are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34297?source=see_link\">",
"     \"Indications and contraindications for cardiac transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/24/28040?source=see_link\">",
"     \"Acute cardiac allograft rejection: Diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PRECONCEPTION CARE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Preconception counseling",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fertility issues should be discussed with all women as many transplant recipients are fertile. Transplant recipients need to know what to expect in terms of their own outcome and that for their potential children [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20487/abstract/7\">",
"     7",
"    </a>",
"    ]. As recommended by the American Society of Transplantation (AST) consensus conference on reproductive issues, preconception counseling should be introduced during the pretransplant evaluation (or earlier) and should be followed up throughout the post-transplant process [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20487/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The reason for the mother's cardiac transplant should be investigated and discussed in terms of risk of recurrence in mother or offspring. Some women, for example, have received cardiac allografts because of severe peripartum cardiomyopathy and are theoretically at risk for recurrent problems in future pregnancies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/62/18410?source=see_link\">",
"     \"Peripartum cardiomyopathy\"",
"    </a>",
"    .) Others may have had congenital heart disease; the offspring of these women are at increased risk of having cardiac defects (concordant or discordant with the mother), as high as 10 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20487/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Timing of pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most experts recommend that cardiac transplant recipients avoid pregnancy during the first year post transplantation when the risk of rejection is greatest and immunosuppressive therapy most aggressive. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/15/22775?source=see_link\">",
"     \"Prognosis after cardiac transplantation\"",
"    </a>",
"    .) Contraception during this period is important as fertility is not affected by these medications. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/24/39306?source=see_link\">",
"     \"Overview of contraception\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A baseline assessment should be performed prior to conception, including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Renal function tests (eg, serum creatinine, creatinine clearance and protein excretion)",
"     </li>",
"     <li>",
"      Evaluation of cardiac function (eg, echocardiogram, cardiac catheterization)",
"     </li>",
"     <li>",
"      Endomyocardial biopsy to look for evidence of rejection [",
"      <a class=\"abstract\" href=\"UTD.htm?20/0/20487/abstract/10,11\">",
"       10,11",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Liver function tests",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The AST consensus conference recommended the following criteria (not specific for cardiac transplantation) for timing of pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20487/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      No rejection in the past year",
"     </li>",
"     <li>",
"      Adequate and stable graft function",
"     </li>",
"     <li>",
"      No acute infections that might impact the fetus",
"     </li>",
"     <li>",
"      Maintenance immunosuppression at stable dosing",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A multidisciplinary care team with members from maternal-fetal medicine, neonatology, psychology, transplant surgery, cardiology, pharmacy, anesthesiology, specialty nursing, and social services should be available for counseling and care of the woman, as needed, throughout pregnancy and the postpartum period.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Vaccination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients should ideally be vaccinated pretransplant against influenza, pneumococcus, hepatitis B and tetanus [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20487/abstract/8\">",
"     8",
"    </a>",
"    ]. If not, the patient should be vaccinated before pregnancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/53/32602?source=see_link\">",
"     \"Immunizations during pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     MATERNAL PHYSIOLOGY AND THE HEART TRANSPLANT RECIPIENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many physiologic adaptive changes occur during early pregnancy, which serve to promote fetal growth and development. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/40/20105?source=see_link\">",
"     \"Maternal cardiovascular and hemodynamic adaptations to pregnancy\"",
"    </a>",
"    .) However, several of these changes are not beneficial to the cardiac transplant recipient [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20487/abstract/2\">",
"     2",
"    </a>",
"    ]. The physiologic changes associated with pregnancy and the attendant concerns in the pregnant heart transplant recipient are listed in Table 1 (",
"    <a class=\"graphic graphic_table graphicRef66004 \" href=\"UTD.htm?15/17/15644\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In addition, the normal resting sinus rate of the denervated heart is usually greater than 80 bpm and may exceed 100 bpm in hearts transplanted from young donors. The heart rate is higher than in normals because of the loss of vagal neural inputs which have a negative chronotropic effect. There may be partial reinnervation of cardiac sympathetic nerves following cardiac transplantation, but sinus tachycardia is common. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/1/23576?source=see_link\">",
"     \"Arrhythmias following cardiac transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     MATERNAL RISKS IN PREGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Significant potential concerns for the pregnant cardiac transplant recipient are rejection, infection, hypertension, and preeclampsia [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20487/abstract/1,4,5,12-14\">",
"     1,4,5,12-14",
"    </a>",
"    ]. Limited data are available on the incidence of each of these problems.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Rejection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of acute rejection is",
"    <strong>",
"     not",
"    </strong>",
"    increased in pregnant transplant recipients. Rejection was reported in 21 percent of 33 cardiac transplant recipients with 54 pregnancies in the 2004 National Transplantation Pregnancy Registry (NTPR) report [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20487/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/24/28040?source=see_link\">",
"     \"Acute cardiac allograft rejection: Diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/6/14441?source=see_link\">",
"     \"Acute cardiac allograft rejection: Treatment\"",
"    </a>",
"    .) The process of chronic rejection of the allograft is also not affected by pregnancy-related changes in the maternal immune system; thus immunosuppressive agents must be continued and adjusted to maintain prepregnancy drug levels. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/22/36201?source=see_link\">",
"     \"Immunology of the maternal-fetal interface\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hyperemesis gravidarum may lead to decreased absorption and inadequate immunosuppression [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20487/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/15/41207?source=see_link\">",
"     \"Clinical features and evaluation of nausea and vomiting of pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infections from bacterial, viral, and fungal organisms are common in immunosuppressed individuals. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/47/29433?source=see_link\">",
"     \"Infection in the solid organ transplant recipient\"",
"    </a>",
"    .) Infection was reported in 11 percent of pregnancies in the 2004 NTPR report [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20487/abstract/15\">",
"     15",
"    </a>",
"    ]. The obstetrician should be vigilant in assessing for community acquired infection (eg, pneumonia, urinary tract infection) and preventing infections related to pregnancy complications (eg, preterm premature rupture of membranes) and obstetrical procedures (eg, cesarean section).",
"   </p>",
"   <p>",
"    Cardiac transplant recipients who were initially seronegative for cytomegalovirus (CMV), but received a graft from a CMV positive donor, are at high risk for CMV disease, similar to the observations with other organ transplants. Seropositive recipients are also at risk for both reactivation of latent virus and superinfection with a new viral strain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/2/29738?source=see_link\">",
"     \"Cytomegalovirus infection in renal transplant recipients\"",
"    </a>",
"    .) The risk is highest in the first six months after transplant. The possibility and perinatal consequences of maternal CMV viremia should be considered in these women and they should be counseled of the potential risk. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/21/12634?source=see_link\">",
"     \"Cytomegalovirus infection in pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/47/29433?source=see_link\">",
"     \"Infection in the solid organ transplant recipient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/51/36664?source=see_link\">",
"     \"Cytomegalovirus infection and disease in newborns, infants, children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Abnormal liver function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormal liver function tests during pregnancy are common in transplant recipients. The cause can be difficult to identify and may be multifactorial, including drug toxicity, cholestasis,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    preeclampsia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Hypertension and preeclampsia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertension and preeclampsia are major factors responsible for the increased prevalence of preterm delivery and fetal growth restriction in transplant recipients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/20/27978?source=see_link\">",
"     \"Preeclampsia: Clinical features and diagnosis\"",
"    </a>",
"    .) As an example, one review of 25 completed pregnancies in heart transplant recipients reported 18 cases of",
"    <span class=\"nowrap\">",
"     hypertension/preeclampsia,",
"    </span>",
"    10 preterm deliveries, and five small for gestational age infants [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20487/abstract/16\">",
"     16",
"    </a>",
"    ]. Hypertension during pregnancy was reported in 46 percent and preeclampsia was reported in 10 percent of pregnancies in the 2004 NTPR report [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20487/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The 2005 AST consensus opinion stated that blood pressure should be maintained close to normal [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20487/abstract/8\">",
"     8",
"    </a>",
"    ], although it was noted that this target differs from higher blood pressure goals of current guidelines for pregnant women with chronic hypertension without end organ damage. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/7/13434?source=see_link\">",
"     \"Management of hypertension in pregnant and postpartum women\"",
"    </a>",
"    .) The treatment of hypertension is not affected by pregnancy, with the exception of angiotensin converting enzyme (ACE) inhibitors, which should be avoided because of teratogenic effects. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/32/1543?source=see_link\">",
"     \"Angiotensin converting enzyme inhibitors and receptor blockers in pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/7/13434?source=see_link\">",
"     \"Management of hypertension in pregnant and postpartum women\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is no drug that has consistently prevented preeclampsia in studies of high risk patients, although low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    is used by many providers. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/40/41609?source=see_link\">",
"     \"Prevention of preeclampsia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     FETAL RISKS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Potential fetal risks among cardiac transplant recipients include premature delivery and low birth weight, although the total number of fetuses studied is too low for definitive conclusions. The incidence of spontaneous abortion among heart transplant recipients (rates of 6 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20487/abstract/17\">",
"     17",
"    </a>",
"    ] and 17 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20487/abstract/15\">",
"     15",
"    </a>",
"    ]) appears to be similar compared to that in nontransplanted populations. High rates of preterm delivery (32 to 36 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20487/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]) and low birth weight (&lt;2500 gms) (20 to 80 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20487/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]) have been observed. Any infant born preterm or small for gestational age is at risk of long-term complications, such as neurodevelopmental abnormalities. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/11/14520?source=see_link\">",
"     \"Incidence and mortality of the premature infant\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/23/9593?source=see_link\">",
"     \"Small for gestational age infant\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Maternal monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fluoroscopically guided maternal right ventricular biopsies to monitor for rejection expose the fetus to radiation, so alternative approaches such as echocardiographically guided biopsies may be employed [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20487/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Maternal medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoids (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    ), calcineurin inhibitors (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    ), and antimetabolic agents (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    ) are immunosuppressive drugs for prevention of transplant rejection. Potential risks associated with use of these drugs and recommendations for use in pregnancy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/59/38842?source=see_link\">",
"     \"Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It should be emphatically stated that the benefits of immunosuppressive therapy in transplant recipients generally outweigh the slightly increased risk of adverse pregnancy outcome and most women taking these drugs will have normal, healthy babies [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20487/abstract/5\">",
"     5",
"    </a>",
"    ]. Transplant recipients are generally maintained at the lowest effective dose of their maintenance immunosuppressive regimen of glucocorticoids,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     INTRAPARTUM RISKS AND MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;An intrapartum care plan should be established in conjunction with the multidisciplinary team caring for the gravida. Questions regarding induction of labor, mode of delivery,",
"    <span class=\"nowrap\">",
"     analgesia/anesthesia,",
"    </span>",
"    antibiotic prophylaxis, cardiovascular monitoring, and timing of delivery are best individualized to the woman's clinical circumstances.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Mode of delivery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vaginal delivery induced at or near term helps to insure that the necessary clinical resources and personnel are available. Cesarean delivery should be reserved for the usual obstetrical indications [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20487/abstract/5,8\">",
"     5,8",
"    </a>",
"    ]. However, in one review the cesarean delivery rate among cardiac transplantation patients was higher than in a control group (33 versus 23 percent), despite this recommendation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20487/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/26/29097?source=see_link&amp;anchor=H18#H18\">",
"     \"Acquired heart disease and pregnancy\", section on 'Management of labor and delivery'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Antibiotic prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2007 AHA endocarditis prophylaxis guidelines recommend prophylaxis for patients at highest risk, including those with cardiac \"valvulopathy\" in a transplanted heart [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20487/abstract/18\">",
"     18",
"    </a>",
"    ]. Valvulopathy is defined as documentation of substantial leaflet pathology and regurgitation. For women with structural cardiac disease but without one of the highest risk lesions, the AHA does not consider an uncomplicated vaginal or cesarean delivery an indication for antibiotic prophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20487/abstract/1,8\">",
"     1,8",
"    </a>",
"    ]. However, I favor antibiotic prophylaxis for delivery in patients with high risk lesions, since there is no assurance that a given delivery will be uncomplicated and potential risk factors for bacteremia during delivery have not been identified. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/36/585?source=see_link\">",
"     \"Antimicrobial prophylaxis for bacterial endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Anesthesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intramuscular or intravenous opiates are used to relieve pain and apprehension. Lumbar epidural anesthesia is effective in controlling labor pain and is recommended because it lowers pain-induced elevations of sympathetic activity. Epidural anesthesia has been used successfully in cardiac transplant recipients for both vaginal and cesarean delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20487/abstract/3,19\">",
"     3,19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Stress dose steroids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women who received greater than 20 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    per day for more than three weeks in the six months prior to surgery should be assumed to have suppression of hypothalamic-pituitary-adrenal function. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/42/23208?source=see_link&amp;anchor=H18#H18\">",
"     \"Pharmacologic use of glucocorticoids\", section on 'HPA axis suppression'",
"    </a>",
"    .) These individuals should receive peripartum stress glucocorticoid coverage.",
"   </p>",
"   <p>",
"    One approach is to provide high doses of glucocorticoids starting at the time of active labor. A continuous infusion of 10 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    per hour, or the equivalent amount of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    , eliminates the possibility of glucocorticoid deficiency. The glucocorticoid dose can be halved the day after delivery, and the maintenance dosage usually can be resumed on the second postpartum day. An alternative regimen is described in Table 4 (",
"    <a class=\"graphic graphic_table graphicRef73698 \" href=\"UTD.htm?11/5/11355\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/47/42745?source=see_link&amp;anchor=H19#H19\">",
"     \"Treatment of adrenal insufficiency in adults\", section on 'Illness or surgery'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Maternal monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pregnant mother should have continuous electrocardiographic monitoring during delivery to evaluate for ischemia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    arrhythmias, in addition to routine assessment of vital signs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/31/7674?source=see_link\">",
"     \"Ventricular arrhythmias during pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/1/14362?source=see_link\">",
"     \"Supraventricular arrhythmias during pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/1/23576?source=see_link\">",
"     \"Arrhythmias following cardiac transplantation\"",
"    </a>",
"    .) Coronary vasculopathy is more common in these organs, while the clinical signs and symptoms of ischemia are greatly attenuated owing to the denervated state of the transplanted heart. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/25/44441?source=see_link\">",
"     \"Pathogenesis of and risk factors for cardiac allograft vasculopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/9/18585?source=see_link\">",
"     \"Natural history and diagnosis of cardiac allograft vasculopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/12/42184?source=see_link\">",
"     \"Prevention and treatment of cardiac allograft vasculopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Invasive cardiovascular monitoring is not routinely required. The risks of these devices outweigh the potential benefit in most clinical scenarios. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27128?source=see_link\">",
"     \"Pulmonary artery catheterization: Indications and complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     POSTPARTUM RISKS AND MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risks of maternal compromise increase substantially immediately postpartum. Cardiac output increases to 80 percent above prelabor values due to significant autotransfusion associated with uterine involution. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/40/20105?source=see_link\">",
"     \"Maternal cardiovascular and hemodynamic adaptations to pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Drug toxicity is more likely postpartum. Careful attention to immunosuppressive drug levels,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    in particular, is warranted as maternal intravascular volume and glomerular hyperfiltration return to normal.",
"   </p>",
"   <p>",
"    Serial electrocardiograms, echocardiograms, and isoenzymes are helpful in evaluating left ventricular function during this high risk period [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20487/abstract/10\">",
"     10",
"    </a>",
"    ]. Cardiac biopsy is indicated if acute rejection is suspected.",
"   </p>",
"   <p>",
"    Breastfeeding is generally discouraged because of passage of immunosuppressive drugs, particularly",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , to the baby. Continuing immunosuppressive therapy is vital for the mother and should be carefully maintained [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20487/abstract/5\">",
"     5",
"    </a>",
"    ]. The AST consensus opinion was that breast feeding need not be viewed as absolutely contraindicated [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20487/abstract/8\">",
"     8",
"    </a>",
"    ]. A discussion with the baby's pediatrician regarding the risks versus benefits of breast-feeding, taking into account individual circumstances, is worthwhile. Psychologic support is also important because postpartum depression can be exaggerated by chronic steroid use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Female transplant recipients usually have normal fertility. Physicians need to discuss fertility issues with these women and should counsel their patients regarding the timing of pregnancy, as well as the risks and alternatives [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20487/abstract/7\">",
"     7",
"    </a>",
"    ]. The cardiovascular changes associated with pregnancy are generally well tolerated by the heart transplant recipient. Hypertension, premature delivery, lower fetal birth weight, and preeclampsia are risks that are augmented in heart transplant recipients. However, most pregnancies after cardiac transplantation have successful outcomes for mother and baby. A multidisciplinary team approach to the care of these high-risk parturients is not only prudent, but recommended.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20487/abstract/1\">",
"      Branch KR, Wagoner LE, McGrory CH, et al. Risks of subsequent pregnancies on mother and newborn in female heart transplant recipients. J Heart Lung Transplant 1998; 17:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20487/abstract/2\">",
"      Cupples SA. Cardiac transplantation in women. Crit Care Nurs Clin North Am 1997; 9:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20487/abstract/3\">",
"      Kim KM, Sukhani R, Slogoff S, Tomich PG. Central hemodynamic changes associated with pregnancy in a long-term cardiac transplant recipient. Am J Obstet Gynecol 1996; 174:1651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20487/abstract/4\">",
"      Radomski JS, Ahlswede BA, Jarrell BE, et al. Outcomes of 500 pregnancies in 335 female kidney, liver, and heart transplant recipients. Transplant Proc 1995; 27:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20487/abstract/5\">",
"      Troch&eacute; V, Ville Y, Fernandez H. Pregnancy after heart or heart-lung transplantation: a series of 10 pregnancies. Br J Obstet Gynaecol 1998; 105:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20487/abstract/6\">",
"      L&ouml;wenstein BR, Vain NW, Perrone SV, et al. Successful pregnancy and vaginal delivery after heart transplantation. Am J Obstet Gynecol 1988; 158:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20487/abstract/7\">",
"      Ross LF. Ethical considerations related to pregnancy in transplant recipients. N Engl J Med 2006; 354:1313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20487/abstract/8\">",
"      McKay DB, Josephson MA, Armenti VT, et al. Reproduction and transplantation: report on the AST Consensus Conference on Reproductive Issues and Transplantation. Am J Transplant 2005; 5:1592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20487/abstract/9\">",
"      Whittemore R, Wells JA, Castellsague X. A second-generation study of 427 probands with congenital heart defects and their 837 children. J Am Coll Cardiol 1994; 23:1459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20487/abstract/10\">",
"      Akin SJ. Pregnancy after heart transplantation. Prog Cardiovasc Nurs 1992; 7:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20487/abstract/11\">",
"      Key TC, Resnik R, Dittrich HC, Reisner LS. Successful pregnancy after cardiac transplantation. Am J Obstet Gynecol 1989; 160:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20487/abstract/12\">",
"      Armenti, VT, Stefanosky, EV, Cater, JR, et al. Pregnancy in transplant recipients. J Transplant Coordination 1995; 5:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20487/abstract/13\">",
"      Wagoner LE, Taylor DO, Olsen SL, et al. Immunosuppressive therapy, management, and outcome of heart transplant recipients during pregnancy. J Heart Lung Transplant 1993; 12:993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20487/abstract/14\">",
"      Wu DW, Wilt J, Restaino S. Pregnancy after thoracic organ transplantation. Semin Perinatol 2007; 31:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20487/abstract/15\">",
"      Armenti VT, Radomski JS, Moritz MJ, et al. Report from the National Transplantation Pregnancy Registry (NTPR): outcomes of pregnancy after transplantation. Clin Transpl 2004; :103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20487/abstract/16\">",
"      Scott JR, Wagoner LE, Olsen SL, et al. Pregnancy in heart transplant recipients: management and outcome. Obstet Gynecol 1993; 82:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20487/abstract/17\">",
"      Sibanda N, Briggs JD, Davison JM, et al. Pregnancy after organ transplantation: a report from the UK Transplant pregnancy registry. Transplantation 2007; 83:1301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20487/abstract/18\">",
"      Wilson W, Taubert KA, Gewitz M, et al. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation 2007; 116:1736.",
"     </a>",
"    </li>",
"    <li>",
"     Mendelson MA. Pregnancy after cardiac transplantation. In: Principles and practice of medical therapy in pregnancy, Gleicher N (Ed), Norwalk, Appleton &amp; Lange, 1992. p.841.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3529 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-115.66.252.144-564C5304BD-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_0_20487=[""].join("\n");
var outline_f20_0_20487=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PRECONCEPTION CARE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Preconception counseling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Timing of pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Vaccination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      MATERNAL PHYSIOLOGY AND THE HEART TRANSPLANT RECIPIENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      MATERNAL RISKS IN PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Rejection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Abnormal liver function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Hypertension and preeclampsia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      FETAL RISKS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Maternal monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Maternal medications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      INTRAPARTUM RISKS AND MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Mode of delivery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Antibiotic prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Anesthesia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Stress dose steroids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Maternal monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      POSTPARTUM RISKS AND MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/3529\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/3529|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/17/15644\" title=\"table 1\">",
"      Changes in pregnancy and heart transplant concerns",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/5/11355\" title=\"table 2\">",
"      Stress dose steroids",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/26/29097?source=related_link\">",
"      Acquired heart disease and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/24/28040?source=related_link\">",
"      Acute cardiac allograft rejection: Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/6/14441?source=related_link\">",
"      Acute cardiac allograft rejection: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/32/1543?source=related_link\">",
"      Angiotensin converting enzyme inhibitors and receptor blockers in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/36/585?source=related_link\">",
"      Antimicrobial prophylaxis for bacterial endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/1/23576?source=related_link\">",
"      Arrhythmias following cardiac transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/15/41207?source=related_link\">",
"      Clinical features and evaluation of nausea and vomiting of pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/51/36664?source=related_link\">",
"      Cytomegalovirus infection and disease in newborns, infants, children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/21/12634?source=related_link\">",
"      Cytomegalovirus infection in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/2/29738?source=related_link\">",
"      Cytomegalovirus infection in renal transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/53/32602?source=related_link\">",
"      Immunizations during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/22/36201?source=related_link\">",
"      Immunology of the maternal-fetal interface",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/11/14520?source=related_link\">",
"      Incidence and mortality of the premature infant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34297?source=related_link\">",
"      Indications and contraindications for cardiac transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/47/29433?source=related_link\">",
"      Infection in the solid organ transplant recipient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/7/13434?source=related_link\">",
"      Management of hypertension in pregnant and postpartum women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/40/20105?source=related_link\">",
"      Maternal cardiovascular and hemodynamic adaptations to pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/9/18585?source=related_link\">",
"      Natural history and diagnosis of cardiac allograft vasculopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/24/39306?source=related_link\">",
"      Overview of contraception",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/25/44441?source=related_link\">",
"      Pathogenesis of and risk factors for cardiac allograft vasculopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/62/18410?source=related_link\">",
"      Peripartum cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/42/23208?source=related_link\">",
"      Pharmacologic use of glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/20/27978?source=related_link\">",
"      Preeclampsia: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/12/42184?source=related_link\">",
"      Prevention and treatment of cardiac allograft vasculopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/40/41609?source=related_link\">",
"      Prevention of preeclampsia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/15/22775?source=related_link\">",
"      Prognosis after cardiac transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27128?source=related_link\">",
"      Pulmonary artery catheterization: Indications and complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/23/9593?source=related_link\">",
"      Small for gestational age infant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/1/14362?source=related_link\">",
"      Supraventricular arrhythmias during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/47/42745?source=related_link\">",
"      Treatment of adrenal insufficiency in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/59/38842?source=related_link\">",
"      Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/31/7674?source=related_link\">",
"      Ventricular arrhythmias during pregnancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_0_20488="IHC sentinel lymph node metast";
var content_f20_0_20488=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F64086&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F64086&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Immunohistochemical staining of melanoma metastasis within a sentinel lymph node",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 372px; height: 450px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Low power light photomicrographs of immunohistochemical stains for S-100 (top panel) and MART-1 (bottom panel) in a sentinel lymph node that has been counterstained with hematoxylin and eosin.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Vincent Liu, MD and April Wang Armstrong, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_0_20488=[""].join("\n");
var outline_f20_0_20488=null;
var title_f20_0_20489="Overview of Niemann-Pick disease";
var content_f20_0_20489=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of Niemann-Pick disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/0/20489/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/0/20489/contributors\">",
"     Robert P Cruse, DO",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/0/20489/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/0/20489/contributors\">",
"     Marc C Patterson, MD, FRACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/0/20489/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/0/20489/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/0/20489/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Niemann-Pick disease (NPD) is a group of autosomal recessive disorders associated with splenomegaly, variable neurologic deficits, and the storage of sphingomyelin.",
"   </p>",
"   <p>",
"    This topic will review the classification, clinical manifestations, diagnosis, and management of NPD. Other lysosomal storage disorders are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/49/27414?source=see_link\">",
"     \"Neurologic manifestations of Fabry disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/11/9402?source=see_link\">",
"     \"Gaucher disease: Pathogenesis, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/60/4038?source=see_link\">",
"     \"Krabbe disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/27/42421?source=see_link\">",
"     \"Metachromatic leukodystrophy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/6/7274?source=see_link\">",
"     \"Clinical features and diagnosis of the mucopolysaccharidoses\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLASSIFICATION AND CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Niemann-Pick disease (NPD), also called sphingomyelin-cholesterol lipidosis, is a group of autosomal recessive disorders associated with splenomegaly, variable neurologic deficits, and the storage of sphingomyelin. Niemann-Pick disease originally was defined in terms of its histology as a reticuloendotheliosis. It now is subdivided into two major categories (",
"    <a class=\"graphic graphic_table graphicRef51071 \" href=\"UTD.htm?37/50/38700\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Niemann-Pick disease type A and type B are allelic disorders caused by mutations in the sphingomyelin phosphodiesterase-1 gene (SMPD1), and characterized by a primary deficiency of acid sphingomyelinase activity",
"     </li>",
"     <li>",
"      Niemann-Pick disease type C is caused by mutations of the NPC1 and NPC2 genes that result in impaired cellular processing and transport of low-density lipoprotein (LDL) cholesterol",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     NPD type A",
"    </span>",
"    &nbsp;&mdash;&nbsp;Niemann-Pick disease type A (NPD-A; MIM 257200) is the acute neuronopathic form. The incidence of NPD-A is highest among Ashkenazi Jews, in whom the gene frequency is estimated to be 1:100. The overall prevalence of acid sphingomyelinase deficiency (types A and B combined) is estimated to be 1:250,000 [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20489/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Affected patients present with hepatosplenomegaly, feeding difficulties, and loss of early motor skills in the first few months of life. Rapid, progressive, and profound loss of neurologic function leading to death occurs by two to three years of age. A peripheral neuropathy is manifest as hypotonia and absent reflexes [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20489/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Storage of sphingomyelin in pulmonary macrophages leads to interstitial lung disease, frequent respiratory infections, and often to respiratory failure [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20489/abstract/4\">",
"     4",
"    </a>",
"    ]. Macular cherry red spots (seen on funduscopic examination) are eventually present in all affected individuals (",
"    <a class=\"graphic graphic_picture graphicRef65650 \" href=\"UTD.htm?19/14/19680\">",
"     picture 1",
"    </a>",
"    ), although they may not be observed early in the course of the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20489/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a natural history study of 10 infants with NPD-A, all except one infant had a normal neonatal course and early development [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20489/abstract/5\">",
"     5",
"    </a>",
"    ]. The one exception had jaundice that resolved without treatment. The first detected sign of the disease was organomegaly, noted at a median of three months (range two to four). The median age at diagnosis was six months. A cherry red spot was evident in all infants by 12 months of age, but was absent in several on initial examination. No infant progressed beyond the gross motor milestone of sitting with support; none ever crawled on all fours or walked. Social smile was retained well into the disease course, and was lost at a median age of 19 months. Death (from respiratory failure in nine patients and bleeding in one) occurred at a median age of 27 months (range 19 to 35).",
"   </p>",
"   <p>",
"    The laboratory findings may include lipid abnormalities such as decreased high-density lipoprotein (HDL) cholesterol, hypertriglyceridemia, and increased LDL cholesterol [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20489/abstract/6\">",
"     6",
"    </a>",
"    ]. In the natural history study discussed above, all infants had low fasting HDL cholesterol values (mean 11.2",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [0.29",
"    <span class=\"nowrap\">",
"     mmol/L])",
"    </span>",
"    from the earliest age at which they were obtained [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20489/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Large lipid laden foam cells are seen in the reticuloendothelial system of the spleen, bone marrow, lymph nodes, blood vessels, peripheral nerve Schwann cells, central nervous system, and retinal cells [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20489/abstract/7\">",
"     7",
"    </a>",
"    ]. Electron microscopy reveals lysosomal inclusions and myelin inclusions in peripheral nerves, indicating a severe myelinopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20489/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Type A disease is caused by mutations in the acid sphingomyelinase gene, also known as the sphingomyelin phosphodiesterase 1 or SMPD1 gene, on chromosome 11p15, that result in complete absence of residual acid sphingomyelinase activity and subsequent lysosomal accumulation of sphingomyelin [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20489/abstract/8-10\">",
"     8-10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     NPD type B",
"    </span>",
"    &nbsp;&mdash;&nbsp;Niemann-Pick disease type B (NPD-B; MIM 607616) is pan-ethnic and generally later in onset and less severe than NPD-A, with a good prognosis for survival into adulthood [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20489/abstract/4\">",
"     4",
"    </a>",
"    ]. As already mentioned, the overall prevalence of acid sphingomyelinase deficiency (types A and B combined) is estimated to be 1:250,000 [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20489/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    NPD-B is characterized by the development of hepatosplenomegaly during infancy or childhood. Most affected patients have thrombocytopenia secondary to hypersplenism. Liver involvement can be severe, with infiltration of foamy histiocytes, ballooning of hepatocytes, and fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20489/abstract/11\">",
"     11",
"    </a>",
"    ]. Other systemic manifestations include short stature with delayed skeletal maturation, interstitial lung disease, hyperlipidemia, and ocular abnormalities (macular halos and cherry red maculae, (",
"    <a class=\"graphic graphic_picture graphicRef65650 \" href=\"UTD.htm?19/14/19680\">",
"     picture 1",
"    </a>",
"    )) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20489/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. The natural history is one of progressive hypersplenism and gradual deterioration of pulmonary function [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20489/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most patients with NPD-B have no neurologic abnormalities. However, in those who survive early childhood, prolonged nerve conduction velocities and varying degrees of central nervous system involvement may be present, including cerebellar signs, nystagmus, extrapyramidal involvement, mental retardation, psychiatric disorders, and peripheral neuropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20489/abstract/4,16-20\">",
"     4,16-20",
"    </a>",
"    ]. In one series of 64 patients with NPD-B, neurologic abnormalities were observed in 30 percent; these were minor and nonprogressive in 22 percent, and global and progressive in 8 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20489/abstract/20\">",
"     20",
"    </a>",
"    ]. In the latter group, the onset of neurologic abnormalities occurred between the ages of two and seven years.",
"   </p>",
"   <p>",
"    Although data are limited, brain MRI may show pronounced cerebellar and mild supratentorial atrophy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20489/abstract/19\">",
"     19",
"    </a>",
"    ]. Other laboratory abnormalities may include liver dysfunction, decreased HDL cholesterol, hypertriglyceridemia, and increased LDL cholesterol [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20489/abstract/6\">",
"     6",
"    </a>",
"    ]. The atherogenic lipid profile worsens over time, whereas the liver dysfunction remains stable [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20489/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    NPD-B is associated with mutations of the acid sphingomyelinase gene (SMPD1 gene) that result in acid sphingomyelinase deficiency with some residual activity of the enzyme [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20489/abstract/9,10,21\">",
"     9,10,21",
"    </a>",
"    ]. In two studies, for example, acid sphingomyelinase activity in patients with NPD-B was 4 percent of normal compared with undetectable activity in patients with NPD-A [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20489/abstract/9,21\">",
"     9,21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     NPD type C",
"    </span>",
"    &nbsp;&mdash;&nbsp;Niemann-Pick disease type C (NPD-C) can present from the perinatal period until late adulthood [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20489/abstract/22-26\">",
"     22-26",
"    </a>",
"    ]. The disorder has an estimated prevalence of 1:150,000 in Europe [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20489/abstract/24\">",
"     24",
"    </a>",
"    ]. NPD-C has two genotypes related to mutations in the NPC1 gene (NPD-C1; MIM 257220) or to mutations in the NPC2 gene (NPD-C2; MIM 607625). Systemic involvement of liver, spleen or lung, is present in &ge;85 percent of patients, and precedes the development of neurologic symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20489/abstract/26\">",
"     26",
"    </a>",
"    ]. The age on onset and clinical presentation of NPD-C is highly variable.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most patients with NPD-C have disease onset in middle to late childhood after normal early development. These patients typically have cerebellar involvement characterized by clumsiness and gait problems progressing to frank ataxia, and slow cognitive deterioration [",
"      <a class=\"abstract\" href=\"UTD.htm?20/0/20489/abstract/24\">",
"       24",
"      </a>",
"      ]. Vertical supranuclear ophthalmoplegia is another early manifestation (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/8/28806?source=see_link\">",
"       \"Supranuclear disorders of gaze in children\"",
"      </a>",
"      ). Progressive dystonia, dysarthria, and dysphagia occur, eventually impairing oral feeding, and approximately one-third of patients develop seizures. Death typically occurs from aspiration pneumonia in the second or third decade of life [",
"      <a class=\"abstract\" href=\"UTD.htm?20/0/20489/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Neonatal onset of NPD-C may occur, presenting with severe hepatic disease from infiltration of the liver [",
"      <a class=\"abstract\" href=\"UTD.htm?20/0/20489/abstract/27\">",
"       27",
"      </a>",
"      ]. In addition, pulmonary disease with respiratory failure secondary to alveolar proteinosis may accompany neonatal hepatic disease or occur as the initial presentation [",
"      <a class=\"abstract\" href=\"UTD.htm?20/0/20489/abstract/28,29\">",
"       28,29",
"      </a>",
"      ]. Fetal onset of NPD-C is most often associated with ultrasonographic findings of splenomegaly, hepatomegaly, and ascites or fetal hydrops [",
"      <a class=\"abstract\" href=\"UTD.htm?20/0/20489/abstract/25\">",
"       25",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      A separate infantile form presents with hypotonia and developmental delay with little or no hepatic and pulmonary involvement [",
"      <a class=\"abstract\" href=\"UTD.htm?20/0/20489/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Adult onset of NPD-C may present with ataxia, supranuclear vertical gaze palsy, cognitive impairment, and other symptoms similar to earlier onset disease, except that progression is generally much slower [",
"      <a class=\"abstract\" href=\"UTD.htm?20/0/20489/abstract/24,31\">",
"       24,31",
"      </a>",
"      ]. Other adults present with cognitive dysfunction or psychiatric disturbances [",
"      <a class=\"abstract\" href=\"UTD.htm?20/0/20489/abstract/32-37\">",
"       32-37",
"      </a>",
"      ]. In some cases of NPD-C, subtle premonitory signs or symptoms in childhood, such as splenomegaly, hepatomegaly, learning difficulty, deafness, or impaired vertical gaze, may precede neurologic deterioration in adulthood [",
"      <a class=\"abstract\" href=\"UTD.htm?20/0/20489/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Brain MRI in two patients with NPD-C showed symmetrical cerebral and cerebellar atrophy and thinning of the corpus callosum [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20489/abstract/38\">",
"     38",
"    </a>",
"    ]. Magnetic resonance spectroscopy (MRS) may show early changes prior to MRI findings, but data are limited. Reported findings include decreased n-acetyl aspartate",
"    <span class=\"nowrap\">",
"     /",
"    </span>",
"    creatine ratios in the frontal and parietal cortex, centrum semiovale and caudate nucleus with increased choline",
"    <span class=\"nowrap\">",
"     /",
"    </span>",
"    creatinine ratios in the frontal cortex and centrum semiovale [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20489/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Genetics of NPD-C",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two separate disease gene loci for NPD-C: the NPC1 gene on chromosome 18q11-q12, and the NPC2 gene (also called the HE1 gene) on chromosome 14q24.3 [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20489/abstract/23,40,41\">",
"     23,40,41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mutations in the NPC1 gene can be identified in approximately 90 percent of NPD-C cases, while mutations in NPC2 account for approximately 4 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20489/abstract/42-44\">",
"     42-44",
"    </a>",
"    ]. So-called Niemann-Pick type D is an allelic variant of NPD-C that results from a point mutation of NPC1 and occurs in descendants of an Acadian couple who were born in the late 1600s in Nova Scotia [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20489/abstract/45,46\">",
"     45,46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    NPC1 encodes a large membrane glycoprotein primarily located to late endosomes; this protein plays a role in the intracellular trafficking, levels, and distribution of LDL cholesterol [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20489/abstract/47-50\">",
"     47-50",
"    </a>",
"    ]. Disruption of this trafficking leads to lipid accumulation and neuronal degeneration [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20489/abstract/51\">",
"     51",
"    </a>",
"    ]. NPC2 encodes a small soluble lysosomal protein previously known as cholesterol-binding protein [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20489/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mutations in both the NPC1 and NPC2 genes result in the accumulation of unesterified cholesterol and glycolipids in the",
"    <span class=\"nowrap\">",
"     lysosomal/late",
"    </span>",
"    endosomal system. The biochemical pattern is identical. The precise functions and relationship of the two genes remains unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20489/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of Niemann-Pick disease (NPD) first depends upon an appreciation of the variable phenotypic manifestations.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The definitive diagnosis of NPD-A and NPD-B requires demonstration of acid sphingomyelinase deficiency, with residual acid sphingomyelinase activity &lt;10 percent of controls.",
"     </li>",
"     <li>",
"      The definitive diagnosis of NPD-C requires demonstration of abnormal intracellular cholesterol trafficking by the impaired response to LDL-cholesterol loading in cultured fibroblasts, as shown by reduced cholesterol esterification and excessive cholesterol accumulation (visualized by positive filipin staining).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    NPD is often erroneously omitted from the differential diagnosis in cases that lack organomegaly, but this is not a universal feature. In addition, common screening tests for metabolic diseases such as amino or organic acids are typically normal in NPD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Diagnosis of NPD-A and NPD-B (acid sphingomyelinase deficiency)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of NPD-A is suggested by the following clinical features [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20489/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hepatosplenomegaly",
"     </li>",
"     <li>",
"      Interstitial lung disease",
"     </li>",
"     <li>",
"      Macular cherry red spot",
"     </li>",
"     <li>",
"      Developmental delay",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The diagnosis of NPD-B is suggested by the following clinical features [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20489/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hepatosplenomegaly with thrombocytopenia",
"     </li>",
"     <li>",
"      Interstitial lung disease",
"     </li>",
"     <li>",
"      Lipid abnormalities, particularly decreased serum HDL cholesterol concentration, increased LDL cholesterol, and hypertriglyceridemia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The diagnosis of acid sphingomyelinase deficiency (ie, NPD-A or NPD-B, depending on clinical context) is confirmed when residual acid sphingomyelinase activity in peripheral blood leukocytes or cultured skin fibroblasts is &lt;10 percent of controls [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20489/abstract/4,53\">",
"     4,53",
"    </a>",
"    ]. In rare cases, the use of a so-called \"artificial\" substrate rather than the natural sphingomyelin substrate has led to falsely normal or enhanced laboratory determination of sphingomyelinase activity [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20489/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Molecular genetic testing can also confirm the diagnosis of acid sphingomyelinase deficiency if it identifies both disease-causing alleles, but such testing should only be used after biochemical testing for acid sphingomyelinase activity [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20489/abstract/4\">",
"     4",
"    </a>",
"    ]. Three common SMPD1 mutations account for approximately 90 percent of NPD-A cases among Ashkenazi Jews [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20489/abstract/55\">",
"     55",
"    </a>",
"    ], and another common SMPD1 mutation accounts for approximately 90 percent of NPD-B cases among patients of North African descent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20489/abstract/56\">",
"     56",
"    </a>",
"    ]. Thus, for patients of Ashkenazi Jewish or North African descent, targeted mutation analysis is the preferred initial method of molecular genetic testing [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20489/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sequence analysis of SMPD1 is appropriate if targeted mutation analysis does not identify both mutations in patients with confirmed acid sphingomyelinase deficiency. In such patients, the mutation detection rate of sequence analysis is approximately 99 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20489/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Diagnosis of NPD-C",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of NPD-C is suspected on the basis of the clinical features and confirmed by fibroblast cell culture with filipin staining, which demonstrates intense punctuate pattern of fluorescence concentrated around the nucleus, consistent with unesterified cholesterol.",
"   </p>",
"   <p>",
"    The following clinical features are associated with NPD-C:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Newborns may present with ascites, abnormal liver function tests, prolonged jaundice, and pulmonary infiltrates. Infants may show persistent hypotonia [",
"      <a class=\"abstract\" href=\"UTD.htm?20/0/20489/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In early childhood, hepatosplenomegaly is common. In late childhood, vertical supranuclear gaze palsy, ataxia, dystonia or seizures may be prominent [",
"      <a class=\"abstract\" href=\"UTD.htm?20/0/20489/abstract/22,57\">",
"       22,57",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Gelastic cataplexy with abnormal polysomnograms is a prominent feature in up to 20 percent of children [",
"      <a class=\"abstract\" href=\"UTD.htm?20/0/20489/abstract/58\">",
"       58",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In adults, dementia, depression, bipolar disease [",
"      <a class=\"abstract\" href=\"UTD.htm?20/0/20489/abstract/36\">",
"       36",
"      </a>",
"      ] or schizophrenia may be the only symptoms [",
"      <a class=\"abstract\" href=\"UTD.htm?20/0/20489/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A Suspicion Index tool (",
"    <a class=\"graphic graphic_figure graphicRef85656 \" href=\"UTD.htm?15/57/16273\">",
"     figure 1",
"    </a>",
"    ) may be useful as a screen for NPD-C [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20489/abstract/59\">",
"     59",
"    </a>",
"    ]. A risk prediction score of &ge;70 indicates a strong suspicion for NPD-C. The index was derived by a retrospective review that compared the clinical features of patients with NPD-C confirmed by filipin staining (n = 71), noncases excluded from the diagnosis of NPD-C by negative filipin staining (n = 64), and control patients who had at least one characteristic symptom of NPD-C (n = 81). Individual signs and symptoms were analyzed by logistic regression to develop prediction scores for NPD-C.",
"   </p>",
"   <p>",
"    The clinical features most strongly associated with NPD-C were vertical supranuclear gaze palsy, gelastic cataplexy, isolated unexplained splenomegaly, prolonged neonatal jaundice or cholestasis, and premature cognitive decline or dementia (",
"    <a class=\"graphic graphic_figure graphicRef85656 \" href=\"UTD.htm?15/57/16273\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20489/abstract/59\">",
"     59",
"    </a>",
"    ]. Gelastic cataplexy had a high specificity but low sensitivity for NPD-C, and was noted to be rare among adults. Premature cognitive decline or dementia was common in NPD-C but was not highly specific.",
"   </p>",
"   <p>",
"    The diagnosis of NPD-C is confirmed by fibroblast cell culture. Findings include abnormal intracellular accumulation of unesterified cholesterol and glycolipids in the",
"    <span class=\"nowrap\">",
"     lysosomal/late",
"    </span>",
"    endosomal system [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20489/abstract/30,60,61\">",
"     30,60,61",
"    </a>",
"    ]. Formal esterification studies demonstrate delayed low-density lipoprotein-derived cholesterol esterification. Filipin staining shows an intense punctuate pattern of fluorescence concentrated around the nucleus, consistent with unesterified cholesterol.",
"   </p>",
"   <p>",
"    Biopsies of tissues other than skin are rarely required for the diagnosis of NPD-C since the development of biochemical tests on cultured fibroblasts [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20489/abstract/24\">",
"     24",
"    </a>",
"    ]. Nonetheless, it is prudent to send a portion of the skin biopsy for electron microscopy to confirm the diagnosis in biochemical 'variant' cases. Foam cells (ie, lipid laden macrophages) occur in bone marrow, spleen and liver. Sea blue histiocytes may be found in bone marrow. Characteristic cytoplasmic bodies can be seen by electron microscopy of skin, rectal neurons, and liver or brain biopsies [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20489/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Genetic testing is commercially available. An abnormal NPCI gene (mapped at 18q11) is found in approximately 90 percent of NPD-C cases. The NPC2 gene defect (mapped at 14q24.3) is found in less than 5 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20489/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no treatment for Niemann-Pick disease (NPD) that is proven to modify the onset or neurologic progression of the disease, or to prolong lifespan. However, some patients with NPD-C may benefit from treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/13/24788?source=see_link\">",
"     miglustat",
"    </a>",
"    (see",
"    <a class=\"local\" href=\"#H97251296\">",
"     'Miglustat'",
"    </a>",
"    below). Cholesterol lowering agents lower the free cholesterol in the liver but the clinical course is unchanged [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20489/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Supportive care",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of all forms of NPD is supportive.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9862510\">",
"    <span class=\"h3\">",
"     NPD-A",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infants with NPD-A may temporarily benefit from physical and occupational therapy, periodic nutritional assessments, and possibly a feeding tube for nutrition. Sedatives may be helpful for sleep difficulty and irritability [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20489/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9862587\">",
"    <span class=\"h3\">",
"     NPD-B",
"    </span>",
"    &nbsp;&mdash;&nbsp;Suggested surveillance for patients with NPD-B includes periodic assessment (every 6 to 12 months) of height and growth in children, weight in patients of all ages, nutrition, changes in activity level, bleeding, shortness of breath, abdominal pain, and neurologic function [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20489/abstract/4\">",
"     4",
"    </a>",
"    ]. Concomitantly, the following tests should be monitored [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20489/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Platelet count",
"     </li>",
"     <li>",
"      Liver enzymes",
"     </li>",
"     <li>",
"      Fasting lipid profile",
"     </li>",
"     <li>",
"      Pulmonary function tests",
"     </li>",
"     <li>",
"      Chest radiography",
"     </li>",
"     <li>",
"      Skeletal evaluation with dual-energy X-ray absorptiometry (DXA)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with NPD-B who have symptomatic pulmonary disease may benefit from supplemental oxygen. Severe bleeding from thrombocytopenia can lead to the need for transfusion of blood products. In adults with hyperlipidemia, treatment is suggested to correct elevated total cholesterol. Avoidance of contact sports is suggested for patients with splenomegaly [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20489/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9862524\">",
"    <span class=\"h3\">",
"     NPD-C",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with NPD-C, physical therapy may be beneficial for maintaining mobility. Swallowing function should be monitored periodically, and gastrostomy tube placement may be useful to prevent aspiration",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    inadequate nutrition in patients with progressive dysphagia. The treatment of seizures, dystonia, and cataplexy is suggested and may be partially effective. Bowel regimens may be helpful for preventing severe constipation in patients with reduced mobility [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20489/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Evidence from a single case report suggests that bronchoalveolar lavage can improve pulmonary function in children with pulmonary infiltrates and recurrent pulmonary infections [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20489/abstract/64\">",
"     64",
"    </a>",
"    ]. Some experts suggest the use of chest physical therapy and aggressive bronchodilation therapy with antibiotic treatment of intercurrent infections for preventing secondary pulmonary complications [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20489/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Investigational approaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a persistent search for new treatment approaches. Evaluation of novel therapies is ongoing and may offer some hope for the future.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H97251296\">",
"    <span class=\"h3\">",
"     Miglustat",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon the observation that glycolipids were increased in NPD-C cells, substrate reduction therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/13/24788?source=see_link\">",
"     miglustat",
"    </a>",
"    , an inhibitor of glycosphingolipids biosynthesis, was shown to decrease lipid storage, improve endosomal uptake, and normalize lipid trafficking in B lymphocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20489/abstract/65\">",
"     65",
"    </a>",
"    ]. Limited clinical data suggest that miglustat can prevent or reduce disease progression in some cases of NPD-C.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a preliminary open-label randomized controlled trial, patients &ge;12 years old with NPD-C assigned to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/13/24788?source=see_link\">",
"       miglustat",
"      </a>",
"      200 mg three times daily (n = 20) demonstrated nonsignificant improvement in horizontal saccadic eye movement velocity (the primary outcome measure) at 12 months compared with patients assigned to standard care (n = 9) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/0/20489/abstract/66\">",
"       66",
"      </a>",
"      ]. The difference between groups was statistically significant after excluding patients taking benzodiazepines. Improvement or stabilization with miglustat, statistically nonsignificant in most cases, was also seen in clinically relevant secondary outcome measures, including swallowing capacity, hearing acuity, and ambulation.",
"     </li>",
"     <li>",
"      A subsequent study described early",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/13/24788?source=see_link\">",
"       miglustat",
"      </a>",
"      treatment of two children with NPD-C, one a girl with early infantile onset and mild axial hypotonia who started treatment at age 7 months, and the second a boy with no neurologic symptoms who started treatment at age 19 months [",
"      <a class=\"abstract\" href=\"UTD.htm?20/0/20489/abstract/67\">",
"       67",
"      </a>",
"      ]. After seven and five years of therapy, respectively, both children remain without neurologic symptoms.",
"     </li>",
"     <li>",
"      A case series of 16 symptomatic children of different ages treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/13/24788?source=see_link\">",
"       miglustat",
"      </a>",
"      for six months to four years for NPD-C reported that patients with more severe disease, generally those with infantile NPD-C, showed greater deterioration during miglustat therapy than patients with less severe disease, generally those with juvenile-onset NPD-C [",
"      <a class=\"abstract\" href=\"UTD.htm?20/0/20489/abstract/68\">",
"       68",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/13/24788?source=see_link\">",
"     miglustat",
"    </a>",
"    may be beneficial for delaying the progression of the neurologic manifestations of NPD-C in children without severe neurologic symptoms at the start of treatment. However, expert consensus guidelines note that miglustat should not be given to patients who have no neurologic manifestations because some remain asymptomatic for long periods of time [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20489/abstract/69\">",
"     69",
"    </a>",
"    ]. In accord with these guidelines, we suggest miglustat for patients with NPD-C who have mild to moderate neurologic, psychiatric, or cognitive manifestations. Patients and their families should be informed that the effectiveness of miglustat for NPD-C is unproven, and that the best attainable outcome of therapy is neurologic stabilization or a slower rate of neurologic disease progression. The available clinical studies suggest that miglustat has no benefit for cholestatic or systemic symptoms.",
"   </p>",
"   <p>",
"    The suggested dose for adults and adolescents (age &ge;12 years) is 600 mg daily given in three divided doses. The",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/13/24788?source=see_link\">",
"     miglustat",
"    </a>",
"    dose in children 4 to 11 years of age is based upon body surface area (BSA):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      600 daily in three divided doses for BSA &gt;1.25 m",
"      <sup>",
"       2",
"      </sup>",
"     </li>",
"     <li>",
"      400 mg daily in two divided doses for BSA 0.89 to 1.25 m",
"      <sup>",
"       2",
"      </sup>",
"     </li>",
"     <li>",
"      300 mg daily in three divided doses for BSA 0.74 to 0.88 m",
"      <sup>",
"       2",
"      </sup>",
"     </li>",
"     <li>",
"      200 mg daily in two divided doses for BSA 0.48 to 0.73 m",
"      <sup>",
"       2",
"      </sup>",
"     </li>",
"     <li>",
"      100 mg once daily for BSA &le;0.47 m",
"      <sup>",
"       2",
"      </sup>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Few children &lt;4 years old with NPD-C have been treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/13/24788?source=see_link\">",
"     miglustat",
"    </a>",
"    and optimal dosing is uncertain; one study used miglustat 250",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per day [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20489/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most common side effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/13/24788?source=see_link\">",
"     miglustat",
"    </a>",
"    include gastrointestinal symptoms (eg, diarrhea, flatulence), weight loss, and tremor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H97251303\">",
"    <span class=\"h3\">",
"     Other experimental therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following reports illustrate the range of experimental therapies for NPD:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hematopoietic stem cell transplantation (HSCT) did not modify the neurological course in an acid sphingomyelinase deficient mouse model, although increased Purkinje cells were noted in the cerebellum and decreased sphingomyelin storage was noted in spinal cord neurons [",
"      <a class=\"abstract\" href=\"UTD.htm?20/0/20489/abstract/70\">",
"       70",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In utero stem cell transplant in NPD has been shown to have only a transitory benefit [",
"      <a class=\"abstract\" href=\"UTD.htm?20/0/20489/abstract/71\">",
"       71",
"      </a>",
"      ]. Allogeneic or bone marrow treatment has generally not modified the neurologic course in patients [",
"      <a class=\"abstract\" href=\"UTD.htm?20/0/20489/abstract/72,73\">",
"       72,73",
"      </a>",
"      ]. However, there are rare case reports of successful HSCT in children with NPD- B [",
"      <a class=\"abstract\" href=\"UTD.htm?20/0/20489/abstract/73,74\">",
"       73,74",
"      </a>",
"      ]. Transplant related complications included chronic graft versus host disease of the skin, and renal tubular dysfunction.",
"     </li>",
"     <li>",
"      Retroviral mediated transfer using acid sphingomyelinase (ASM) cDNA in cultured fibroblasts of affected patients resulted in up to a 16 fold increase in ASM activity [",
"      <a class=\"abstract\" href=\"UTD.htm?20/0/20489/abstract/75\">",
"       75",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Direct intracerebral transplant of neural progenitor cells into the mouse model of NPD-A resulted in up to five times more ASM activity and lead to reversal of distended lysosomal pathology in transplanted cells in vivo [",
"      <a class=\"abstract\" href=\"UTD.htm?20/0/20489/abstract/76\">",
"       76",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      (an agent that among other effects may reduce oxidative damage) in combination with vitamin E (D-alpha tocopherol, also an antioxidant), did not have significant effect in the mouse model of NPD-C [",
"      <a class=\"abstract\" href=\"UTD.htm?20/0/20489/abstract/77\">",
"       77",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another approach is based on the observation that neurosteroids, made in the central nervous system, affect neuronal growth and differentiation, and modulate brain functions [",
"      <a class=\"abstract\" href=\"UTD.htm?20/0/20489/abstract/78\">",
"       78",
"      </a>",
"      ]. Disordered cholesterol trafficking might disrupt neurosteroidogenesis, thereby contributing to the NPD-C phenotype. Treatment with allopregnanolone in the NPD-C mouse delayed neurological symptoms, increased Purkinje cells, decreased cortical ganglioside storage and doubled life span [",
"      <a class=\"abstract\" href=\"UTD.htm?20/0/20489/abstract/79\">",
"       79",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Glial activation may be important in pathogenesis of neurodegenerative disorders such as NPD. In support of this hypothesis, intracerebral transplantation of bone marrow-derived mesenchymal stem cells in NPD-C mice suppressed neuroglial inflammation and resulted in reduced cerebellar pathology [",
"      <a class=\"abstract\" href=\"UTD.htm?20/0/20489/abstract/80\">",
"       80",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The compound NP-27 appears promising in cell culture experiments; NP-27 corrected the NPD-C phenotype as assessed by four different measures of cholesterol homeostasis [",
"      <a class=\"abstract\" href=\"UTD.htm?20/0/20489/abstract/81\">",
"       81",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Genetic counseling",
"    </span>",
"    &nbsp;&mdash;&nbsp;All types of NPD are autosomal recessive disorders. At the time of conception, siblings of an affected patient with NPD have a 25 percent chance of being affected with the disease, a 50 percent chance of being an unaffected carrier and 25 percent chance of being unaffected and not a carrier.",
"   </p>",
"   <p>",
"    Prenatal testing for pregnancies at 25 percent risk of NPD-A or NPD-B can be accomplished by measuring sphingomyelinase activity in amniotic fibroblasts [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20489/abstract/52,82\">",
"     52,82",
"    </a>",
"    ], or by molecular genetic testing if both disease-causing SMPD1 alleles have been identified in an affected family member [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20489/abstract/4\">",
"     4",
"    </a>",
"    ]. Additionally, screening for population-specific mutations is feasible for individuals of Ashkenazi Jewish descent, and North African descent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20489/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/24/12681?source=see_link&amp;anchor=H39#H39\">",
"     \"Prenatal screening for genetic disease in the Ashkenazi Jewish population\", section on 'Niemann-Pick disease type A'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Prenatal testing for pregnancies at 25 percent risk of NPD-C is available using chorionic villus sampling at 10 to 12 weeks or fetal cells obtained by amniocentesis at 15 to 18 weeks. Biochemical testing can be done only when the proband has the typical biochemical phenotype. Molecular genetic testing is possible when the two disease-causing NPC1 (or NPC2) mutations have been identified in the proband, or when family studies have shown informative linked markers [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20489/abstract/24,52\">",
"     24,52",
"    </a>",
"    ]. Mutation testing allows early and fast (48 hours) prenatal diagnosis on the proband [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20489/abstract/83,84\">",
"     83,84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Carrier detection can be offered by molecular testing if the NPC1 or NPC2 gene has been identified in the proband.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3119447\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Niemann-Pick disease (NPD; also called sphingomyelin-cholesterol lipidosis) is a group of autosomal recessive disorders associated with splenomegaly, variable neurologic deficits, and the storage of sphingomyelin (",
"      <a class=\"graphic graphic_table graphicRef51071 \" href=\"UTD.htm?37/50/38700\">",
"       table 1",
"      </a>",
"      ). Niemann-Pick disease types A and B are allelic disorders caused by mutations in the SMPD1 gene, and characterized by a primary deficiency of acid sphingomyelinase activity. Type C is caused by mutations of the NPC1 and NPC2 genes that result in impaired cellular processing and transport of low-density lipoprotein (LDL) cholesterol. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Classification and clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Niemann-Pick disease type A (NPD-A) is the acute neuronopathic form. The incidence of NPD-A is highest among Ashkenazi Jews. Affected patients present with hepatosplenomegaly, feeding difficulties and loss of early motor skills in the first few months of life. Rapid, progressive, and profound loss of neurologic function leading to death occurs by two to three years of age. Additional manifestations include peripheral neuropathy, hypotonia, loss of reflexes, and interstitial lung disease. Macular cherry red spots are eventually present in all affected individuals (",
"      <a class=\"graphic graphic_picture graphicRef65650 \" href=\"UTD.htm?19/14/19680\">",
"       picture 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'NPD type A'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Niemann-Pick disease type B (NPD-B) is pan-ethnic and generally later in onset and less severe than NPD-A, with a good prognosis for survival into adulthood. Hepatosplenomegaly develops during infancy or childhood. Other systemic manifestations include short stature with delayed skeletal maturation, interstitial lung disease, hyperlipidemia, and ocular abnormalities (",
"      <a class=\"graphic graphic_picture graphicRef65650 \" href=\"UTD.htm?19/14/19680\">",
"       picture 1",
"      </a>",
"      ). The natural history is one of progressive hypersplenism and gradual deterioration of pulmonary function. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'NPD type B'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Niemann-Pick disease type C (NPD-C) can present from the perinatal period until late adulthood. Most patients with NPD-C have disease onset in middle to late childhood, typically with cerebellar symptoms, slow cognitive deterioration, vertical supranuclear gaze palsy, and progressive dystonia, dysarthria, and dysphagia. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'NPD type C'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of NPD first depends upon an appreciation of the variable phenotypic manifestations. The definitive diagnosis of NPD-A and NPD-B requires demonstration of acid sphingomyelinase deficiency. The definitive diagnosis of NPD-C requires demonstration of abnormal intracellular cholesterol trafficking by the impaired response to LDL-cholesterol loading in cultured fibroblasts. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The management of all forms of NPD is supportive. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is no treatment for NPD that is proven to modify the onset or neurologic progression of the disease, or prolong lifespan. However, limited data suggest that",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/13/24788?source=see_link\">",
"       miglustat",
"      </a>",
"      may be beneficial for some patients with NPD-C. Therefore, for children and adults with NPD-C who have mild to moderate neurologic, psychiatric, or cognitive manifestations, we suggest miglustat treatment (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H97251296\">",
"       'Miglustat'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20489/abstract/1\">",
"      Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA 1999; 281:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20489/abstract/2\">",
"      Gumbinas M, Larsen M, Mei Liu H. Peripheral neuropathy in classic Niemann-Pick disease: ultrastructure of nerves and skeletal muscles. Neurology 1975; 25:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20489/abstract/3\">",
"      Landrieu P, Sa&iuml;d G. Peripheral neuropathy in type A Niemann-Pick disease. A morphological study. Acta Neuropathol 1984; 63:66.",
"     </a>",
"    </li>",
"    <li>",
"     McGovern MM, Schuchman EH. Acid sphingomyelinase deficiency. In: GeneReviews. file://www.ncbi.nlm.nih.gov/books/NBK1370/ (Accessed on December 06, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20489/abstract/5\">",
"      McGovern MM, Aron A, Brodie SE, et al. Natural history of Type A Niemann-Pick disease: possible endpoints for therapeutic trials. Neurology 2006; 66:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20489/abstract/6\">",
"      McGovern MM, Pohl-Worgall T, Deckelbaum RJ, et al. Lipid abnormalities in children with types A and B Niemann Pick disease. J Pediatr 2004; 145:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20489/abstract/7\">",
"      Wenger DA, Kudoh T, Sattler M, et al. Niemann-Pick disease type B: prenatal diagnosis and enzymatic and chemical studies on fetal brain and liver. Am J Hum Genet 1981; 33:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20489/abstract/8\">",
"      da Veiga Pereira L, Desnick RJ, Adler DA, et al. Regional assignment of the human acid sphingomyelinase gene (SMPD1) by PCR analysis of somatic cell hybrids and in situ hybridization to 11p15.1----p15.4. Genomics 1991; 9:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20489/abstract/9\">",
"      Graber D, Salvayre R, Levade T. Accurate differentiation of neuronopathic and nonneuronopathic forms of Niemann-Pick disease by evaluation of the effective residual lysosomal sphingomyelinase activity in intact cells. J Neurochem 1994; 63:1060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20489/abstract/10\">",
"      Takahashi T, Suchi M, Desnick RJ, et al. Identification and expression of five mutations in the human acid sphingomyelinase gene causing types A and B Niemann-Pick disease. Molecular evidence for genetic heterogeneity in the neuronopathic and non-neuronopathic forms. J Biol Chem 1992; 267:12552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20489/abstract/11\">",
"      Takahashi T, Akiyama K, Tomihara M, et al. Heterogeneity of liver disorder in type B Niemann-Pick disease. Hum Pathol 1997; 28:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20489/abstract/12\">",
"      Wasserstein MP, Larkin AE, Glass RB, et al. Growth restriction in children with type B Niemann-Pick disease. J Pediatr 2003; 142:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20489/abstract/13\">",
"      Guillemot N, Troadec C, de Villemeur TB, et al. Lung disease in Niemann-Pick disease. Pediatr Pulmonol 2007; 42:1207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20489/abstract/14\">",
"      McGovern MM, Wasserstein MP, Aron A, et al. Ocular manifestations of Niemann-Pick disease type B. Ophthalmology 2004; 111:1424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20489/abstract/15\">",
"      Wasserstein MP, Desnick RJ, Schuchman EH, et al. The natural history of type B Niemann-Pick disease: results from a 10-year longitudinal study. Pediatrics 2004; 114:e672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20489/abstract/16\">",
"      Sogawa H, Horino K, Nakamura F, et al. Chronic Niemann-Pick disease with sphingomyelinase deficiency in two brothers with mental retardation. Eur J Pediatr 1978; 128:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20489/abstract/17\">",
"      Elleder M, Cihula J. Niemann-Pick disease (variation in the sphingomyelinase deficient group). Neurovisceral phenotype (A) with an abnormally protracted clinical course and variable expression of neurological symptomatology in three siblings. Eur J Pediatr 1983; 140:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20489/abstract/18\">",
"      Dubois G, Mussini JM, Auclair M, et al. Adult sphingomyelinase deficiency: report of 2 patients who initially presented with psychiatric disorders. Neurology 1990; 40:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20489/abstract/19\">",
"      Obenberger J, Seidl Z, Pavl�� H, Elleder M. MRI in an unusually protracted neuronopathic variant of acid sphingomyelinase deficiency. Neuroradiology 1999; 41:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20489/abstract/20\">",
"      Wasserstein MP, Aron A, Brodie SE, et al. Acid sphingomyelinase deficiency: prevalence and characterization of an intermediate phenotype of Niemann-Pick disease. J Pediatr 2006; 149:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20489/abstract/21\">",
"      Vanier MT, Rousson R, Garcia I, et al. Biochemical studies in Niemann-Pick disease. III. In vitro and in vivo assays of sphingomyelin degradation in cultured skin fibroblasts and amniotic fluid cells for the diagnosis of the various forms of the disease. Clin Genet 1985; 27:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20489/abstract/22\">",
"      Brady RO, Filling-Katz MR, Barton NW, Pentchev PG. Niemann-Pick disease types C and D. Neurol Clin 1989; 7:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20489/abstract/23\">",
"      Vanier MT. Phenotypic and genetic heterogeneity in Niemann-Pick disease type C: current knowledge and practical implications. Wien Klin Wochenschr 1997; 109:68.",
"     </a>",
"    </li>",
"    <li>",
"     Patterson M. Niemann-Pick disease type C. In: GeneReviews. www.ncbi.nlm.nih.gov/books/NBK1296/ (Accessed on December 06, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20489/abstract/25\">",
"      Spiegel R, Raas-Rothschild A, Reish O, et al. The clinical spectrum of fetal Niemann-Pick type C. Am J Med Genet A 2009; 149A:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20489/abstract/26\">",
"      Vanier MT. Niemann-Pick disease type C. Orphanet J Rare Dis 2010; 5:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20489/abstract/27\">",
"      Kelly DA, Portmann B, Mowat AP, et al. Niemann-Pick disease type C: diagnosis and outcome in children, with particular reference to liver disease. J Pediatr 1993; 123:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20489/abstract/28\">",
"      Bjurulf B, Spetalen S, Erichsen A, et al. Niemann-Pick disease type C2 presenting as fatal pulmonary alveolar lipoproteinosis: morphological findings in lung and nervous tissue. Med Sci Monit 2008; 14:CS71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20489/abstract/29\">",
"      Griese M, Brasch F, Aldana VR, et al. Respiratory disease in Niemann-Pick type C2 is caused by pulmonary alveolar proteinosis. Clin Genet 2010; 77:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20489/abstract/30\">",
"      Vanier MT, Wenger DA, Comly ME, et al. Niemann-Pick disease group C: clinical variability and diagnosis based on defective cholesterol esterification. A collaborative study on 70 patients. Clin Genet 1988; 33:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20489/abstract/31\">",
"      Fink JK, Filling-Katz MR, Sokol J, et al. Clinical spectrum of Niemann-Pick disease type C. Neurology 1989; 39:1040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20489/abstract/32\">",
"      Shulman LM, David NJ, Weiner WJ. Psychosis as the initial manifestation of adult-onset Niemann-Pick disease type C. Neurology 1995; 45:1739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20489/abstract/33\">",
"      Imrie J, Vijayaraghaven S, Whitehouse C, et al. Niemann-Pick disease type C in adults. J Inherit Metab Dis 2002; 25:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20489/abstract/34\">",
"      Kl&uuml;nemann HH, Elleder M, Kaminski WE, et al. Frontal lobe atrophy due to a mutation in the cholesterol binding protein HE1/NPC2. Ann Neurol 2002; 52:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20489/abstract/35\">",
"      Josephs KA, Van Gerpen MW, Van Gerpen JA. Adult onset Niemann-Pick disease type C presenting with psychosis. J Neurol Neurosurg Psychiatry 2003; 74:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20489/abstract/36\">",
"      Sullivan D, Walterfang M, Velakoulis D. Bipolar disorder and Niemann-Pick disease type C. Am J Psychiatry 2005; 162:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20489/abstract/37\">",
"      S&eacute;vin M, Lesca G, Baumann N, et al. The adult form of Niemann-Pick disease type C. Brain 2007; 130:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20489/abstract/38\">",
"      Palmeri S, Battisti C, Federico A, Guazzi GC. Hypoplasia of the corpus callosum in Niemann-Pick type C disease. Neuroradiology 1994; 36:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20489/abstract/39\">",
"      Tedeschi G, Bonavita S, Barton NW, et al. Proton magnetic resonance spectroscopic imaging in the clinical evaluation of patients with Niemann-Pick type C disease. J Neurol Neurosurg Psychiatry 1998; 65:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20489/abstract/40\">",
"      Morris JA, Zhang D, Coleman KG, et al. The genomic organization and polymorphism analysis of the human Niemann-Pick C1 gene. Biochem Biophys Res Commun 1999; 261:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20489/abstract/41\">",
"      Naureckiene S, Sleat DE, Lackland H, et al. Identification of HE1 as the second gene of Niemann-Pick C disease. Science 2000; 290:2298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20489/abstract/42\">",
"      Greer WL, Dobson MJ, Girouard GS, et al. Mutations in NPC1 highlight a conserved NPC1-specific cysteine-rich domain. Am J Hum Genet 1999; 65:1252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20489/abstract/43\">",
"      Yamamoto T, Nanba E, Ninomiya H, et al. NPC1 gene mutations in Japanese patients with Niemann-Pick disease type C. Hum Genet 1999; 105:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20489/abstract/44\">",
"      Park WD, O'Brien JF, Lundquist PA, et al. Identification of 58 novel mutations in Niemann-Pick disease type C: correlation with biochemical phenotype and importance of PTC1-like domains in NPC1. Hum Mutat 2003; 22:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20489/abstract/45\">",
"      Winsor EJ, Welch JP. Genetic and demographic aspects of Nova Scotia Niemann-Pick disease (type D). Am J Hum Genet 1978; 30:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20489/abstract/46\">",
"      Greer WL, Riddell DC, Gillan TL, et al. The Nova Scotia (type D) form of Niemann-Pick disease is caused by a G3097--&gt;T transversion in NPC1. Am J Hum Genet 1998; 63:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20489/abstract/47\">",
"      Carstea ED, Morris JA, Coleman KG, et al. Niemann-Pick C1 disease gene: homology to mediators of cholesterol homeostasis. Science 1997; 277:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20489/abstract/48\">",
"      Cruz JC, Sugii S, Yu C, Chang TY. Role of Niemann-Pick type C1 protein in intracellular trafficking of low density lipoprotein-derived cholesterol. J Biol Chem 2000; 275:4013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20489/abstract/49\">",
"      Millard EE, Srivastava K, Traub LM, et al. Niemann-pick type C1 (NPC1) overexpression alters cellular cholesterol homeostasis. J Biol Chem 2000; 275:38445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20489/abstract/50\">",
"      Davies JP, Chen FW, Ioannou YA. Transmembrane molecular pump activity of Niemann-Pick C1 protein. Science 2000; 290:2295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20489/abstract/51\">",
"      Patel SC, Suresh S, Kumar U, et al. Localization of Niemann-Pick C1 protein in astrocytes: implications for neuronal degeneration in Niemann- Pick type C disease. Proc Natl Acad Sci U S A 1999; 96:1657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20489/abstract/52\">",
"      Vanier MT. Prenatal diagnosis of Niemann-Pick diseases types A, B and C. Prenat Diagn 2002; 22:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20489/abstract/53\">",
"      van Diggelen OP, Voznyi YV, Keulemans JL, et al. A new fluorimetric enzyme assay for the diagnosis of Niemann-Pick A/B, with specificity of natural sphingomyelinase substrate. J Inherit Metab Dis 2005; 28:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20489/abstract/54\">",
"      Harzer K, Rolfs A, Bauer P, et al. Niemann-Pick disease type A and B are clinically but also enzymatically heterogeneous: pitfall in the laboratory diagnosis of sphingomyelinase deficiency associated with the mutation Q292 K. Neuropediatrics 2003; 34:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20489/abstract/55\">",
"      Schuchman EH, Miranda SR. Niemann-Pick disease: mutation update, genotype/phenotype correlations, and prospects for genetic testing. Genet Test 1997; 1:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20489/abstract/56\">",
"      Vanier MT, Ferlinz K, Rousson R, et al. Deletion of arginine (608) in acid sphingomyelinase is the prevalent mutation among Niemann-Pick disease type B patients from northern Africa. Hum Genet 1993; 92:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20489/abstract/57\">",
"      Lengyel D, Weissert M, Schmid L, Gottlob I. [Eye movement abnormalities as a sign for the diagnosis in Niemann-Pick disease type C]. Klin Monbl Augenheilkd 1999; 214:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20489/abstract/58\">",
"      Kandt RS, Emerson RG, Singer HS, et al. Cataplexy in variant forms of Niemann-Pick disease. Ann Neurol 1982; 12:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20489/abstract/59\">",
"      Wijburg FA, Sedel F, Pineda M, et al. Development of a suspicion index to aid diagnosis of Niemann-Pick disease type C. Neurology 2012; 78:1560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20489/abstract/60\">",
"      Pentchev PG, Comly ME, Kruth HS, et al. A defect in cholesterol esterification in Niemann-Pick disease (type C) patients. Proc Natl Acad Sci U S A 1985; 82:8247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20489/abstract/61\">",
"      Imrie J, Wraith JE. Isolated splenomegaly as the presenting feature of Niemann-Pick disease type C. Arch Dis Child 2001; 84:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20489/abstract/62\">",
"      Boustany RN, Kaye E, Alroy J. Ultrastructural findings in skin from patients with Niemann-Pick disease, type C. Pediatr Neurol 1990; 6:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20489/abstract/63\">",
"      Patterson MC, Di Bisceglie AM, Higgins JJ, et al. The effect of cholesterol-lowering agents on hepatic and plasma cholesterol in Niemann-Pick disease type C. Neurology 1993; 43:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20489/abstract/64\">",
"      Palmeri S, Tarugi P, Sicurelli F, et al. Lung involvement in Niemann-Pick disease type C1: improvement with bronchoalveolar lavage. Neurol Sci 2005; 26:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20489/abstract/65\">",
"      Lachmann RH, te Vruchte D, Lloyd-Evans E, et al. Treatment with miglustat reverses the lipid-trafficking defect in Niemann-Pick disease type C. Neurobiol Dis 2004; 16:654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20489/abstract/66\">",
"      Patterson MC, Vecchio D, Prady H, et al. Miglustat for treatment of Niemann-Pick C disease: a randomised controlled study. Lancet Neurol 2007; 6:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20489/abstract/67\">",
"      Di Rocco M, Dardis A, Madeo A, et al. Early miglustat therapy in infantile Niemann-Pick disease type C. Pediatr Neurol 2012; 47:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20489/abstract/68\">",
"      Pineda M, Perez-Poyato MS, O'Callaghan M, et al. Clinical experience with miglustat therapy in pediatric patients with Niemann-Pick disease type C: a case series. Mol Genet Metab 2010; 99:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20489/abstract/69\">",
"      Patterson MC, Hendriksz CJ, Walterfang M, et al. Recommendations for the diagnosis and management of Niemann-Pick disease type C: an update. Mol Genet Metab 2012; 106:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20489/abstract/70\">",
"      Miranda SR, Erlich S, Friedrich VL Jr, et al. Hematopoietic stem cell gene therapy leads to marked visceral organ improvements and a delayed onset of neurological abnormalities in the acid sphingomyelinase deficient mouse model of Niemann-Pick disease. Gene Ther 2000; 7:1768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20489/abstract/71\">",
"      Touraine JL, Raudrant D, Golfier F, et al. Reappraisal of in utero stem cell transplantation based on long-term results. Fetal Diagn Ther 2004; 19:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20489/abstract/72\">",
"      Victor S, Coulter JB, Besley GT, et al. Niemann-Pick disease: sixteen-year follow-up of allogeneic bone marrow transplantation in a type B variant. J Inherit Metab Dis 2003; 26:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20489/abstract/73\">",
"      Vellodi A, Hobbs JR, O'Donnell NM, et al. Treatment of Niemann-Pick disease type B by allogeneic bone marrow transplantation. Br Med J (Clin Res Ed) 1987; 295:1375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20489/abstract/74\">",
"      Shah AJ, Kapoor N, Crooks GM, et al. Successful hematopoietic stem cell transplantation for Niemann-Pick disease type B. Pediatrics 2005; 116:1022.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20489/abstract/75\">",
"      Suchi M, Dinur T, Desnick RJ, et al. Retroviral-mediated transfer of the human acid sphingomyelinase cDNA: correction of the metabolic defect in cultured Niemann-Pick disease cells. Proc Natl Acad Sci U S A 1992; 89:3227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20489/abstract/76\">",
"      Shihabuddin LS, Numan S, Huff MR, et al. Intracerebral transplantation of adult mouse neural progenitor cells into the Niemann-Pick-A mouse leads to a marked decrease in lysosomal storage pathology. J Neurosci 2004; 24:10642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20489/abstract/77\">",
"      Bascu&ntilde;an-Castillo EC, Erickson RP, Howison CM, et al. Tamoxifen and vitamin E treatments delay symptoms in the mouse model of Niemann-Pick C. J Appl Genet 2004; 45:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20489/abstract/78\">",
"      P&eacute;rez-Poyato MS, Pineda M. New agents and approaches to treatment in Niemann-Pick type C disease. Curr Pharm Biotechnol 2011; 12:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20489/abstract/79\">",
"      Griffin LD, Gong W, Verot L, Mellon SH. Niemann-Pick type C disease involves disrupted neurosteroidogenesis and responds to allopregnanolone. Nat Med 2004; 10:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20489/abstract/80\">",
"      Bae JS, Furuya S, Ahn SJ, et al. Neuroglial activation in Niemann-Pick Type C mice is suppressed by intracerebral transplantation of bone marrow-derived mesenchymal stem cells. Neurosci Lett 2005; 381:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20489/abstract/81\">",
"      Liscum L, Arnio E, Anthony M, et al. Identification of a pharmaceutical compound that partially corrects the Niemann-Pick C phenotype in cultured cells. J Lipid Res 2002; 43:1708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20489/abstract/82\">",
"      Wenger DA, Wharton C, Sattler M, Clark C. Niemann-Pick disease: prenatal diagnoses and studies of sphingomyelinase activities. Am J Med Genet 1978; 2:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20489/abstract/83\">",
"      Morisot C, Millat G, Coeslier A, et al. [Fatal neonatal respiratory distress in Niemann-Pick C2 and prenatal diagnosis with mutations in gene HE1/NPC2]. Arch Pediatr 2005; 12:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20489/abstract/84\">",
"      Millat G, Ba&iuml;lo N, Molinero S, et al. Niemann-Pick C disease: use of denaturing high performance liquid chromatography for the detection of NPC1 and NPC2 genetic variations and impact on management of patients and families. Mol Genet Metab 2005; 86:220.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6196 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-221.179.173.170-189A616C48-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_0_20489=[""].join("\n");
var outline_f20_0_20489=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H3119447\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLASSIFICATION AND CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      NPD type A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      NPD type B",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      NPD type C",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Genetics of NPD-C",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Diagnosis of NPD-A and NPD-B (acid sphingomyelinase deficiency)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Diagnosis of NPD-C",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Supportive care",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9862510\">",
"      - NPD-A",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9862587\">",
"      - NPD-B",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9862524\">",
"      - NPD-C",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Investigational approaches",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H97251296\">",
"      - Miglustat",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H97251303\">",
"      - Other experimental therapies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Genetic counseling",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3119447\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6196\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6196|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/57/16273\" title=\"figure 1\">",
"      Suspicion Index tool for NPD-C",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6196|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/14/19680\" title=\"picture 1\">",
"      Cherry red spot",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6196|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/50/38700\" title=\"table 1\">",
"      Genetics and clinical features NPD",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/6/7274?source=related_link\">",
"      Clinical features and diagnosis of the mucopolysaccharidoses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/11/9402?source=related_link\">",
"      Gaucher disease: Pathogenesis, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/60/4038?source=related_link\">",
"      Krabbe disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/27/42421?source=related_link\">",
"      Metachromatic leukodystrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/49/27414?source=related_link\">",
"      Neurologic manifestations of Fabry disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/24/12681?source=related_link\">",
"      Prenatal screening for genetic disease in the Ashkenazi Jewish population",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/8/28806?source=related_link\">",
"      Supranuclear disorders of gaze in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_0_20490="Clinical manifestations, diagnosis and prognosis of Crohn's disease in adults";
var content_f20_0_20490=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations, diagnosis and prognosis of Crohn's disease in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/0/20490/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/0/20490/contributors\">",
"     Mark A Peppercorn, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/0/20490/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/0/20490/contributors\">",
"     Paul Rutgeerts, MD, PhD, FRCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/0/20490/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/0/20490/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/0/20490/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H12689022\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Crohn's disease (CD) is a disorder of uncertain etiology that is characterized by transmural inflammation of the gastrointestinal tract. CD may involve the entire gastrointestinal tract from mouth to the perianal area:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Approximately 80 percent of patients have small bowel involvement, usually in the distal ileum, with one-third of patients having ileitis exclusively.",
"     </li>",
"     <li>",
"      Approximately 50 percent of patients have ileocolitis, which refers to involvement of both the ileum and colon.",
"     </li>",
"     <li>",
"      Approximately 20 percent have disease limited to the colon. In contrast to rectal involvement in patients with ulcerative colitis, one-half of CD patients with colitis have sparing of the rectum.",
"     </li>",
"     <li>",
"      Approximately one-third of patients have perianal disease.",
"     </li>",
"     <li>",
"      Approximately 5 to 15 percent have predominant involvement of the mouth or gastroduodenal area, while fewer patients have involvement of the esophagus and proximal small bowel. This topic review will discuss the clinical manifestations, diagnosis, differential diagnosis, and natural history of CD. The management of this disorder is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/54/19305?source=see_link\">",
"       \"Overview of the medical management of mild to moderate Crohn's disease in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/11/6329?source=see_link\">",
"       \"Overview of the medical management of severe or refractory Crohn's disease in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12689029\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical manifestations of Crohn's disease (CD) are more variable than those of ulcerative colitis. Patients can have symptoms for many years prior to diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20490/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Fatigue, prolonged diarrhea with abdominal pain, weight loss, and fever, with or without gross bleeding, are the hallmarks of CD [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20490/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12689036\">",
"    <span class=\"h2\">",
"     Abdominal pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Crampy abdominal pain is a common manifestation of CD, regardless of disease distribution. The transmural nature of the inflammatory process results in fibrotic strictures. These strictures often lead to repeated episodes of small bowel, or less commonly colonic, obstruction. A patient with disease limited to the distal ileum frequently presents with right lower quadrant pain. Occasionally, patients will have no clinical manifestations of CD until luminal narrowing causes constipation and early signs of obstruction with abdominal pain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12689043\">",
"    <span class=\"h2\">",
"     Diarrhea",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diarrhea is a common presentation, but often fluctuates over a long period of time. A history of prolonged diarrhea without bleeding but with other features suggestive of inflammatory bowel disease (IBD) (eg, skin, eye, or joint problems, or a family history of IBD) should suggest the diagnosis of CD. Diarrhea associated with CD may have multiple causes, including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Excessive fluid secretion and impaired fluid absorption by inflamed small or large bowel",
"     </li>",
"     <li>",
"      Bile salt malabsorption due to an inflamed or resected terminal ileum",
"     </li>",
"     <li>",
"      Steatorrhea related to loss of bile salts",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12689050\">",
"    <span class=\"h2\">",
"     Bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although stools frequently reveal the presence of microscopic levels of blood (eg, positive guaiac or immunochemical test), gross bleeding is less frequent than in ulcerative colitis. An exception to this are some patients with Crohn's colitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12689057\">",
"    <span class=\"h2\">",
"     Fistulas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transmural bowel inflammation is associated with the development of sinus tracts. Sinus tracts that penetrate the serosa can give rise to fistulas. Penetration of the bowel wall most often presents as an indolent process, and not as an acute abdomen.",
"   </p>",
"   <p>",
"    Fistulas are tracts or communications that connect two epithelial-lined organs. Common sites for fistulas connect the intestine to bladder (enterovesical), to skin (enterocutaneous), to bowel (enteroenteric), and to the vagina (enterovaginal).",
"   </p>",
"   <p>",
"    In a population-based study of patients with CD, the cumulative risk of developing a fistula was 33 and 50 percent after 10 and 20 years, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20490/abstract/5\">",
"     5",
"    </a>",
"    ]. Up to 45 percent of patients develop a fistula before diagnosis of CD [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20490/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical manifestation of the fistula depends upon the area of involvement adjacent to the diseased bowel segment.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Enteroenteric fistulas may be asymptomatic or present as a palpable mass",
"     </li>",
"     <li>",
"      Enterovesical fistulas lead to recurrent urinary tract infections, often with multiple organisms, and to pneumaturia",
"     </li>",
"     <li>",
"      Fistulas to the retroperitoneum may lead to psoas abscesses or ureteral obstruction with hydronephrosis",
"     </li>",
"     <li>",
"      Enterovaginal fistulas may present with passage of gas or feces through the vagina",
"     </li>",
"     <li>",
"      Enterocutaneous fistulas can cause bowel contents to drain to the surface of the skin",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12689064\">",
"    <span class=\"h2\">",
"     Phlegmon/abscess",
"    </span>",
"    &nbsp;&mdash;&nbsp;All sinus tracts do not lead to fistulas. Sinus tracts may present as a phlegmon, a walled off inflammatory mass without bacterial infection that may be palpable on physical examination. Ileal involvement is suggested by a mass in the right lower quadrant.",
"   </p>",
"   <p>",
"    Some sinus tracts lead to abscess formation and an acute presentation of localized peritonitis with fever, abdominal pain and tenderness. Diffuse peritonitis due to abscess perforation is a rare but recognized complication of CD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12689071\">",
"    <span class=\"h2\">",
"     Perianal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptoms and signs related to perianal disease occur in more than one-third of patients with CD and may dominate the clinical picture. These include perianal pain and drainage from large skin tags, anal fissures, perirectal abscesses, and anorectal fistulas. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/43/25273?source=see_link\">",
"     \"Perianal complications of Crohn's disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12689078\">",
"    <span class=\"h2\">",
"     Malabsorption",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bile acids are normally absorbed by specific receptors in the distal ileum. Bile salt malabsorption occurs when more than 50 to 60 cm of terminal ileum is diseased or resected. Unabsorbed bile salts enter the colon resulting in a secretory or \"bile salt\" diarrhea. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/21/38232?source=see_link\">",
"     \"Clinical features and diagnosis of malabsorption\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Increased synthesis partially compensates for the loss of bile salts. However, compensation is inadequate with disease or resection of more than 100 cm of the terminal ileum, leading to depletion of the bile salt pool and fat malabsorption. Thus:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A watery diarrhea may result related to the effects of bile acids on colonic water and electrolyte absorption.",
"     </li>",
"     <li>",
"      Steatorrhea is possible with a more severe degree of bile acid malabsorption, since the concentration of bile acids required for micelles for fat absorption is impaired.",
"     </li>",
"     <li>",
"      Steatorrhea may also result from bacterial overgrowth from small bowel strictures, enterocolonic fistulas, and extensive jejunal disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Steatorrhea can lead to severe malnutrition, clotting abnormalities, osteomalacia, and hypocalcemia, which may cause tetany.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12689085\">",
"    <span class=\"h2\">",
"     Other gastrointestinal involvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical manifestations of other sites of gastrointestinal involvement in CD are variable and infrequent. Examples include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Severe oral involvement may present with aphthous ulcers or pain in the mouth and gums.",
"     </li>",
"     <li>",
"      Esophageal involvement may present with odynophagia and dysphagia.",
"     </li>",
"     <li>",
"      Gastroduodenal CD, seen in up to 15 percent of patients, may present with upper abdominal pain and symptoms of gastric outlet obstruction [",
"      <a class=\"abstract\" href=\"UTD.htm?20/0/20490/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Gallstones may form since the reduction in the bile acid to cholesterol ratio makes bile more lithogenic and abnormalities in bilirubin metabolism predispose to pigment stones [",
"      <a class=\"abstract\" href=\"UTD.htm?20/0/20490/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12689092\">",
"    <span class=\"h2\">",
"     Systemic symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fatigue is a common feature of CD. Weight loss is often related to decreased oral intake since patients with obstructing segments of bowel feel better when they do not eat. Weight loss may also be related to malabsorption.",
"   </p>",
"   <p>",
"    Fever occurs less frequently and may be due to the inflammatory process itself or may be the result of a perforation with a complicating peribowel infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12689099\">",
"    <span class=\"h2\">",
"     Extraintestinal manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;CD and ulcerative colitis share a number of extraintestinal manifestations generally related to inflammatory disease activity (",
"    <a class=\"graphic graphic_table graphicRef81867 \" href=\"UTD.htm?27/32/28173\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20490/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These manifestations, which tend to be more frequent with colonic involvement, include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Arthritis",
"      </strong>",
"      &ndash; Primarily involving large joints in approximately 20 percent of patients without synovial destruction, arthritis is the most common extraintestinal manifestation. Central or axial arthritis, such as sacroiliitis, or ankylosing spondylitis, may also occur. An undifferentiated spondyloarthropathy or ankylosing spondylitis may be the presenting manifestation of CD. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/44/25289?source=see_link\">",
"       \"Arthritis associated with gastrointestinal disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Eye involvement",
"      </strong>",
"      &ndash; Eye manifestations in approximately 5 percent of patients include uveitis, iritis, and episcleritis (",
"      <a class=\"graphic graphic_picture graphicRef75384 graphicRef70384 \" href=\"UTD.htm?1/4/1089\">",
"       picture 1A-B",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/24/41350?source=see_link\">",
"       \"Skin and eye manifestations of inflammatory bowel disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Skin disorders",
"      </strong>",
"      &ndash; Dermatologic manifestations occur in approximately 10 percent of patients and include erythema nodosum and pyoderma gangrenosum (",
"      <a class=\"graphic graphic_picture graphicRef71344 graphicRef53733 graphicRef52528 \" href=\"UTD.htm?26/5/26712\">",
"       picture 2A-C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      <strong>",
"       Primary sclerosing cholangitis",
"      </strong>",
"      &ndash; This typically presents in approximately 5 percent of patients with an elevation in the serum alkaline phosphatase or gamma glutamyl transpeptidase (GGT) concentration. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/63/22521?source=see_link\">",
"       \"Clinical manifestations and diagnosis of primary sclerosing cholangitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Secondary amyloidosis",
"      </strong>",
"      is very rare but may lead to renal failure and other organ system involvement [",
"      <a class=\"abstract\" href=\"UTD.htm?20/0/20490/abstract/9\">",
"       9",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/14/33000?source=see_link\">",
"       \"Causes and diagnosis of secondary (AA) amyloidosis and relation to rheumatic diseases\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Venous and arterial thromboembolism",
"      </strong>",
"      resulting from hypercoagulability (",
"      <a class=\"graphic graphic_table graphicRef68675 \" href=\"UTD.htm?32/51/33595\">",
"       table 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/0/20490/abstract/10-15\">",
"       10-15",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/11/6329?source=see_link&amp;anchor=H286979610#H286979610\">",
"       \"Overview of the medical management of severe or refractory Crohn's disease in adults\", section on 'Venous thromboembolism'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Renal stones",
"      </strong>",
"      &ndash; Calcium oxalate and uric acid kidney stones can result from steatorrhea and diarrhea [",
"      <a class=\"abstract\" href=\"UTD.htm?20/0/20490/abstract/16\">",
"       16",
"      </a>",
"      ]. Uric acid stones can result from dehydration and metabolic acidosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/53/33626?source=see_link\">",
"       \"Risk factors for calcium stones in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/62/3047?source=see_link\">",
"       \"Uric acid nephrolithiasis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Bone loss and osteoporosis",
"      </strong>",
"      may result related to glucocorticoid use and impaired vitamin D and calcium absorption [",
"      <a class=\"abstract\" href=\"UTD.htm?20/0/20490/abstract/17,18\">",
"       17,18",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/54/30569?source=see_link\">",
"       \"Metabolic bone disease in inflammatory bowel disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Vitamin B12 deficiency",
"      </strong>",
"      &ndash; A clinical picture of pernicious anemia can result from severe ileal disease since vitamin B12 is absorbed in the distal 50 to 60 cm of ileum [",
"      <a class=\"abstract\" href=\"UTD.htm?20/0/20490/abstract/19\">",
"       19",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/0/5130?source=see_link\">",
"       \"Diagnosis and treatment of vitamin B12 and folate deficiency\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Pulmonary involvement",
"      </strong>",
"      &ndash; Pulmonary manifestations of inflammatory bowel disease include bronchiectasis, chronic bronchitis, interstitial lung disease, bronchiolitis obliterans with organizing pneumonia (BOOP), sarcoidosis, necrobiotic lung nodules, pulmonary infiltrates with eosinophilia (PIE) syndrome, serositis, and pulmonary embolism. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/22/29034?source=see_link&amp;anchor=H5621233#H5621233\">",
"       \"Pulmonary complications of inflammatory bowel disease\", section on 'Primary respiratory involvement'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12689106\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The extensive differential diagnosis associated with Crohn's disease (CD) varies with the site of involvement and the chronicity of the clinical presentation. In many patients, the early symptoms of CD are mild and nonspecific. The differential diagnosis includes irritable bowel syndrome, lactose intolerance, infectious colitis, and ulcerative colitis.",
"   </p>",
"   <p>",
"    A consistent history (right lower quadrant pain, prolonged diarrhea, bleeding, fever, and family history of IBD) and abnormal laboratory tests (anemia, iron deficiency) may lead one to suspect CD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12689113\">",
"    <span class=\"h2\">",
"     Irritable bowel syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;A diagnosis of irritable bowel syndrome (IBS) is often made initially with subsequent studies revealing the underlying diagnosis of CD. IBS is characterized by chronic abdominal pain and altered bowel habits in the absence of an organic cause. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/59/22455?source=see_link\">",
"     \"Clinical manifestations and diagnosis of irritable bowel syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12689120\">",
"    <span class=\"h2\">",
"     Lactose intolerance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intolerance to lactose-containing foods (primarily dairy products) is a common problem and the diagnosis often initially confused with CD. Clinical symptoms of lactose intolerance include diarrhea, abdominal pain, and flatulence after ingestion of milk or milk-containing products. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/32/5641?source=see_link\">",
"     \"Lactose intolerance\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12689127\">",
"    <span class=\"h2\">",
"     Infectious colitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients presenting with diarrhea (especially with acute symptoms), infections including Shigella, Salmonella, Campylobacter, E. coli 0157:H, Yersinia, parasites and amebiasis should be excluded. Clostridium difficile infection should be considered, particularly in patients recently treated with antibiotics. In immunocompromised patients, cytomegalovirus infection can mimic CD.",
"   </p>",
"   <p>",
"    One fresh stool sample for these agents should be obtained in most patients; in addition, tissue endoscopic biopsies should be analyzed for CMV in immunocompromised patients.",
"   </p>",
"   <p>",
"    In patients with primarily small bowel involvement, Yersinia can cause an acute ileitis indistinguishable clinically from acute Crohn's ileitis. Both tuberculosis and amebiasis can mimic CD of the ileum and cecum. Sexually transmitted diseases (including N. gonorrhoeae and C. trachomatis) can cause rectal lesions and perianal fistulas that resemble CD [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20490/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/44/24265?source=see_link\">",
"     \"Differential diagnosis of microbial foodborne disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/28/33224?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of giardiasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12689134\">",
"    <span class=\"h2\">",
"     Ulcerative colitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;When CD involves the colon, it must be distinguished from ulcerative colitis since both the medical and surgical therapies of these disorders can differ. Several findings suggest CD:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Involvement of the small bowel",
"     </li>",
"     <li>",
"      Sparing of the rectum",
"     </li>",
"     <li>",
"      Absence of gross bleeding",
"     </li>",
"     <li>",
"      Presence of perianal disease",
"     </li>",
"     <li>",
"      Focality of gross and microscopic lesions, the presence of granulomas, or the occurrence of fistulas",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In approximately 10 to 15 percent of patients with inflammatory bowel disease, the distinction between CD and ulcerative colitis cannot be made; such patients are referred to as having indeterminate colitis. Some patients may initially be diagnosed with ulcerative colitis or CD but it evolves with time to the opposite diagnosis. One report suggested that an evolution to a diagnosis of CD was more likely in patients initially diagnosed with ulcerative colitis who presented with non-bloody diarrhea or weight loss [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20490/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12689141\">",
"    <span class=\"h2\">",
"     Other disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the segmental nature of CD, a variety of disorders can mimic the clinical presentation. These include appendicitis, diverticulitis, diverticular colitis, ischemic colitis, and a perforating or obstructing carcinoma. Lymphoma, chronic ischemia, endometriosis, and carcinoid can all give a radiologic and clinical picture that is easily confused with CD of the small bowel.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12689148\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of Crohn's disease (CD) is usually established with endoscopic findings or imaging studies in a patient with a compatible clinical history. Physical examination may be normal or show nonspecific signs (pallor, weight loss) suggestive of CD. More specific findings include perianal skin tags, sinus tracts, and abdominal tenderness. (See",
"    <a class=\"local\" href=\"#H12689029\">",
"     'Clinical manifestations'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Presenting symptoms frequently determine the order of subsequent testing. Colonoscopy is the most appropriate initial test for patients presenting with predominant diarrhea, while imaging studies may be more appropriate for those presenting with abdominal pain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12689155\">",
"    <span class=\"h2\">",
"     Laboratory studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial blood studies for patients presenting with history and examination suggesting CD should include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Complete blood count (CBC)",
"     </li>",
"     <li>",
"      Blood chemistry including electrolytes, renal function tests, liver function tests, and blood glucose",
"     </li>",
"     <li>",
"      Erythrocyte sedimentation rate (ESR)",
"     </li>",
"     <li>",
"      C-reactive protein (CRP)",
"     </li>",
"     <li>",
"      Serum iron and vitamin B12 levels",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Routine laboratory tests may be normal or they may reveal anemia, iron deficiency, elevated white blood cell count, B12 deficiency,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    elevated erythrocyte sedimentation rate or CRP.",
"   </p>",
"   <p>",
"    If diarrhea is present, a stool specimen should be sent for culture and examination for ova and parasites.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2893457\">",
"    <span class=\"h2\">",
"     Endoscopy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12689162\">",
"    <span class=\"h3\">",
"     Colonoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Colonoscopy with intubation of the terminal ileum is used to establish the diagnosis of ileocolonic CD. Endoscopic features include focal ulcerations adjacent to areas of normal appearing mucosa along with polypoid mucosal changes that give a cobblestone appearance (",
"    <a class=\"graphic graphic_picture graphicRef74646 \" href=\"UTD.htm?20/31/20982\">",
"     picture 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14089?source=see_link&amp;anchor=H5#H5\">",
"     \"Endoscopic diagnosis of inflammatory bowel disease\", section on 'Endoscopic findings in Crohn's disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Skip areas of involvement are typical with segments of normal appearing bowel interrupted by large areas of disease. This pattern is different from the continuous involvement in ulcerative colitis. Pseudopolyps (hypertrophied masses of mucous membrane resembling polyps), as seen in ulcerative colitis, are also often present.",
"   </p>",
"   <p>",
"    The major findings on intestinal biopsy are focal ulcerations, and acute and chronic inflammation. These findings are usually confirmatory rather than diagnostic. The focality of the inflammation differs from the diffuse pattern seen typically in ulcerative colitis.",
"   </p>",
"   <p>",
"    Granulomas may be noted in up to 30 percent of patients with CD and are diagnostic of the disorder if appropriate infections are excluded (",
"    <a class=\"graphic graphic_picture graphicRef81744 \" href=\"UTD.htm?29/47/30448\">",
"     picture 4",
"    </a>",
"    ). Thus, demonstration of a granuloma is not required for establishing the diagnosis, nor does its presence confirm the diagnosis, since granulomas may be seen with other disorders including Yersinia spp., Beh&ccedil;et's disease, tuberculosis, and lymphoma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2893408\">",
"    <span class=\"h3\">",
"     Wireless capsule endoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Wireless capsule endoscopy provides another means to visualize the small bowel, and is being used increasingly for the evaluation of suspected and established small bowel Crohn&rsquo;s disease. It may detect suggestive lesions not visible by other small bowel studies (",
"    <a class=\"graphic graphic_picture graphicRef76042 \" href=\"UTD.htm?18/60/19406\">",
"     picture 5",
"    </a>",
"    ). It should not be performed in patients with a suspected intestinal stricture since the capsule may not be able to pass through the stricture, thus requiring surgical removal. It has the advantage of providing visualization of the small bowel without exposing the patient to ionizing radiation. Capsule endoscopy after a negative ileocolonoscopy and negative CT enterography or small bowel follow through (SBFT) has not been demonstrated to be a cost-effective third test [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20490/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17178?source=see_link\">",
"     \"Wireless video capsule endoscopy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12689169\">",
"    <span class=\"h2\">",
"     Imaging studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Imaging studies are most useful to evaluate the upper gastrointestinal tract and allow documentation of the length and location of strictures in areas not accessible by colonoscopy. Imaging has traditionally involved",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    studies, such as barium enema or upper gastrointestinal series with small bowel follow through (SBFT), though the use of computed tomography (CT) and magnetic resonance imaging (MRI) is becoming more common.",
"   </p>",
"   <p>",
"    Many examinations (eg, x-rays,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    enemas, CT scans, and fluoroscopy) expose patients to ionizing radiation, which is associated with an increased risk of malignancy. In one study, the radiation exposure from radiographic studies over a five-year period was assessed in 371 patients with Crohn&rsquo;s disease [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20490/abstract/22\">",
"     22",
"    </a>",
"    ]. The mean cumulative radiation exposure over five years was 14 milli-Sieverts (mSv), with a range of 0 to 303 mSv. The median cumulative radiation exposure was lower, at 3 mSv. While the majority of patients had a cumulative exposure of less than 50 mSv (a cutoff used by some investigators to identify patients at high risk of complications from radiation exposure), 27 patients (7 percent) had a cumulative exposure of more than 50 mSv. The risks associated with radiation exposure have led some investigators to advocate for the judicious use of studies that employ ionizing radiation, especially in children and young adults, and prompted the development of contrast enhanced ultrasound to assess disease activity [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20490/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/17/21785?source=see_link\">",
"     \"Radiation-related risks of imaging studies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12689176\">",
"    <span class=\"h3\">",
"     Colonic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Colonoscopy is the preferred study for evaluation of the lower bowel.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     Barium",
"    </a>",
"    enema is a less desirable alternative, but may be indicated when a complete colonoscopy cannot be performed for technical reasons.",
"   </p>",
"   <p>",
"    Air-contrast",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    enema may not detect early subtle changes of CD, but may detect aphthous lesions, and can document the extent of disease and the distribution and severity of early colonic strictures. Sacculations may be seen in patients with chronic involvement (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef52610 graphicRef75400 \" href=\"UTD.htm?6/37/6738\">",
"     image 1A-B",
"    </a>",
"    ). It may also reveal small perforations with fistula tracts.",
"   </p>",
"   <p>",
"    MRI can be used for the detection of perianal fistulas (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef72435 \" href=\"UTD.htm?38/33/39442\">",
"     image 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef50476 \" href=\"UTD.htm?42/9/43154\">",
"     image 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/43/25273?source=see_link\">",
"     \"Perianal complications of Crohn's disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/25/39319?source=see_link&amp;anchor=H4#H4\">",
"     \"The role of imaging tests in the evaluation of anal abscesses and fistulas\", section on 'Magnetic resonance imaging'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12689183\">",
"    <span class=\"h3\">",
"     Small bowel disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiologic imaging is generally needed to evaluate patients with probable small bowel disease. Several imaging modalities are available, including conventional upper gastrointestinal series with SBFT, CT and CT enterography, enteroclysis, and MRI and MR enterography. While CT enterography and MR enterography are being done more frequently, in general, the initial study remains the conventional upper gastrointestinal series with SBFT.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Upper gastrointestinal series with SBFT involves ingestion of a",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"       barium",
"      </a>",
"      solution with subsequent radiologic imaging of the small intestine. Typical features of small bowel CD include narrowing of the lumen with nodularity and ulceration, a \"string\" sign when luminal narrowing becomes more advanced or with severe spasm, a cobblestone appearance, fistulas and abscess formation, and separation of bowel loops, a manifestation of transmural inflammation with bowel wall thickening (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef67391 graphicRef50309 graphicRef80832 graphicRef81129 graphicRef57661 graphicRef53956 graphicRef72882 \" href=\"UTD.htm?35/25/36250\">",
"       image 4A-G",
"      </a>",
"      ). Antral narrowing and segmental stricturing of the duodenum are suggestive of gastroduodenal CD (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef77013 graphicRef78617 graphicRef81537 \" href=\"UTD.htm?21/19/21815\">",
"       image 5A-C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Standard CT (with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"       barium",
"      </a>",
"      solution) and CT enterography are useful for evaluating the small bowel, as well as extraintestinal complications, such as intraabdominal abscesses [",
"      <a class=\"abstract\" href=\"UTD.htm?20/0/20490/abstract/24\">",
"       24",
"      </a>",
"      ]. CT enterography involves ingestion of a neutral contrast agent to distend the small bowel, followed by CT imaging of the abdomen. Neutral contrast allows for better evaluation of the wall of the small bowel, which is difficult to see when standard barium solutions are used. CT enterography is a cost-effective alternative in patients with a high pretest likelihood of CD [",
"      <a class=\"abstract\" href=\"UTD.htm?20/0/20490/abstract/9\">",
"       9",
"      </a>",
"      ]. CT enterography should be considered as the central study of the small bowel if there is a clinical concern about an associated abscess (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef72882 \" href=\"UTD.htm?24/11/24753\">",
"       image 4G",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      MRI is another option for visualization of the small bowel and identification of extraluminal findings and complications [",
"      <a class=\"abstract\" href=\"UTD.htm?20/0/20490/abstract/25-27\">",
"       25-27",
"      </a>",
"      ]. Increasing mural thickness, high mural signal intensity (possibly reflecting edema), and a layered pattern of enhancement reflect histologic features of acute small bowel inflammation on MRI imaging [",
"      <a class=\"abstract\" href=\"UTD.htm?20/0/20490/abstract/28\">",
"       28",
"      </a>",
"      ]. Magnetic resonance (MR) enterography like CT enterography, uses neutral contrast for better evaluation of the wall of the small bowel and has high accuracy in the detection of inflammation associated with Crohn&rsquo;s disease [",
"      <a class=\"abstract\" href=\"UTD.htm?20/0/20490/abstract/29,30\">",
"       29,30",
"      </a>",
"      ]. In one study, 44 consecutive patients with ileal or ileocolonic Crohn&rsquo;s disease underwent MR enterography, CT enterography, and ileocolonoscopy for measurement of disease activity and detection of Crohn&rsquo;s related complications [",
"      <a class=\"abstract\" href=\"UTD.htm?20/0/20490/abstract/29\">",
"       29",
"      </a>",
"      ]. Both CT and MR enterography demonstrated similar accuracy for disease location, wall thickening and enhancement, enlarged nodes, and involvement of perivisceral fat, but MR enterography demonstrated higher accuracy in the detection of strictures (0.95 versus 0.91). In per-segment analysis, as compared to CT enterography, MR enterography was significantly more accurate in the detection of ileal wall enhancement (0.88 versus 0.81). MRI also has the advantage of avoiding radiation exposure. However, because of the high cost of MRI and MR enterography as well as limited availability, it is used less frequently than CT or conventional imaging to diagnose CD.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12689190\">",
"    <span class=\"h2\">",
"     Serologic markers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disease markers to aid in the diagnosis of CD or indicate its severity have been described; however, their accuracy and predictive value remain to be determined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12689197\">",
"    <span class=\"h3\">",
"     Antibody tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of autoantibodies have been detected in patients with inflammatory bowel disease. Antibody tests have shown promise in distinguishing CD from ulcerative colitis and in predicting the disease course of inflammatory bowel disease in some reports [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20490/abstract/31-34\">",
"     31-34",
"    </a>",
"    ]. However, prospective longitudinal studies are needed to clarify whether these markers have real predictive value and should lead to aggressive therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20490/abstract/35-37\">",
"     35-37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Antineutrophil cytoplasmic antibodies (pANCA) and anti-Saccharomyces cerevisiae antibodies (ASCA)",
"      </strong>",
"      &ndash; pANCA and ASCA have been proposed as a means for diagnosing IBD and distinguishing CD from ulcerative colitis. One study included 582 adult patients with established diagnoses (407 with CD, 147 with ulcerative colitis, and 28 with indeterminate colitis) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/0/20490/abstract/38\">",
"       38",
"      </a>",
"      ]. The sensitivity of the antibody tests alone or in combination was in the range of 40 to 60 percent, and the specificity was greater than 90 percent for distinguishing patients with IBD from controls. Specificity was slightly less for distinguishing ulcerative colitis from CD (",
"      <a class=\"graphic graphic_table graphicRef79477 \" href=\"UTD.htm?18/43/19132\">",
"       table 3",
"      </a>",
"      ). Similar results have been described in several other reports [",
"      <a class=\"abstract\" href=\"UTD.htm?20/0/20490/abstract/39,40\">",
"       39,40",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The accuracy of these tests for categorizing patients with indeterminate colitis (the setting in which they are most likely to be needed) is uncertain [",
"      <a class=\"abstract\" href=\"UTD.htm?20/0/20490/abstract/38,41-43\">",
"       38,41-43",
"      </a>",
"      ]. One of the largest prospective studies to address this issue focused on 97 adults who underwent antibody testing and then were followed clinically [",
"      <a class=\"abstract\" href=\"UTD.htm?20/0/20490/abstract/43\">",
"       43",
"      </a>",
"      ]. A diagnosis of ulcerative colitis or CD was established in 31 patients (32 percent). ASCA",
"      <span class=\"nowrap\">",
"       +/pANCA",
"      </span>",
"      - correlated with CD in 8 of 10 patients, while ASCA",
"      <span class=\"nowrap\">",
"       -/pANCA",
"      </span>",
"      + correlated with UC in 7 of 11 patients.",
"      <br/>",
"      <br/>",
"      ASCA were present in 50 percent of patients with celiac disease in one report, suggesting that they may reflect a nonspecific immune response in the course of small bowel disease [",
"      <a class=\"abstract\" href=\"UTD.htm?20/0/20490/abstract/44\">",
"       44",
"      </a>",
"      ]. It has also been described in association with cystic fibrosis [",
"      <a class=\"abstract\" href=\"UTD.htm?20/0/20490/abstract/45\">",
"       45",
"      </a>",
"      ] and intestinal tuberculosis [",
"      <a class=\"abstract\" href=\"UTD.htm?20/0/20490/abstract/46\">",
"       46",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Anti-OmpC antibody",
"      </strong>",
"      &ndash; The anti-OmpC antibody has been identified as a potential serologic marker of IBD [",
"      <a class=\"abstract\" href=\"UTD.htm?20/0/20490/abstract/35,47,48\">",
"       35,47,48",
"      </a>",
"      ]. The OmpC is an outer membrane porin, E. coli protein that is immunoreactive to pANCA monoclonal antibodies [",
"      <a class=\"abstract\" href=\"UTD.htm?20/0/20490/abstract/49\">",
"       49",
"      </a>",
"      ]. Anti-OmpC antibodies were present in 46 percent of 303 adults with CD in one study [",
"      <a class=\"abstract\" href=\"UTD.htm?20/0/20490/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Additional antibody tests continue to be developed, including antibodies against laminaribioside, chitobioside, or mannan [",
"      <a class=\"abstract\" href=\"UTD.htm?20/0/20490/abstract/50\">",
"       50",
"      </a>",
"      ], and CBir1 flagellin [",
"      <a class=\"abstract\" href=\"UTD.htm?20/0/20490/abstract/51\">",
"       51",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although commercially available, the accuracy and predictive value of antibody tests for the diagnosis of IBD and the disease course and severity continue to be elucidated [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20490/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. Furthermore, the prevalence of these antibodies in patients with a variety of inflammatory diseases affecting the gut has not been well studied. Thus, antibody tests should only be used as an adjunct to conventional testing and clinical diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12689204\">",
"    <span class=\"h3\">",
"     C-reactive protein",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elevated levels of C-reactive protein (CRP) have been observed in patients with inflammatory bowel disease and are generally higher in CD than in ulcerative colitis. CRP determination may have a role in distinguishing between these diseases, as well as in differentiating patients with IBD from those with symptoms caused by other disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20490/abstract/54-58\">",
"     54-58",
"    </a>",
"    ]. Levels of CRP are reported to correlate with CD activity [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20490/abstract/59-61\">",
"     59-61",
"    </a>",
"    ]. Some studies have suggested that increased CRP levels predict the risk of relapse in patients with CD [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20490/abstract/62,63\">",
"     62,63",
"    </a>",
"    ], but discordant results have also been published [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20490/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It has been suggested that CRP may help in prediction of the outcome and risk of surgery and in identification of patients who are likely to benefit most from specific treatments [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20490/abstract/65,66\">",
"     65,66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CRP levels are often used in clinical trials of therapy in IBD. One study, however, found that CRP levels correlated with endoscopic but not clinical disease activity [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20490/abstract/67\">",
"     67",
"    </a>",
"    ]. Furthermore, CRP levels varied significantly based upon the presence of certain genetic polymorphisms.",
"   </p>",
"   <p>",
"    The use of CRP for the above indications has not been sufficiently validated for routine clinical application.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9948756\">",
"    <span class=\"h2\">",
"     Stool markers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Testing for fecal calprotectin may help identify patients with intestinal inflammation, though it is not routinely done in clinical practice. In a meta-analysis that included six studies with 670 adult patients, the presence of fecal calprotectin was 93 percent sensitive and 96 percent specific for identifying patients with inflammatory bowel disease [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20490/abstract/68\">",
"     68",
"    </a>",
"    ], using ileocolonoscopy with histology as the reference standard.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12689218\">",
"    <span class=\"h1\">",
"     CANCER RISK",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies conflict regarding the risk of colon cancer in patients with longstanding Crohn's colitis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20490/abstract/69-72\">",
"     69-72",
"    </a>",
"    ]. This is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/7/25722?source=see_link&amp;anchor=H8#H8\">",
"     \"Colorectal cancer surveillance in inflammatory bowel disease\", section on 'Crohn's disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Increases in incidence of squamous cell carcinoma of the anus and skin, duodenal neoplasia, testicular cancer, and miscellaneous other cancers have all been reported in Crohn's disease (CD), although the strength of these associations is unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20490/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients receiving thiopurines for inflammatory bowel disease have an increased risk of developing lymphoproliferative disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20490/abstract/74\">",
"     74",
"    </a>",
"    ]. Analyses of lymphoma risk in patients receiving biologic agents directed against tumor necrosis factor (TNF)-alpha are confounded by concomitant use of immunosuppressive agents in most of these patients. It is unclear whether exposure to both an immunomodulator and an anti-TNF agent increases the risk of non-Hodgkin lymphoma relative to those treated with immunomodulators alone [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20490/abstract/75,76\">",
"     75,76",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/31/7673?source=see_link\">",
"     \"Immunomodulator therapy in Crohn's disease\"",
"    </a>",
"    .) However, one type of lymphoma, the hepatosplenic T-cell lymphoma, seems to occur mainly in young male patients receiving a combination of anti-TNF and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20490/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12689225\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The typical course in patients with Crohn's disease (CD) involving the small",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    large intestine is one of intermittent exacerbation of symptoms followed by periods of remission.",
"   </p>",
"   <p>",
"    Approximately 10 to 20 percent of patients experience a prolonged remission after initial presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20490/abstract/77,78\">",
"     77,78",
"    </a>",
"    ]. Another study found that 53 percent of patients developed stricturing or penetrating disease at 10 years follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20490/abstract/78\">",
"     78",
"    </a>",
"    ]. Predictors of a severe course include age less than 40, the presence of perianal or rectal disease, smoking, low education level, and initial requirement for glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20490/abstract/79,80\">",
"     79,80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a study of 306 patients (45 percent with ileal disease, 32 percent with colonic disease, and 19 percent with ileocolonic disease), 81 percent had",
"    <span class=\"nowrap\">",
"     nonstricturing/nonpenetrating",
"    </span>",
"    disease at baseline [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20490/abstract/81\">",
"     81",
"    </a>",
"    ]. The cumulative risk of developing either complication at 90 days was 19 percent, at one year was 22 percent, at five years was 34 percent, and at 20 years was 51 percent. Factors associated with complications included disease extent at baseline. Patients with ileal disease had a 9-fold increased risk compared with those with colonic disease, and patients with ileocolonic disease had a 6-fold increased risk. In addition, use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/44/22215?source=see_link\">",
"     mesalamine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    in the first 90 days increased the risk of complications twofold. Finally, perianal disease increased the risk of complications, though the results were of borderline significance (HR 1.69, 95% CI 0.99 to 2.86).",
"   </p>",
"   <p>",
"    The following observations were made in a systematic review of the literature and guideline published by the American College of Gastroenterology [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20490/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients who are in remission for one year have an 80 percent chance of remaining in remission for the subsequent years",
"     </li>",
"     <li>",
"      Patients who have active disease within the past year have a 70 percent chance of remaining active in the forthcoming year and a 50 percent chance of being in remission within the ensuing three years",
"     </li>",
"     <li>",
"      Overall, 13 percent of patients will have a relapse-free course, while 20 percent have annual relapses, and 67 percent have a combination of years in relapse and years in remission within the first eight years after initial diagnosis",
"     </li>",
"     <li>",
"      Fewer than 5 percent will have a continuous course of active disease.",
"     </li>",
"     <li>",
"      Recurrence of perianal fistulas after medical or surgical therapy is common (59 to 82 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Many patients with CD ultimately require surgical intervention with intestinal resection because of intractability of symptoms, obstruction, or perforation. Some patients tend to follow a pattern of either recurrent obstruction or recurrent perforations; the latter group has been reported to have a more aggressive form of the disease leading to earlier postoperative recurrence and the need for more surgery. Genetic studies have suggested that there may be a molecular basis for more aggressive disease [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20490/abstract/82,83\">",
"     82,83",
"    </a>",
"    ]. However, clinically distinct disease patterns have not been observed in all studies [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20490/abstract/84,85\">",
"     84,85",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/50/4906?source=see_link\">",
"     \"Surgical management of ulcerative colitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12689232\">",
"    <span class=\"h2\">",
"     Mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies addressing whether overall life expectancy is decreased in patients with CD have produced disparate results, reflecting the heterogeneity of the disease, biases related to specific study populations, and variable lengths of follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20490/abstract/86-95\">",
"     86-95",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Estimates of the standardized mortality ratio (an approximation of the risk of death compared to the general population) from population-based studies range from no increased risk to a fivefold increased risk of death [",
"    <a class=\"abstract\" href=\"UTD.htm?20/0/20490/abstract/93,94,96,97\">",
"     93,94,96,97",
"    </a>",
"    ]. This range reflects a varying spectrum of disease severity in different populations. An interpretation of these data is that CD is associated with only a modest decrease in overall life expectancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?9/56/10115?source=see_link\">",
"       \"Patient information: Crohn's disease in adults (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?23/40/24196?source=see_link\">",
"       \"Patient information: Crohn's disease (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12689246\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Crohn's disease (CD) is a disorder of uncertain etiology characterized by transmural inflammation of the gastrointestinal tract. CD may involve the entire gastrointestinal tract from the mouth to the perianal area. (See",
"      <a class=\"local\" href=\"#H12689022\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical manifestations of CD are variable and patients can have symptoms for many years prior to diagnosis. Prolonged diarrhea with abdominal pain, with or without gross bleeding, fatigue, and weight loss are the hallmarks of CD. (See",
"      <a class=\"local\" href=\"#H12689029\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients can present with symptoms secondary to the transmural involvement of the bowel, including fistulas, phlegmon, abscess, perianal disease,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      malabsorption. Extraintestinal manifestations, such as arthritis, eye and skin disorders, biliary tract involvement, and kidney stones may occur and tend to be more frequent with colonic involvement. (See",
"      <a class=\"local\" href=\"#H12689029\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The extensive differential diagnosis associated with CD varies with the site of involvement and the chronicity of the clinical presentation. (See",
"      <a class=\"local\" href=\"#H12689106\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of CD is established with endoscopic and imaging studies of the bowel in a patient with a compatible clinical history. Colonoscopy with intubation of the terminal ileum is used to establish the diagnosis of ileocolonic CD. Upper gastrointestinal series with small bowel follow through (SBFT) is often the initial test to evaluate the small intestine. Standard computed tomography (CT) and CT enterography should be considered as the central study of the small bowel if there is a clinical concern about an associated abscess. Wireless capsule endoscopy may also be useful for detecting small bowel involvement. (See",
"      <a class=\"local\" href=\"#H12689148\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although several serologic markers for CD are commercially available, the accuracy and predictive value of these markers for the diagnosis of CD remain to be elucidated. (See",
"      <a class=\"local\" href=\"#H12689190\">",
"       'Serologic markers'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The typical course in patients with CD involving the small",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      large intestine is one of intermittent exacerbations of symptoms followed by periods of remission. (See",
"      <a class=\"local\" href=\"#H12689225\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20490/abstract/1\">",
"      Farmer RG, Hawk WA, Turnbull RB Jr. Clinical patterns in Crohn's disease: a statistical study of 615 cases. Gastroenterology 1975; 68:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20490/abstract/2\">",
"      Pimentel M, Chang M, Chow EJ, et al. Identification of a prodromal period in Crohn's disease but not ulcerative colitis. Am J Gastroenterol 2000; 95:3458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20490/abstract/3\">",
"      Burgmann T, Clara I, Graff L, et al. The Manitoba Inflammatory Bowel Disease Cohort Study: prolonged symptoms before diagnosis--how much is irritable bowel syndrome? Clin Gastroenterol Hepatol 2006; 4:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20490/abstract/4\">",
"      Mekhjian HS, Switz DM, Melnyk CS, et al. Clinical features and natural history of Crohn's disease. Gastroenterology 1979; 77:898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20490/abstract/5\">",
"      Schwartz DA, Loftus EV Jr, Tremaine WJ, et al. The natural history of fistulizing Crohn's disease in Olmsted County, Minnesota. Gastroenterology 2002; 122:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20490/abstract/6\">",
"      Lichtenstein GR, Hanauer SB, Sandborn WJ, Practice Parameters Committee of American College of Gastroenterology. Management of Crohn's disease in adults. Am J Gastroenterol 2009; 104:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20490/abstract/7\">",
"      Annunziata ML, Caviglia R, Papparella LG, Cicala M. Upper gastrointestinal involvement of Crohn's disease: a prospective study on the role of upper endoscopy in the diagnostic work-up. Dig Dis Sci 2012; 57:1618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20490/abstract/8\">",
"      Hutchinson R, Tyrrell PN, Kumar D, et al. Pathogenesis of gall stones in Crohn's disease: an alternative explanation. Gut 1994; 35:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20490/abstract/9\">",
"      Levesque BG, Cipriano LE, Chang SL, et al. Cost effectiveness of alternative imaging strategies for the diagnosis of small-bowel Crohn's disease. Clin Gastroenterol Hepatol 2010; 8:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20490/abstract/10\">",
"      Bernstein CN, Blanchard JF, Houston DS, Wajda A. The incidence of deep venous thrombosis and pulmonary embolism among patients with inflammatory bowel disease: a population-based cohort study. Thromb Haemost 2001; 85:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20490/abstract/11\">",
"      Solem CA, Loftus EV, Tremaine WJ, Sandborn WJ. Venous thromboembolism in inflammatory bowel disease. Am J Gastroenterol 2004; 99:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20490/abstract/12\">",
"      Irving PM, Pasi KJ, Rampton DS. Thrombosis and inflammatory bowel disease. Clin Gastroenterol Hepatol 2005; 3:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20490/abstract/13\">",
"      Spina L, Saibeni S, Battaglioli T, et al. Thrombosis in inflammatory bowel diseases: role of inherited thrombophilia. Am J Gastroenterol 2005; 100:2036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20490/abstract/14\">",
"      Novacek G, Weltermann A, Sobala A, et al. Inflammatory bowel disease is a risk factor for recurrent venous thromboembolism. Gastroenterology 2010; 139:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20490/abstract/15\">",
"      Murthy SK, Nguyen GC. Venous thromboembolism in inflammatory bowel disease: an epidemiological review. Am J Gastroenterol 2011; 106:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20490/abstract/16\">",
"      Obialo CI, Clayman RV, Matts JP, et al. Pathogenesis of nephrolithiasis post-partial ileal bypass surgery: case-control study. The POSCH Group. Kidney Int 1991; 39:1249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20490/abstract/17\">",
"      Silvennoinen JA, Karttunen TJ, Niemel&auml; SE, et al. A controlled study of bone mineral density in patients with inflammatory bowel disease. Gut 1995; 37:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20490/abstract/18\">",
"      Semeao EJ, Stallings VA, Peck SN, Piccoli DA. Vertebral compression fractures in pediatric patients with Crohn's disease. Gastroenterology 1997; 112:1710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20490/abstract/19\">",
"      Headstrom PD, Rulyak SJ, Lee SD. Prevalence of and risk factors for vitamin B(12) deficiency in patients with Crohn's disease. Inflamm Bowel Dis 2008; 14:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20490/abstract/20\">",
"      Lanjouw E, van Daele PL, Raes MP, van der Meijden WI. Consecutively acquired sexually transmitted infections mimicking Crohn's disease. Am J Gastroenterol 2009; 104:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20490/abstract/21\">",
"      Melmed GY, Elashoff R, Chen GC, et al. Predicting a change in diagnosis from ulcerative colitis to Crohn's disease: a nested, case-control study. Clin Gastroenterol Hepatol 2007; 5:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20490/abstract/22\">",
"      Kroeker KI, Lam S, Birchall I, Fedorak RN. Patients with IBD are exposed to high levels of ionizing radiation through CT scan diagnostic imaging: a five-year study. J Clin Gastroenterol 2011; 45:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20490/abstract/23\">",
"      De Franco A, Di Veronica A, Armuzzi A, et al. Ileal Crohn disease: mural microvascularity quantified with contrast-enhanced US correlates with disease activity. Radiology 2012; 262:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20490/abstract/24\">",
"      Siddiki HA, Fidler JL, Fletcher JG, et al. Prospective comparison of state-of-the-art MR enterography and CT enterography in small-bowel Crohn's disease. AJR Am J Roentgenol 2009; 193:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20490/abstract/25\">",
"      Masselli G, Casciani E, Polettini E, Gualdi G. Comparison of MR enteroclysis with MR enterography and conventional enteroclysis in patients with Crohn's disease. Eur Radiol 2008; 18:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20490/abstract/26\">",
"      Lin MF, Narra V. Developing role of magnetic resonance imaging in Crohn's disease. Curr Opin Gastroenterol 2008; 24:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20490/abstract/27\">",
"      Fidler J. MR imaging of the small bowel. Radiol Clin North Am 2007; 45:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20490/abstract/28\">",
"      Punwani S, Rodriguez-Justo M, Bainbridge A, et al. Mural inflammation in Crohn disease: location-matched histologic validation of MR imaging features. Radiology 2009; 252:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20490/abstract/29\">",
"      Fiorino G, Bonifacio C, Peyrin-Biroulet L, et al. Prospective comparison of computed tomography enterography and magnetic resonance enterography for assessment of disease activity and complications in ileocolonic Crohn's disease. Inflamm Bowel Dis 2011; 17:1073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20490/abstract/30\">",
"      Friedrich C, Fajfar A, Pawlik M, et al. Magnetic resonance enterography with and without biphasic contrast agent enema compared to conventional ileocolonoscopy in patients with Crohn's disease. Inflamm Bowel Dis 2012; 18:1842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20490/abstract/31\">",
"      Dotan I. Serologic markers in inflammatory bowel disease: tools for better diagnosis and disease stratification. Expert Rev Gastroenterol Hepatol 2007; 1:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20490/abstract/32\">",
"      Murphy SJ, Kornbluth A. Serologic and genetic markers do not aid in the determination of the clinical course and severity of patients with inflammatory bowel disease. Inflamm Bowel Dis 2008; 14:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20490/abstract/33\">",
"      Devlin SM, Dubinsky MC. Determination of serologic and genetic markers aid in the determination of the clinical course and severity of patients with IBD. Inflamm Bowel Dis 2008; 14:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20490/abstract/34\">",
"      Zhang Z, Li C, Zhao X, et al. Anti-Saccharomyces cerevisiae antibodies associate with phenotypes and higher risk for surgery in Crohn's disease: a meta-analysis. Dig Dis Sci 2012; 57:2944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20490/abstract/35\">",
"      Mow WS, Vasiliauskas EA, Lin YC, et al. Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease. Gastroenterology 2004; 126:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20490/abstract/36\">",
"      Ferrante M, Henckaerts L, Joossens M, et al. New serological markers in inflammatory bowel disease are associated with complicated disease behaviour. Gut 2007; 56:1394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20490/abstract/37\">",
"      Dubinsky MC, Kugathasan S, Mei L, et al. Increased immune reactivity predicts aggressive complicating Crohn's disease in children. Clin Gastroenterol Hepatol 2008; 6:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20490/abstract/38\">",
"      Peeters M, Joossens S, Vermeire S, et al. Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease. Am J Gastroenterol 2001; 96:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20490/abstract/39\">",
"      Ruemmele FM, Targan SR, Levy G, et al. Diagnostic accuracy of serological assays in pediatric inflammatory bowel disease. Gastroenterology 1998; 115:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20490/abstract/40\">",
"      Sandborn WJ, Loftus EV, Colombel JF. Utility of perinuclear anti-neutrophil cytoplasmic antibodies (PANCA), anti-saccharomyces cerevesiae (ASCA), and anti-pancreatic antibodies (APA) as serologic markers in a population based cohort of patients with Crohn's disease (CD) and ulcerative colitis (UC) (abstract). Gastroenterology 2000; 118:A106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20490/abstract/41\">",
"      Boon N, Hanauer SB, Kiseil J. The clinical significance of pANCA and ASCA in indeterminate colitis (abstract). Gastroenterology 1999; 116:A671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20490/abstract/42\">",
"      Schwartz S, Ammirati M, Korelitz BI, Gleim GM. Identification of indeterminate colitis using PANCA and ASCA (abstract). Gastroenterology 2000; 118:A352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20490/abstract/43\">",
"      Joossens S, Reinisch W, Vermeire S, et al. The value of serologic markers in indeterminate colitis: a prospective follow-up study. Gastroenterology 2002; 122:1242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20490/abstract/44\">",
"      Granito A, Zauli D, Muratori P, et al. Anti-Saccharomyces cerevisiae and perinuclear anti-neutrophil cytoplasmic antibodies in coeliac disease before and after gluten-free diet. Aliment Pharmacol Ther 2005; 21:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20490/abstract/45\">",
"      Condino AA, Hoffenberg EJ, Accurso F, et al. Frequency of ASCA seropositivity in children with cystic fibrosis. J Pediatr Gastroenterol Nutr 2005; 41:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20490/abstract/46\">",
"      Makharia GK, Sachdev V, Gupta R, et al. Anti-Saccharomyces cerevisiae antibody does not differentiate between Crohn's disease and intestinal tuberculosis. Dig Dis Sci 2007; 52:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20490/abstract/47\">",
"      Nakamura RM, Barry M. Serologic markers in inflammatory bowel disease (IBD). MLO Med Lab Obs 2001; 33:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20490/abstract/48\">",
"      Zholudev A, Zurakowski D, Young W, et al. Serologic testing with ANCA, ASCA, and anti-OmpC in children and young adults with Crohn's disease and ulcerative colitis: diagnostic value and correlation with disease phenotype. Am J Gastroenterol 2004; 99:2235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20490/abstract/49\">",
"      Cohavy O, Bruckner D, Gordon LK, et al. Colonic bacteria express an ulcerative colitis pANCA-related protein epitope. Infect Immun 2000; 68:1542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20490/abstract/50\">",
"      Dotan I, Fishman S, Dgani Y, et al. Antibodies against laminaribioside and chitobioside are novel serologic markers in Crohn's disease. Gastroenterology 2006; 131:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20490/abstract/51\">",
"      Targan SR, Landers CJ, Yang H, et al. Antibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn's disease. Gastroenterology 2005; 128:2020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20490/abstract/52\">",
"      Kaul A, Hutfless S, Liu L, et al. Serum anti-glycan antibody biomarkers for inflammatory bowel disease diagnosis and progression: a systematic review and meta-analysis. Inflamm Bowel Dis 2012; 18:1872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20490/abstract/53\">",
"      Coukos JA, Howard LA, Weinberg JM, et al. ASCA IgG and CBir antibodies are associated with the development of Crohn's disease and fistulae following ileal pouch-anal anastomosis. Dig Dis Sci 2012; 57:1544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20490/abstract/54\">",
"      Beattie RM, Walker-Smith JA, Murch SH. Indications for investigation of chronic gastrointestinal symptoms. Arch Dis Child 1995; 73:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20490/abstract/55\">",
"      Shine B, Berghouse L, Jones JE, Landon J. C-reactive protein as an aid in the differentiation of functional and inflammatory bowel disorders. Clin Chim Acta 1985; 148:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20490/abstract/56\">",
"      Poullis AP, Zar S, Sundaram KK, et al. A new, highly sensitive assay for C-reactive protein can aid the differentiation of inflammatory bowel disorders from constipation- and diarrhoea-predominant functional bowel disorders. Eur J Gastroenterol Hepatol 2002; 14:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20490/abstract/57\">",
"      Vermeire S, Van Assche G, Rutgeerts P. C-reactive protein as a marker for inflammatory bowel disease. Inflamm Bowel Dis 2004; 10:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20490/abstract/58\">",
"      Schoepfer AM, Trummler M, Seeholzer P, et al. Discriminating IBD from IBS: comparison of the test performance of fecal markers, blood leukocytes, CRP, and IBD antibodies. Inflamm Bowel Dis 2008; 14:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20490/abstract/59\">",
"      Fagan EA, Dyck RF, Maton PN, et al. Serum levels of C-reactive protein in Crohn's disease and ulcerative colitis. Eur J Clin Invest 1982; 12:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20490/abstract/60\">",
"      Solem CA, Loftus EV, Tremaine WJ. Correlation of C-reactive protein (CRP) with clinical, radiographic, and endoscopic activity in inflammatory bowel disease (abstract). Gastroenterology 2004; 26 (Suppl):A477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20490/abstract/61\">",
"      Chamouard P, Richert Z, Meyer N, et al. Diagnostic value of C-reactive protein for predicting activity level of Crohn's disease. Clin Gastroenterol Hepatol 2006; 4:882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20490/abstract/62\">",
"      Boirivant M, Leoni M, Tariciotti D, et al. The clinical significance of serum C reactive protein levels in Crohn's disease. Results of a prospective longitudinal study. J Clin Gastroenterol 1988; 10:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20490/abstract/63\">",
"      Consigny Y, Modigliani R, Colombel JF. Biological markers of short term relapse in Crohn's disease (abstract). Gastroenterology 2001; 20:A53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20490/abstract/64\">",
"      Wright JP, Young GO, Tigler-Wybrandi N. Predictors of acute relapse of Crohn's disease. A laboratory and clinical study. Dig Dis Sci 1987; 32:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20490/abstract/65\">",
"      Travis SP, Farrant JM, Ricketts C, et al. Predicting outcome in severe ulcerative colitis. Gut 1996; 38:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20490/abstract/66\">",
"      Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997; 337:1029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20490/abstract/67\">",
"      Jones J, Loftus EV Jr, Panaccione R, et al. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease. Clin Gastroenterol Hepatol 2008; 6:1218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20490/abstract/68\">",
"      van Rheenen PF, Van de Vijver E, Fidler V. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. BMJ 2010; 341:c3369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20490/abstract/69\">",
"      Ekbom A, Helmick C, Zack M, Adami HO. Increased risk of large-bowel cancer in Crohn's disease with colonic involvement. Lancet 1990; 336:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20490/abstract/70\">",
"      Choi PM, Zelig MP. Similarity of colorectal cancer in Crohn's disease and ulcerative colitis: implications for carcinogenesis and prevention. Gut 1994; 35:950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20490/abstract/71\">",
"      Kvist N, Jacobsen O, N&oslash;rgaard P, et al. Malignancy in Crohn's disease. Scand J Gastroenterol 1986; 21:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20490/abstract/72\">",
"      Jess T, Loftus EV Jr, Velayos FS, et al. Risk of intestinal cancer in inflammatory bowel disease: a population-based study from olmsted county, Minnesota. Gastroenterology 2006; 130:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20490/abstract/73\">",
"      Hemminki K, Li X, Sundquist J, Sundquist K. Cancer risks in Crohn disease patients. Ann Oncol 2009; 20:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20490/abstract/74\">",
"      Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 2009; 374:1617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20490/abstract/75\">",
"      Kotlyar DS, Osterman MT, Diamond RH, et al. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2011; 9:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20490/abstract/76\">",
"      Kandiel A, Fraser AG, Korelitz BI, et al. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 2005; 54:1121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20490/abstract/77\">",
"      Farmer RG, Whelan G, Fazio VW. Long-term follow-up of patients with Crohn's disease. Relationship between the clinical pattern and prognosis. Gastroenterology 1985; 88:1818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20490/abstract/78\">",
"      Solberg IC, Vatn MH, H&oslash;ie O, et al. Clinical course in Crohn's disease: results of a Norwegian population-based ten-year follow-up study. Clin Gastroenterol Hepatol 2007; 5:1430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20490/abstract/79\">",
"      Beaugerie L, Seksik P, Nion-Larmurier I, et al. Predictors of Crohn's disease. Gastroenterology 2006; 130:650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20490/abstract/80\">",
"      Cosnes J, Bourrier A, Nion-Larmurier I, et al. Factors affecting outcomes in Crohn's disease over 15 years. Gut 2012; 61:1140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20490/abstract/81\">",
"      Thia KT, Sandborn WJ, Harmsen WS, et al. Risk factors associated with progression to intestinal complications of Crohn's disease in a population-based cohort. Gastroenterology 2010; 139:1147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20490/abstract/82\">",
"      Ahmad T, Armuzzi A, Bunce M, et al. The molecular classification of the clinical manifestations of Crohn's disease. Gastroenterology 2002; 122:854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20490/abstract/83\">",
"      Cuthbert AP, Fisher SA, Mirza MM, et al. The contribution of NOD2 gene mutations to the risk and site of disease in inflammatory bowel disease. Gastroenterology 2002; 122:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20490/abstract/84\">",
"      Sachar DB, Subramani K, Mauer K, et al. Patterns of postoperative recurrence in fistulizing and stenotic Crohn's disease. a retrospective cohort study of 71 patients. J Clin Gastroenterol 1996; 22:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20490/abstract/85\">",
"      Aeberhard P, Berchtold W, Riedtmann HJ, Stadelmann G. Surgical recurrence of perforating and nonperforating Crohn's disease. A study of 101 surgically treated Patients. Dis Colon Rectum 1996; 39:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20490/abstract/86\">",
"      Weedon DD, Shorter RG, Ilstrup DM, et al. Crohn's disease and cancer. N Engl J Med 1973; 289:1099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20490/abstract/87\">",
"      Prior P, Gyde S, Cooke WT, et al. Mortality in Crohn's disease. Gastroenterology 1981; 80:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20490/abstract/88\">",
"      Weterman IT, Biemond I, Pe&ntilde;a AS. Mortality and causes of death in Crohn's disease. Review of 50 years' experience in Leiden University Hospital. Gut 1990; 31:1387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20490/abstract/89\">",
"      Persson PG, Bernell O, Leijonmarck CE, et al. Survival and cause-specific mortality in inflammatory bowel disease: a population-based cohort study. Gastroenterology 1996; 110:1339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20490/abstract/90\">",
"      Loftus EV Jr, Silverstein MD, Sandborn WJ, et al. Crohn's disease in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival. Gastroenterology 1998; 114:1161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20490/abstract/91\">",
"      Palli D, Trallori G, Saieva C, et al. General and cancer specific mortality of a population based cohort of patients with inflammatory bowel disease: the Florence Study. Gut 1998; 42:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20490/abstract/92\">",
"      Ekbom A, Helmick CG, Zack M, et al. Survival and causes of death in patients with inflammatory bowel disease: a population-based study. Gastroenterology 1992; 103:954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20490/abstract/93\">",
"      Probert CS, Jayanthi V, Wicks AC, Mayberry JF. Mortality from Crohn's disease in Leicestershire, 1972-1989: an epidemiological community based study. Gut 1992; 33:1226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20490/abstract/94\">",
"      Jess T, Winther KV, Munkholm P, et al. Mortality and causes of death in Crohn's disease: follow-up of a population-based cohort in Copenhagen County, Denmark. Gastroenterology 2002; 122:1808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20490/abstract/95\">",
"      Card T, Hubbard R, Logan RF. Mortality in inflammatory bowel disease: a population-based cohort study. Gastroenterology 2003; 125:1583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20490/abstract/96\">",
"      Canavan C, Abrams KR, Mayberry JF. Meta-analysis: mortality in Crohn's disease. Aliment Pharmacol Ther 2007; 25:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/0/20490/abstract/97\">",
"      Hutfless SM, Weng X, Liu L, et al. Mortality by medication use among patients with inflammatory bowel disease, 1996-2003. Gastroenterology 2007; 133:1779.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4070 Version 20.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-210.101.131.231-3DC0084E0B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_0_20490=[""].join("\n");
var outline_f20_0_20490=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12689246\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12689022\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12689029\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12689036\">",
"      Abdominal pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12689043\">",
"      Diarrhea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12689050\">",
"      Bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12689057\">",
"      Fistulas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12689064\">",
"      Phlegmon/abscess",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12689071\">",
"      Perianal disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12689078\">",
"      Malabsorption",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12689085\">",
"      Other gastrointestinal involvement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12689092\">",
"      Systemic symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12689099\">",
"      Extraintestinal manifestations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12689106\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12689113\">",
"      Irritable bowel syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12689120\">",
"      Lactose intolerance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12689127\">",
"      Infectious colitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12689134\">",
"      Ulcerative colitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12689141\">",
"      Other disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12689148\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12689155\">",
"      Laboratory studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2893457\">",
"      Endoscopy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12689162\">",
"      - Colonoscopy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2893408\">",
"      - Wireless capsule endoscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12689169\">",
"      Imaging studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12689176\">",
"      - Colonic disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12689183\">",
"      - Small bowel disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12689190\">",
"      Serologic markers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12689197\">",
"      - Antibody tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12689204\">",
"      - C-reactive protein",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9948756\">",
"      Stool markers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12689218\">",
"      CANCER RISK",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12689225\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12689232\">",
"      Mortality",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12689246\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/4070\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/4070|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?30/19/31039\" title=\"diagnostic image 1A\">",
"      Aphthoid ulcers Crohns BE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?30/42/31406\" title=\"diagnostic image 1B\">",
"      Crohns colitis sacculation BE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?38/33/39442\" title=\"diagnostic image 2\">",
"      Axial MRI showing perianal fistulas in Crohns disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?42/9/43154\" title=\"diagnostic image 3\">",
"      Coronal MRI showing perianal fistulas in Crohns disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?39/30/40431\" title=\"diagnostic image 4A\">",
"      Crohns nodular ileum SBFT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?36/6/36974\" title=\"diagnostic image 4B\">",
"      Crohns colitis ulcers BE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?28/53/29535\" title=\"diagnostic image 4C\">",
"      Crohns string sign SBFT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?21/57/22418\" title=\"diagnostic image 4D\">",
"      Cobblestone in Crohns SBFT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?42/3/43070\" title=\"diagnostic image 4E\">",
"      Crohns fistulae UGI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?20/31/20991\" title=\"diagnostic image 4F\">",
"      Crohns abscess SBFT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?24/11/24753\" title=\"diagnostic image 4G\">",
"      Crohns abscess CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?20/13/20688\" title=\"diagnostic image 5A\">",
"      Gastroduodenal Crohns UGI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?25/13/25823\" title=\"diagnostic image 5B\">",
"      Crohns disease stomach UGI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?5/9/5264\" title=\"diagnostic image 5C\">",
"      Normal upper GI series",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/4070|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/3/33854\" title=\"picture 1A\">",
"      Anterior uveitis in a patient with IBD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/25/37278\" title=\"picture 1B\">",
"      Episcleritis IBD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/28/463\" title=\"picture 2A\">",
"      Erythema nodosum IBD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/17/39187\" title=\"picture 2B\">",
"      Pyoderma gangrenosum early",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?7/47/7920\" title=\"picture 2C\">",
"      Pyoderma gangrenosum cribriform",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/31/20982\" title=\"picture 3\">",
"      Endoscopic findings in Crohns disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/47/30448\" title=\"picture 4\">",
"      Typical granuloma of Crohns disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?18/60/19406\" title=\"picture 5\">",
"      Crohns disease capsule endoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/4070|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/32/28173\" title=\"table 1\">",
"      Extraintestinal manifest IBD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/51/33595\" title=\"table 2\">",
"      Hypercoagulability in IBD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?18/43/19132\" title=\"table 3\">",
"      ASCA pANCA dx IBD",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/44/25289?source=related_link\">",
"      Arthritis associated with gastrointestinal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/14/33000?source=related_link\">",
"      Causes and diagnosis of secondary (AA) amyloidosis and relation to rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/21/38232?source=related_link\">",
"      Clinical features and diagnosis of malabsorption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/59/22455?source=related_link\">",
"      Clinical manifestations and diagnosis of irritable bowel syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/63/22521?source=related_link\">",
"      Clinical manifestations and diagnosis of primary sclerosing cholangitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/7/25722?source=related_link\">",
"      Colorectal cancer surveillance in inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/0/5130?source=related_link\">",
"      Diagnosis and treatment of vitamin B12 and folate deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/44/24265?source=related_link\">",
"      Differential diagnosis of microbial foodborne disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14089?source=related_link\">",
"      Endoscopic diagnosis of inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/28/33224?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of giardiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/31/7673?source=related_link\">",
"      Immunomodulator therapy in Crohn's disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/32/5641?source=related_link\">",
"      Lactose intolerance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/54/30569?source=related_link\">",
"      Metabolic bone disease in inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/54/19305?source=related_link\">",
"      Overview of the medical management of mild to moderate Crohn's disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/11/6329?source=related_link\">",
"      Overview of the medical management of severe or refractory Crohn's disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?23/40/24196?source=related_link\">",
"      Patient information: Crohn's disease (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/56/10115?source=related_link\">",
"      Patient information: Crohn's disease in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/43/25273?source=related_link\">",
"      Perianal complications of Crohn's disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/22/29034?source=related_link\">",
"      Pulmonary complications of inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/17/21785?source=related_link\">",
"      Radiation-related risks of imaging studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/53/33626?source=related_link\">",
"      Risk factors for calcium stones in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/24/41350?source=related_link\">",
"      Skin and eye manifestations of inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/50/4906?source=related_link\">",
"      Surgical management of ulcerative colitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/25/39319?source=related_link\">",
"      The role of imaging tests in the evaluation of anal abscesses and fistulas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/62/3047?source=related_link\">",
"      Uric acid nephrolithiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17178?source=related_link\">",
"      Wireless video capsule endoscopy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_0_20491="ReSoMal composition";
var content_f20_0_20491=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F53739&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F53739&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Composition of oral rehydration salts solution for severely malnourished children (ReSoMal)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Component",
"       </td>",
"       <td class=\"subtitle1\">",
"        Concentration, mmol/L",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Glucose",
"       </td>",
"       <td>",
"        125",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sodium",
"       </td>",
"       <td>",
"        45",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Potassium",
"       </td>",
"       <td>",
"        40",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chloride",
"       </td>",
"       <td>",
"        70",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Citrate",
"       </td>",
"       <td>",
"        7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Magnesium",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Zinc",
"       </td>",
"       <td>",
"        0.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Copper",
"       </td>",
"       <td>",
"        0.045",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Osmolarity",
"       </td>",
"       <td>",
"        300",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Management of Severe Malnutrition: A Manual for Physicians and other Senior Health Workers. World Health Organization, Geneva, 1999. Copyright &copy; 1999 World Health Organization.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_0_20491=[""].join("\n");
var outline_f20_0_20491=null;
var title_f20_0_20492="Circumcision info sheet A";
var content_f20_0_20492=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F65954&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F65954&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Circumcision",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        What is circumcision?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        When a baby boy is born, the end of his penis is covered with a layer of skin called the foreskin. This extra skin has two main functions: to protect the end of the penis, or glans, and to provide sexual pleasure. Circumcision is a procedure that surgically removes this foreskin. Importantly, this is not required by law, nor is it medically necessary - it is a choice made by you, the parent.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        The procedure typically takes anywhere from 10 to 20 minutes, and is performed by a doctor, usually in the nursery before the child goes home after delivery.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Is it painful?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Recent studies have confirmed that babies do experience pain during this procedure, but steps can be taken to minimize this. Often an injection of anesthesia into the base of the penis is given to block the feelings of pain. Also, a sugar solution can be administered to the baby by mouth. Most importantly, you should discuss pain control with the doctor who is performing the circumcision.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        What are the benefits of circumcision?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Circumcision is often performed for religious or cultural reasons. In English speaking, Western countries, most males are circumcised. Conversely, circumcisions for non-religious reasons are rarely done in Europe, Asia, or South America. In the past, up to 90% of all males born in the United States were circumcised, but today that number has dropped to 60%. The reasons that some parents choose to have their son circumcised: they want their son to look like other males in their family, or are afraid they will be picked on for looking different. Also, circumcision has been suggested as a good way to keep the penis clean. This has not been shown to be true.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Some research has shown some medical benefits to having your son circumcised. As an example, some studies have shown a small decrease in risk of urinary infections early in life. And, while extremely rare, the risk of penile cancer is lower in circumcised males. It also may decrease the risk of sexually transmitted diseases. Occasionally a child will need a circumcision later in life because of cancer, injury or infection. Circumcisions may reduce some of these risks but fewer than 10% of uncircumcised males will need the procedure later in life.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        What are the risks of circumcision?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        All surgical procedures, including circumcision, carry risks. These include excessive bleeding, infection, problems with anesthesia, and a poor cosmetic result. Rarely there can be injury to the glans, shaft or urethra of the penis. All of these complications, however, are very rare and affect only a small number of babies.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_0_20492=[""].join("\n");
var outline_f20_0_20492=null;
var title_f20_0_20493="Lactate threshold with training";
var content_f20_0_20493=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F81861&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F81861&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lactate threshold: Effect of training",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 404px; height: 365px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    It is possible to increase the lactate threshold by performing vigorous aerobic training. In this example, the training program increased the lactate threshold from stage 3 (b) to stage 4 (a).",
"    <div class=\"footnotes\">",
"     (b): lactate threshold before a training program; (a): lactate threshold after a training program.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_0_20493=[""].join("\n");
var outline_f20_0_20493=null;
var title_f20_0_20494="OARS institutional questionnaire";
var content_f20_0_20494=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F53022&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=10\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F53022&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=10\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    OARS multidimensional functional assessment questionnaire: Institutional version",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\">",
"        Social resources",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        1. Are you single (never married), married, widowed, divorced, or separated?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1",
"       </td>",
"       <td>",
"        Single (never married)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        2",
"       </td>",
"       <td>",
"        Married",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        3",
"       </td>",
"       <td>",
"        Widowed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        4",
"       </td>",
"       <td>",
"        Divorced",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        5",
"       </td>",
"       <td>",
"        Separated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        -",
"       </td>",
"       <td>",
"        Not answered",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        (If \"2\" ask a.)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"2\">",
"        <strong>",
"         a. Does your spouse live here also?",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent3\">",
"        1",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent3\">",
"        0",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent3\">",
"        -",
"       </td>",
"       <td>",
"        Not answered",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        2. In the past year about how often did you leave here to visit your family and/or friends for weekends or holidays, or to go on shopping trips or outings?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        4",
"       </td>",
"       <td>",
"        Once a week or more",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        3",
"       </td>",
"       <td>",
"        One to three times a month",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        2",
"       </td>",
"       <td>",
"        Less than once a month or only on holidays",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1",
"       </td>",
"       <td>",
"        Never",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        -",
"       </td>",
"       <td>",
"        Not answered",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        3. How many people do you know well enough to visit with in their homes?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        3",
"       </td>",
"       <td>",
"        Five or more",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        2",
"       </td>",
"       <td>",
"        Three or four",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1",
"       </td>",
"       <td>",
"        One or two",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        0",
"       </td>",
"       <td>",
"        None",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        -",
"       </td>",
"       <td>",
"        Not answered",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        4. About how many times did you talk to someone - friends, relatives, or others - on the telephone in the past week (either you called them or they called you)? (If subject has no phone, question still applies.)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        3",
"       </td>",
"       <td>",
"        Once a day or more",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        2",
"       </td>",
"       <td>",
"        Two to six times",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1",
"       </td>",
"       <td>",
"        Not at all",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        -",
"       </td>",
"       <td>",
"        Not answered",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        5. How many times in the past week did you visit with someone, either with people who live here or people who visited you here?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        3",
"       </td>",
"       <td>",
"        Once a day or more",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        2",
"       </td>",
"       <td>",
"        Two to six times",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1",
"       </td>",
"       <td>",
"        Once",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        0",
"       </td>",
"       <td>",
"        Not at all",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        -",
"       </td>",
"       <td>",
"        Not answered",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        6. Do you have someone you can trust and confide in?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        0",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        -",
"       </td>",
"       <td>",
"        Not answered",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        7. Do you find yourself feeling lonely quite often, sometimes, or almost never?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        0",
"       </td>",
"       <td>",
"        Quite often",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1",
"       </td>",
"       <td>",
"        Sometimes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        2",
"       </td>",
"       <td>",
"        Almost never",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        -",
"       </td>",
"       <td>",
"        Not answered",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        8. Do you see your relatives and friends as often as you want to, or not?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1",
"       </td>",
"       <td>",
"        As often as wants to",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        0",
"       </td>",
"       <td>",
"        Not as often as wants to",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        -",
"       </td>",
"       <td>",
"        Not answered",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        9. Is there someone outside this place who would give you any help at all if you were sick or disabled, for example your husband/wife, a member of your family, or a friend?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        0",
"       </td>",
"       <td>",
"        No one is willing and able to help",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        -",
"       </td>",
"       <td>",
"        Not answered",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\">",
"        (If \"Yes\" ask a.",
"        <strong>",
"         and",
"        </strong>",
"        b.)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"3\">",
"        <strong>",
"         a. Is there someone outside this place who would take care of you as long as needed, or only for a short time, or only someone who would help you now and then (for example, taking you to the doctor, or fixing lunch occasionally, etc.)?",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent3\">",
"        3",
"       </td>",
"       <td colspan=\"2\">",
"        Someone who would take care of subject indefinitely (as long as needed)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent3\">",
"        2",
"       </td>",
"       <td colspan=\"2\">",
"        Someone who would take care of subject for a short time (a few weeks to six months)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent3\">",
"        1",
"       </td>",
"       <td colspan=\"2\">",
"        Someone who would help the subject now and then (taking him/her to the doctor or fixing lunch, etc)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent3\">",
"        -",
"       </td>",
"       <td colspan=\"2\">",
"        Not answered",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"3\">",
"        <strong>",
"         b. Who is this person?",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent3\" colspan=\"3\">",
"        Name:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent3\" colspan=\"3\">",
"        Relationship:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent3\" colspan=\"3\">",
"        <strong>",
"         Code:",
"        </strong>",
"        Spouse = 1, Sibling = 2, Offspring = 3, Grandchild = 4, Other kin = 5, Friend = 6, Other = 7",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Copyright &copy; 1975, 1988 Duke University, Center for the Study of Aging and Human Development. All rights reserved. May not be used for financial gain. When reporting on information gathered through this measure please acknowledge the source: Older Americans Resources and Services MFAQ. Permission for use in major studies should be obtained from the Duke Aging Center (see site address below). Further information can be obtained from the website:",
"     <a href=\"file://www.geri.duke.edu\" target=\"_blank\">",
"      file://www.geri.duke.edu",
"     </a>",
"     . Click on Services, then click on Older Americans ..., and from the manual referenced there.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_0_20494=[""].join("\n");
var outline_f20_0_20494=null;
var title_f20_0_20495="Scoliosis truncal asymmetry";
var content_f20_0_20495=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F50532&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F50532&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Truncal asymmetry in scoliosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 266px; height: 406px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGWAQoDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDlVTjP+e9PA4p+2nBa5CRgXjoKeBkYp6rS7aQiJvl+lU5pBnDZzjr6VanPy9cA8VkzPtLuTnPb2qZMqJla9cNuEbEhQM8f/rrk558lseuM4rb1d9ztJIfvcBfasMw7kbZ3OacTZRKBKsCGzn61AVwWIB6Vc+zNkgmhodikk8CtFKw7FezhNw2DyFGfSr7K8QBPU8Yz0qC0+WQOmcVfuZAYScZPpQ3cpIbG5MWFJ3Dvmm+f5UbM4z9Saba5dMqeccj3pt1H5wUDqTUNahYcdRmHly7zn+EelW4rySUS7y+7GetZqRNvCuOBjIrSgQrcELwSOPpUuKJZNbgXUUYUkMOgJ6VYjsIom8yZt0gIIAJxVW1iaNzIjZw2GWujWeH7MC0asT+dZSk0My5opb6YNM+FB7twBWRfRCK5dEOQh3KfWtq6kSWQIg2f1rF1Zm+1hSpzjHFOne4jdsXE8CSeowasBQDkVkaBLtZ4W/CtvGRVS0MupYt2C4buK6ezYPbq3f8AGuVt1y4HrXUWAxCq1UWQyfbnkEg+tG04Gck1Nt7Um2qJICvPemlanxzSbeaBlcrTGWrLAVGVpgVivtTHTirLCo2FMCqy4U49KRl+Y896nZeDn0pjY3H60XGXQvNPC8VIE4/z708LUiIlXmlIFTBKZNhSCKQzPuRubbjgHNY86fugxGCMjH41tTqxlJBrKvFAWQA4A5+tZtlROS1QeZJjsKyicPg9BVzVJX81yvQVlu+TnvWsdjoWwssucgHimzyAAIPmGKiO7J7GkiQzTIAO/NUJlqOQWwiYgfOORUV1LvUYHQ/nRfurXGwEYHy/SnSoGtI2iOWQ4P09aXW4XEsQyksmcg54NaNs0NzuinQZPzKw4wfQ1kxStC+5flHv3q2k6STI6gIP4gehpT7gacduJE8sqwkHGRyDVgWkhjDiNyVG0/KenrVm2024uFFxY/OAMkIwH860bWa5A2eZIhxh0I/r0rmlJgcbeTyW9yJYzyflIPepV1NyOMBfT0rW1az8x9sm0MR8jYwCPSuZuIXgcrIu1h+tbQamgNeC7jldQ/AJ+9TvEUTJBG6HIzw3esVC24N0+tbl9J59lHGclgASe1DVmBh2V1JFcKxOCDXb2s3nxqxHLVxKQZulVgSc9q7yxgMcSqRjAoqtGciWEbWBIroNLfecVjhCOta+jr+9xUxZkzYK9aTbVgpSbK0IKxWmlas7OaRkGKAKpWkKirJTjpTSlMCmy+lRspq4U56VGye1Aymy1C6/O3Perxj9qhdfnbjvQO5fC8Y704LxUgXmnBaQhm04461VuvlwSKv49KqXCfIfzqWUU502oV/Gue1SVVXrye1dLJkRZAy2ORXI6uNzFyQBngY61BcTl9Qx8ykY96ySvzDB6Vq6jneSf4u1Zzj5sDrWsNjdEMp5FSWBwXkI9vpSOhJGOtWo0S3iIPLGre1kIpSATTBQQGPygmlUPZzFJ1Oc8+hFRXK7JQRzmtWzZdRQWl2QsqD91J6+1JuyEXodN0/VLc/ZbhoZgOEk6ZrMm0+S1doLgYbsexqMxSW8pXcEdGwa2YrsatprRykC6gzgnqwrLVPXYZk2F7NZMUErBDxwxrTtL6SfdukbcnK89aw7kcgngkcn0NPtOHbBPTORWnJGSuB2/n2t3p4W5HUcH+61c9dlgrQTATAcqx6ge1QwSy+UUY7gOafHNypbkA4HtWcY8rBoht9PDnzEYFQcFWPNaKRh4jGV+bp14ouQIo1uIP8AVn73samtAuY0U5LHOaTfUCtotgxuDI4+WNsV2Kxjrn8Kis7ZUjGAPm5q8IxnNQ5XMJy1I0jyQMVq6Wm2fkVThQBxmte2jAkXbTiQaRFJtqZFBFOCVqIrlRSFOKnZfSm43LkHIoAgK00pmrG3IpNoFAFVk9qYye1WitMK0DKbpwc1A6fO31q+yjmoHA3t9aYi1jn/AD70oHNP2/5/OlC0MBmKinQtnPYVaC5OKilXk4NQUZc+NrLnBArl9XjDTyccRrn8a6qRdpcMPmfjPpXMeIWRLqRUOSy8/lUlxOIvmLEv79KpuwOxh3q0/wC8MqHtVIED9337VpE3Q8sAxPbtUMjsSw9elNQMQ6MM80qA7AAeBWlxPcgZST15qwdwjUDICcgj1qURZIb+E1dlt9tqxA56/hScirGeLkysGlGX6E+vvUls3lXXmJwaVLVnKsoyMUvkskoyOvNJtPQLD7qHexZPuk7j+NV4wUbZ3Hf2rTsHBlKSAelK1oFu9rHIJxmoU7aCZTtrgLOVznJx+FWp4TF5h6fxCsq4iNteSgHIVuK2LedJ7OTd1Vc5qpLRMFsTaRchspIA0MoIIPY1aihNnKFcbgDmNvUGsHTZHSQK3+8prrrCWO6jiEi5CtyPQ+1ZT0EdDbIPLQ46qKnCcc1WtblGujbKS0ijJOOAKvbazOWW5GBgg4ra04hyCaygtXbFzGRTixG4g+YipMetMt23jNT7a1vcZEVFM244A4qwV4ppWgZDtpjLVjbTCtAEBWmFeeasFTmmleeaoCsyg5qu6fO31q6VqFo2LEgcGgCbHH+felC05Rx/n3p4FAEe2myA8YAOanAxUMgK4yCR1qQKVwoEjE8AKT7V5vq9wZruaTPDfKv0Fd/rokktOBsVjjHc15lrL5lYJjCipW5rTWpmja9wQCAap6rbtFMJVBwRziqsszK5I4J5rXsZFvo/KZtrY6GtPh1NjLgP75sYy4zzTo2Ec2HAKHvRcWslrOyOCCrd6uC0M8e4EdORV3QkS26K0gCnKk8CtB4N1tIn8aHcP9oelZVorxy7DwR+FWBeva3yljvXPNS0UT6UAwIbqpyR7U2a3zMjLyDkfhmorW48rUGK42kEH8atXDFIA5/gYCkwM7JttUeInjqKuXLY8th1DA1W8QLt1GGVRjfGDn1qYsJLSMn72cYpTjZXAz9UXzpSyjneAaWHMVvIBxkfpU7mMX/zcAkEj0wKjutpXIJGF6VSbehBVt3BZOc4PNdNYt5c22M8OOme9crD2I6nr7VsWMx8xCT0IApVVoI7rSo3EoLoqsRjI/iraRcgGqlkqva2koGWLYP0rcihCnA5wTXMZTjcoBPY/lUiKwbhTx7VtWyLkcCtCNFBJIX8qERymZaSBVAYgVoK6kdRUklvHJwyD8Bism8tZLclomJjHOPStE7BaxqgZ6U0rzWTa3zqRvORWvE4lQFT+FNSAaV4ppXipscU0jimBARxTCtWCtMIpgV2U01V+UVMwoUHaOaAGAf5/OngUq4/z9acAKAEApHUMDmpVHFLgcZpAYevYSweQ/dTBPtzXlN1bPLaS3W3gg4U9RXqvjI7NCnIXO9ghHtuFcZJZNC0lq/IdG2nHc4/nx+VC3NIHmMykjLfhT4XeORWTg46itV9NYbuD7ZFPt9MI3GUAbRux7Vtzq1jaIl3dG6t1kkQ71+Uk0afexRErJhQR371cvoootPfYyn5hkfhXOxqJWYDt0z3pRV9CjUvZo/MDwE47g1UunWVAy8etRB1RGDrhsURruhJwR6U7WAkhctKr/xYCn3rcuAXtbgHgh1A/HFZmlQbrkO/QfMR9Oavq5mkiiPAMhlb+gqWIp63J5ktqp6xx7KWAEW6ccg5pgie71RkHIB2j8605rcRW87/AMKLs/pmlN6WGYlj++u2Ljq23PpUurEW5wO52D6etT2No6sqAZPA/Op9d0K8S3Se4U4J2jHammuZEtaGHEcPt9ea0rbKgH34rNWMqVY+laFhIWUBhxnrRUelyYnp/h87YSknRSGGfTaTXXaciy2yuQDvGc1yeiJFI8vl3sZXAUrKMc4rci1O3hiEIRZpEGMwNuC/QCvMk5XuaciZfT5WYqOhxTprny0ZycADNVLG9tzanyS+4kswlBGT3P5VB5c1/bRys8AgMhwAckitYTMp02tje0y4NzbCVxye1TSgPwcFTwRWRPfw2kQG8Iq8DBqa2vJprcP5ZjQ9GPetovuZszriMRysi9AeKtaZKVm2seD0p2px+VMvOSygmqkTFJVb0NGzM3udFimkc0+Mho1I9KQ9a0GRsKjIqZhUbCgCJhSKvyj6U4jmlUfKKYDAP8/jThgEA9TQo/z+NPA6ZFACjGKXFAHFPRT+FICjq+n/ANo6bPaA4ZxlD6MOR+oFclNIl1YOlyoS6VVjdDwySpxn6MM13pBxkDPeuR8Xva3E32cQpLdgDMinaVz05HWgqOuiPPfE9qbJiYLlJE7AdRWTcakLi1jCkAquxitdidEUX6JPEWZk6M+4A9z+VY/iPQ4opFFoweRjgqowAKalFbnWqbS1OR84sSD0A5ye9RPbzCMTIpG4V0Vj4XuX+acEDOcV0NvozBArgMPcVbqpbCscFBD5x3XJ+UDpVuNBOVjiUrEv6V2l74WS7hHkkRyj16NWdbeENTVyuYVH94NU+1TAxpTHbIVh5yMEjrmo1Jgt2diTIwwPaujufC91ZQ+fLbfbNvJSN+n4d65qeS5nnO6MRrnARR0+tNSTGXdAgI3k/fI+ZvQetX9QwYIYI/vyOGOBnIHQe9UreVbeEqcrzknpn2rU0a8sYjJc3UTzXCH5ADwoHTFRa8gH+G0jeWSO6Rd75Yq/GMdvrWx42ItdIKcKjFTGM5J5HWuak1Rby+nnkH7yRseWBgbRznP96tHWFuNYs7Zo5keG3XYqMcMPc+p7VGz1EcTMDlR1IHT8a6vwrpSO1v8AaEO0uHcEdvSo9H8NTXVyF2s7Z57AfjXp/h3w7FYv5kmZJQPwFFWelkKxpaPoFgtoDPaIWf5iM42+38q0oNOgthi3VUXuABVtCR09OakG09+a42mMozWsUqFZYonUjoy8VmXulRNFsiL2/HWE4H4rXQMntUE0YIqRanG22g+Vf+fPcG4UDID9jWjJMJLpY92dpyfb2q7cqYmyORUB2MQ4A3d+K0jV6MzcbkF/L505/wBkYqr0p7ZMzE9zQRzW6kc73NW1nBjCk1bBBPBrAVynP6VftrgE4Jq1IZoMKiapQdwpjirGQnrQo+UU4jmgA4FMQwdR/nvTx7U0Y/z9TTwvNADlUn6VctIDM53H5B+tVl4FT3WoRWdpwQR0z6n0pbasa8jJ8XXslrbwiD93G8mxivXiuPuPtVxeRz2qRx46hhk/jW/cNLqEgab/AFS/dX096nitlHQVhObk9DrptwWxzg0ee6uFnuJW8wD+E4FaUOioDnAya3YYh0wKsrHgVNxuUmYyaYgzxT/7OGOn6VtKgx05qRY80XEc81iUYEU4Wx5JHFb0sAxzUHk9cVNxmSYmVeOnpWZqGg2V7Jvlt1D4+8vHP4V1TQ/L0qJ4BnOKpTa0A4ifwvbRIfKg82MjJXPzqfUZ4rFt/C73Fy21JUiB6txXpTRYPHBpdpAx1FUpO24HJ2/gewIUmeZT/EF4z+Nbdh4d0yzGIbUF/wC/JyTWtGnHSpdnFCk+oEFvapCcRoqZ7AVowoQpJ602Fc5OOtW0UAc1LERqSPpT1bmh/TFRZ+aoYFpDnrTXXOe1NiapWxipAy7xPlweRWIZNkhGMV0F4Pl4rmNSyshNZNEMkkYbgexobjFUDMGjHt3q1bSeZFg/eFb05dGY1I9UPPWlDbeaKStTE1rCbemDVpuax7OXZJgnANbHVRitIspETDmlUfKPpSng0L90VoMjX/P5mpFFNA/z+NTRIzuFA5oYCqpIdv4UBLH0GOa5ySY3lyXGRCpwi+3r9a6LxNJ9j0VoogAznbnuK5yyUBQB7VnVdlY2pRu7mhbx4XpU4B6UyM4NP3ZOKwNiWEYqwAMCqyMO9WVw+0n7w6UhkirmplXApq4yakUcUwGP0qMDrmpnGFNRd8UmAuABzTXTPQU/aDyRkjoaXenmeXuG/GdvegCs0J60wwnvV8JQycUAUFiwQKlSL1qdk7ilIxjFADIwM8VPUYGDUgoARqrsetWGqBxTASN8dan8zABqqDjmnPINtFgEuTkE1zmqKG3GteabqDWZdKGQ4HOKzcSGcxFcYnkizyOcVo2shTa2e/Nc3qcn2TxBEc4SVcVvooAK+pqraCtc1zzz7ZFNNR2khkgyeqnFS1aZytWY3OOR1FbVpJ5kCk9axT1q9pTkMUPStIsRotyaFA2ig9cUi9BWyKEX/P51paeqJG87MMgZPtWanQf57mpVOAQCcHigZmeK5jJFCW/imI/DFZ9qcEVN4rk/48l9Wdv5f41WtW4rKpudNPY00bnNP5B4qFDwKk3DFZSNCeM8Y71ai4FUY29KtxNUAW0zUw6c1XRuKnTkYpgKw4qMrzU5HGKYRSYDQPenhRuLkDeRgnFJjmnY4oAcOlGKBSmmAmBTQOuacKD0pCGNjPFKBSd6eBxTAjao+w9amIPpxUbCmBC6ggg9DUbDHC1MRTWWqGZ04H41VkGelaM0ZPI4NUplwDu5qJESOB8dwFVtrhRyjEH+lXtLuBcWMT9WA2n61a8XQ+fpVwAPugMv4VzfhG6JWWBjwfnWnutBROt099s0iH+LpV496xd/lzxuD0PNbJbIyOh5FOJz1I2dxG6HFTWT7Lhc9CMVATQjBXBq0Zo6I9aaOgpsTbo1OeTTh0FbIsRf8/nTweKjX/P51IAcU2Bz3io/6XYL6I5/lUVsMAVL4pH+m2R7FH/mKbbYNYTOql8JejIxTJZADSrxjFU9TcpGCPWs2aF2GQ5q7C/rWTbSZQHPWr0bcVIGnG2RxVqI8VnW79OavxHIFMRZXpzSNinA8UxqLABpc000q1Ix1GKWgGmIXtSUpPFIaYhMc0o6UL1p3FMBppjKac1NzVARsOajOM1K/Wq8gI5FSAyTAqnN1PFWnb86pzHGaTEYGtputZVz1Q15zoMnkapFk8ZKmvR9WJ8l/wDdNeXQv5d4H6Ykz+tXS6kLc72Y53A+uK0dNm822AP3oxt/D1rKmbjPqAaSyuPInDE/KxwwpLRiqRujebqPzpD60pxngdajYkfSqOQ3NPk324PpVpfuj6Vk6RJklM/StZWG0VtHYtDB/n86kyccVEP6/wBTTweKoZieLUwLOUdnZPzGarWhyvWtHxOm/SGcDmORW/Mgf1rJs2ygxWUzqo7Gsn3RiqupJvgI9BVqEjZnuKScBkIIrJmxjadNmML3ziteF+gNYEi/Z7vj7rGte0kDd6kTNm3FaEXAFZ1ue/atCM5xigRaHSh+BTA/y00k9TQA/nvT19ajj+bk1L04qQFpcUClFMQ0ig0MwBpgOWpoQ9aWmjrTqsBpppBzTyabnNAiN6iapn6VC/AoAqzDkmqNyTzV2U8mqFw/WoAw9VY+U+fQ15ef9Y3sSf1r0fW5NsUnP8Jrzc9z65rWn1IW52u/dBG2eqj+VU7ibYCQeRToXzZxf7oqhdScHP0pNFvY7i3ffbxMe6g/pQzdaSEbIIQeyKP0oag4XuW9KJ+1Ct4YwKxNIUmYtjjitoDgVrDYpEef5/1NPUiowf5n+tOFWwGXkX2iyuIcZ3owH1xXJ6U58pQeuAPy4rs1OCCeg5P0rjNn2bVLuHoFlJH04I/Q1E9jooSN2HpT5BkH0qvbyD1qxnPFZHSZGpRhgSB+NJp02VAz7VYvV4OaxYZjFPt7ZokhM7G2bIFX43AXrWDZTgrxVx7pYly3XsPWshGoZlRctToDJN8x4X0rOska4ffNnH8K+lbUYwvT/wCtSGyRBtXApxPtTNwA60oOaYh1ITS9qYTg0xDHaljB6mopD0+uKljPy+1CAkHWnCmr1pxPFWIa1N6UE4NMZqAGueajZqaz5JFRu3BoEQTnknNZl2+Aauzv19KyLt/vYpMDnPEc2yCUkj7tcIGGB9K7PWba51BZIbTaXVdxB7jNcZPBNbNtuIniI4wy4FaQtYzTVzpEkIsov9yoLGI3uqQwrnarBnPoBzUEcrS28SRDe+MALzzXWaJp40+1/ec3MnMjf0oYVJaWRok8nHAzn+lJ1YD1pEVnOFGa0LC0/icVCOcv6dH5UQ45NXFPyj6UxRgYFOUHaPpW8dhkQP8AP/GlB5pg/wA/macOtVIRJniuX8RL5Ou7xwJowx+oOD/SunBzx3PFc34ukX7ZZAH5tjE/QnioexpS+IktXGM1b8w4rLtX4q4H+XrWR2jbo5zXP3XyXaA8ZrauWznFYGpDzCB3yOatK6sBtQXPkxZPPpWhp8TzuJpsl+w9Kx7CB3lVZeqjIrqbUBEGMYrGStoK5pQDaPoKmaYbeDWZLfLHhR8zn+FasW8MkxEkvy56KKnYGXYyXI9KsgYx602NcAcdKexp2JEPSoZGIBI5NPc8VWlbGc0ARs+4qDxVqMfLVGI7n/GrydaEBIvWnMcimUjHirENJ55NRsfShyc1GSc0ANYgVBI3X0p8hPNVZZOcGgRWuHOMCsa9kIVj3xxWlcvjPNc9qVxtRuaNyZC6V8zXM3PzMEH0H/16vSKkoKzIjqezDd/Oq1goSzjC9xuP1qxmj4Tlk9dBkNvBbjMMKIfZRTi2Tz1PUmhjxTUBZwMUt2JXe5p6XCGyxFaeAgwtQ2cPlRD1qZq0SLFU1IrfKKjWlCnA5rRCIlP+fxpwNRKf8/jTlyeauQiVTyPrXHeK5M66VB4jRQPyNdeD0ri/FiFdbZudrxoQfwNQ9jSluS2knHWrqucVjWcmMAmtASDbx1rI7UPnfrWPctlyauzOT0qq0YldULbd/BOO1aREzT06ZY4Vd2OccH1rShe6vTtj/cx+vc1W0zTIwwChii8KG5/GuotbdVXkfl2rCerEmiLTrCOFcgZfux5rZiTAFRxIAKsAcVKQmx3QUxjxTzjbUb88CrERsfWqV0+M4q3KcCs26YlsCokMmsgTkmrwqvaLtQetWR0oiAoNNdhiimNWgiNic1ETjNSv0NVpGpANkbrVKduallfANZ88hx1pCK19LhSc1yuoXEYnUSqWQnkA1r6lOVBya5oRteXaRqcs7bAPc1cEZTeh0ulq72ztHl4I8Hd6A9Ks5FdJpFjDayQ2KjENxamNhj+NTnP5A1z13A1rcSQPnMbYB9vWqnHqYETVNZ4NwuelQZpY3Mcm70rMDqVXauB6U09ajtJvNgDVIcH6VqhiA4NPU/KKjJYHjkelNFwoGDnI9jVoCMEZ/wA+ppwY1F6/59acCcVbESqeRngetc/4ygLw212ByhMbewJ4P54H41vA8Uy6hS6tZbd+ElQqfY9j+dQOLscJbvg59atrJxWcFe3mkgl+WWI7TnuPWpRJgdcVnbU7oO6uWJJK09LsS7CSXk9h6VW0mza4l8yT7nb3rrLK3CjGOlZylbQGye0hAA4xitKJcD2qGBMdauIvy1CEOUcU/PFJwF96TmrELmmsaQ5xSkcZNAEEx4Oaz0/eXAHWrt221T9Kr2CDeWNQxo0YkAHtUm0URjjilNWkIjYVGetSmmMKYEL9DVOYHFXHqrL3pDM6c4BrJu5CM1rXOOaxNQ4XmpJZgarK2045PYetavgDSybuS+uUOYV2pnpk96yXWSRnkT/lmcD3J7V3NjEbHR7SwRi1wy+ZIT1XNdVKJy1HdkWvyXo1PSjp5QyRy8hzgOD1X8RkVo+JbNby2F5D/ro13Mg7L6e+DVK9ULJCxOTHMhHvyK3P9XM0jbQEfnPQjkEfmaqXYhHCZpCataxHBBqMyWrboc5Ug5BzVEtmudoDV0q62PsJ4razuAIrk4SRICveultGPkDPXFVEZKxx1JH0qJiSxIDHNS5GeDzQDwOTWqGVSf5D+tODcVEDk/596dQxEoPFOB4qHNOBqRmTr+jfbz9ot9qXSrg56OPSuagtJXu1gmjeNlHIYdPoa7zPNUbmTz70jBOzjJpT2NqU3sS2EO1FAHFbUEfymqVqvygYrSiXGK52bk0a8VYQHpUcYqdRQA08Uh9qcwpoqhDuMe9Nc44p1Ry+1ICldMTmprNcRgYwajdMv0q1EuAKlATLkCmk07PFNPNWA0nmmseOOtOpjD0oAifpVWU8GrLe9VZTzSGULjrXP6qSEbHeuguehrm9WOFOfSktyJHPWutJHfw2KW4eVp1xJnpzXp8ePmMXzSMclz1NeU6FbCbxLYOcHM3Ir1mElY0YLxnH+fzrugvdOSW5meIJng05pFC+bGVI+u4VJrWstFPPbtBG+9cM2e55qn4lx9lgVjgTXKJz/vCqGuArqUgJBJCnj6Uqu1xFMcKAO3GKTdzimk0ZwPeucRtafah4VYitYAKMCq2lH/Qkqy1aJFCfxCnA8Co8/MKUHgVaAqj/AA/rRmmBun+fWkJ5pSAkDU4NUOaUH8agZK8gjRmOeATVDTwXzI2csc81Z1O3mTSUnUBo5JBH8vJByO1FrA8R2SgoVA+Vhg1nUehvSRq268Cr0XIFUrYYzV6MjFZGxZQVKtQowxxUitTAVqaDSFuBSAnuaBDi1RyGlJ4qOQ8UgEHWpkNVx1FSqQKBk2eaXPtUYOaMgd6YhTUZJFKWyaYxzTuBHJmqsverLmqs3epGULk8Gua1tgEY+gNdHc5+auT8QOfIcLkkqcYqo6tGc9jL8Jnd4gsc4CiTdmvT9/kQr8/fPNeU+EI2bVbQM2SH+7616fHACpMgMjdhnp1rvgrHIzF12cXT23lKJEtpo3kHbrjP61S1RmN9Jv4OBgVv2GkRz6drcYbEssXlqF7H7wP6VzF5KJpzKCTuVWPsSBkfnms6j90RGTkUHOaZmlB5FYAdZp3FnH7ipyeahsv+PaLHTbUhNbLYoQnHSkDgDBPIpGNQsTuP1qgIvT/PrSE800N0/wA+tNZuamQIeTSg45NRbvelzkYqCjpdFkVrCKIKGbzc8jp3qPWJ0uL4tH82wBCx6kiqmjbzFPlipXJU54xjFVomG7g5Pc+vvUVNjemaEOM5q3GRxVGE9M8VbjOMVibFxAOKfnFQqcAU/dmmIcSKM0w9KTmkA8njpUbEZpxPFNI9aQDV96XmlGKeozSuhjc4HNKDTtuOtGCe3FPmEJk96Y3FSMBio2OOnWgCEnGarzN1zUziTzwysohA+7jnNV5GznPQ0AULv7pzXN3WFvYywyGBQj6jH9a6S475rmdZyFLLww5Bq4boynszK8KRGDxPaxsMFXZST+OK9Hy0WQpwRzk9+tcpYadFfXVjdIzJMpDFh0NdTJBK7KJMqBxj/wCvXcpXRyFjw84R55O8zHJPcDj+Wa4bVLb7Hqd1bYxslbHPYnI/n+ldtHItvDEY+VjOc+vNYvjm2b7Rb36gmOZRGz7cAkdPzqKi0Gc0TxQDkimE8U6Ll1FYiOr0+Tfax47DFTkms3SpPLZoj0xkVoE1rEYhNROfmP1p7HrVd2+dvrVBcjB4/wA+9Rsfmpw7H/PemOeamRSDdir2l2f2tyz5WBRyw7mqEKPNKFiGWwT1xx9a1Ib9bSCO1lkErvIEVY16E+prMo2L021rZIkcqw71wHxk+9ULWyEjEW8iy4GemKqX7Lc6ltBXZGME9AAOTj8q2orqP7NGkChEPAIHOKEubc1vyrQdb6dISA7xp9TzV6PTBnmcn2WobfFxGSDuIOzmpkhVQN7YI6gmqUIk+0ZN/ZqjH7x/0qRdNXnEjcfSsrUbG2u9xVWV8dQTg/rVnSbYWNkqElpieSOf1p8kQ9oy79gXGfMP5Uv9nf8ATX8xUcjl0A+YEds0Rx70PzsCPel7NB7Rjm01z92QflSNpsv99TSyyFExvIPrTIp1UEvMxPpR7KI/aANNlHdKVdPmHUxj8ac0hYfKzYPcVJEWx8x4/Wl7GIe0Y0WEmPvJmgWD4ILjjjpT5HCITlyQM4HWufvvElpavh4ZFPTljyc4o9khe0ZuNp74J3qfwqvJp8uPlKGmW00d5AHR5oz32t0p4MqdJ5sepOafskHtGUp7G6Tny8/RhVCdJIyfMjdcf3lIrod84DKk24kcb1yKwj4mt47kW1+qxyZ27kXcv4+lL2KD2pl3EgycDmuf1VgY2BGeCOnSu8vEsbqMtIi7P768EenSuP1jQppWH2O4hmjPUs4Dr/jSVKzE6iaMzwZqBkuI7PJDKdy+4HWuwv7uRLuHYm6A55zyPwrhvh/ALbxFNBdSBLiLfEoI4Zu/P0Nd/KiKwLHIzz7VulY52VLSdJLe4jcjdFIysD+oqF5ftOl32nztloSHjaRuAvWs5YSuqX8wZtplBb0561F4qjIuYpRkb12t7kUT2BGKDwM4z7UqkhgajzhsY4xxignisRnQop/cSp3GDWpnIB7YrN0hvNtAD1FaB6YrRCEY9arv99vrUpJGagcne31pgRBuMf571E7Ypx7n6f1qBzzUSNEXFBisBKCVaViBjrt71StpUXV7Tf8AKsavMSPZTWzHbf2na2yxSFGjUqQR096wL2FIdXazSVZbqbHm7fuwxDnH1OO1QzRG7bQ50y4uJ+TIAxHcZPFals6BQGVQVAH6VBOyxafNheMKBn6gCoL2aK2hluJfu9h69KuImb+nsMHaPlJyDjvViIh5mD4Lds1nWci/YIpNxVSu7im2mpRXiEAfMpxnPWmI2UKsdhAB9qlTy04zg5xWeu5QxzyMY9asAgHc65JHT3pgSsyEsVyT0qpqd6sFiZM4kxhe341eRPmzgBSOlZWsWUd6jRnlsYAzjI9KoUiPRtSj1C0CMy+ap9c7q0zbqS7HAyKxPDFglmHGzZtOBnsa3nkIxuI56GgUdRiSlFRI0Oe5qQF3Ztp+YDpUEjSIQzHAPAA71PHkMDuIYjmgoa28Mu5Rk9Oap6jolrdzLLLweygdD61pead/KZPr6U2SRVfd98ngD0oEVbCxhty6oZAcY5NTCTYWDnPpmlLPJJlwFVe+ajOTO3y5XtmgBrSSMmEHPcjtWBqOlwTF2liILHqvc1sFnWVwMle6g4qIx/uS2ec/IM5xVIiRllWgk2oSEVQAoOO3WsrXInubTbHbo1x/DJjay89ciujuIMsrlvmPUVkarqsGnBNgMkznAUDPei5Bw/iKC40/XYrqQ4lnUNuU8swwCfavQVdLqCGSElg6j5j3OOf1rzrxWl0fFcUOrTHbME2kDhFbqB+lemWsEUNtHFB/q0X5T16Cgp7GdGmW1AYwd6/qKqeK136dA46rIfxHSrFpI0011Hg7vNUFvXApfEcZmszEgzt5wKl7CRxf8+lGfWm9MD8aTNYlG94fk5dPyrXJ5NcvpM3l3XXg8V0rHkYq4iBj1qBz87fWnsc5qB2G9vrViIyfk/L+tV5D7A1IW+X/AD71BIazmaRFSV0Pyuyn1Vqh8Ox7p725bks23Pcn1pzYWKR89FJ/Sk0FWCRDJAbLfWsjRHUakqnTxnJyyH8Qw/rWB4tM8tnGI+GVsH0Oe9dHdo0mlSxlgrFCAeuOKzJWS+g5+4x8zA4xwK0iBqKsyaPGkSEt5S9Oa53RYriHVwtxISAwYADAx7V1mnySLbx5XC4x8p7VJPDbGYXIQeagxx+XNaIhmhBIGdSMfNljz0qwcNLgcjvWfaZ8xSEwCPWjUL9NOtvM4LM2AT2FAGhMWeRFUkLntSSvGDjALA9aq2s6yBZQ2UPp0FWGQeU2ADznNACSoXkc5AwM5Hekdj5Chh06YpI3D7gOSRipoQVTDHiqArNPE0kcUjbXPPNT+ed20DnoK4rxDNcjWkMKfKGxuNdWnmOQxwGCDOPWnYm5obtq5U5bHIrPnlaS5Vc+XGBzjrVuNN0QYHkjrmqlwytc26DO7nOO/rSHck+225RlMiFVPADdaldz5W4Y5GRXnesfabbUXW2yY9537RnA9q660upXsImAJwMA46D0p2FctGXMIfcPNB4rCvL9UuGTzSGI37cHrWkNrPvaQc9AKxtcttuqWc6oWjCkPgUyGxDdSTOSZCqbcMM81jogvLzdECcOMt7DoKu3lq7RXHlZ3sp2iptAtWtrKJSMOgG/PUnNJiOY+J/nPJazSx7JY/lBHdexroPBmpHUNMjnLEOfkZfQrVzxpp/9reHp8x/voUaRW+gziuU+G12qJc2Z2jH74Z75qt0U9jsdKVraW5SU5ZWLIT/GDVpFYhpX5ZuG+lRyEThQvyyD5lJ6/Sm6ffGeOVZY9kiEqRWexJw15GIb2eMDhXOPpUJrR8QxeVqkh7SAMPes3IrJ7lIkgcpKpHrXVwtvgRu5Fchux0rpNMl32oyeRVRGW2JwTULKdx4709zwfpTWYbjz3qySmThef89ahc5NSMcg/wCfWoHPJrOZpEiu3KWkx/2SK19MUJFbKMA7Rnj2rGuFMkW3GcsB+Gef0roLQYeJdvRf/wBVZoo2kwoOSDishkWHdGp2upJ+oPP9f0q8seELsSOc4qpqyMUgmTb8hMbDucjINaIDaspAsKEnnZ0p0ykqrMcbunFZ2kX8N7YAoMvH8rE9qvsXeRE3DaBxVol7FzTmKoQehOAaxPGdpczIFhkKoR1AzzXQxJGsbICFxyajLJJbyROpYkdCe1UDM3w3aLbWO+eRmLYCqT1rUAlYYTIjPAFVIl8hI1cHao+Rf61NHM2CGbqPvU7ASoWy0e0Db3WrRZnCAYKHg571RgljjDbnzLjJXPOKniQsisrkd8GgCDUbeOaVHfAMP3cd/apEc7Y+Blyc5+lJcLJKwwg9iO9V3EnlnI4TrzTJNJD5aOSRg8DFZ1zM39ooixf6uMvu78kVU1XU/skNvF0diOScZz0qHT737Tf3Mqlm/cqh9ASc/wBDSC5rERXCqZEVyOcsv+FVYpo1LRxxpEgJYACnLMFUJG4Vu5PQVE+x5CTjHsOtMBIShdpAgAzhRmm3E2EJViT0YGoY13yMGBTB+Un1qSWMJCzSctnlvegkimTzApYMPlzxTS+1Cw5/hI9KHnbylYHLEY+lQgMOSMg8mpEW4UMw8p2Lo3y4zjOeK8u8OyHTPFogKfKJHgIPOck4r0u3dRIJAeh6V5r4zUWPi66lgI2nZOv4jP8ASqiUj0jeI3zt2kHGaYSBN5qjBf7x9feuft9TuLm9iZ0yhQHj3Fbly5AJ2jYFzgUSJZleLYwba1lA+ZSVJ9u1czn0rp9fIk0wkHlSDiuVJ4rGRSHA4Na2hzEOyE8HpWPnirWmy7bpAD1oiM6VjgH2qN872+tLITtNRs43HnvViK2eD/n1qFyBk08H+n9ajf2qZotD4CokLMQAqk/pWvp8yyOxUngDPNY0Z+WUBQSVwCfWtHTU8i1YSOdzLgFR7VMUUPXW4ZNV+xRtuHIYnkk47ValuVNvdw7CRFGXdh/e7Vz8emxWAjuZs/bLlisCDqv+2fYda6jRbUHSLyNyQSCrHH3j1J/GrsK5D4XtPs9mVf5TIxJz6DH+NbCOFnVmKhQ2AazoWZVTvtGeP1/lWX4g1I2jwQgORu8wlBk1RNztpghQsG+Y96jgAGWPzPjBIqjodybyyMsqkAnad3U1duHS2wkJ69TQIWRklHAJcDk0xCPskjMBleeafCY4wWBGT15okIRt4IIbgrTQHFPq0v8AbOUjk59uK7qJFkgjZiyM43Fc1kvoijUvPiAMZGcHqD7e1aILEBpAeu01TGiad/KdAN2FFRSOZEyVwoOeOpqYqssYwc44BqDy5EICODjtSEc/4p0yO8ZZgcgMCMkgCodPB0jUYRvVba9gKfMc/vF5H5gY/GulmXcArKCpByuOtYXi+ItpW8dLWRbjjgjBH9M0PcQi+ILFWVDFskztK574z/KtCadJowFQKWGQc4xXK3miG8uVvIZN+/50w2Rg+3rit+zffboky42Lj5uxqhEwkclAnIB2turGvtfW3u5ILuNN8bfKcnmr3mGKRFLZ3HJPaszVPD8d5dGcsSN2QTzihAbMUi3NvCyJsVhvzUGr3MlvaySR/wCsVd1MtFljtYYmfDRgqPcGnXVtuQxvvwVIJapaEV9PvBqFpBcLw8g5x3xXH/EWFP7TtZ9pAlh2H6jiu00ezjsYyIGJjEoGCOg71y/xHjLWsT45iZlB+ppLRjRoeFCJNIglbDMVKZ9CDW2ytkEDCsMVyvgeUDS5UJIRZSAfqM107TqqkEnA6ZqwkZ2uJnT5mU5wwFcpmuvvMNp7gDO/Jrjs8DPWsJhEdn1qW0IW4Q+9QZpYm2yKfepRZ1m7K/WoXPzt9aRG/dKfamPne31rVARKen+fWkamA/5/Onbhg5qWBNarlyvSryXEcErS3DKLcLhj/d4z/Ss+2J85lB+6uaraypl08hhjMkW4DgN84FOMQ5izaM1zLJfTdWG2FX6pHnp9T1P4V1uhlv7NuC0efm456DFcjNci2vkgO0rIMDPbHQV0dldCPS7kyOUJbbx3OKqStsFxQw8hthwx4xT7jThdQ+Z5YyMYB/ixUJQoU2MASM5P5H+dbNsjtGqMTnGc9qCGOsVEFlHCcJtHT1JpYyoDeYcKDjnvSywqgBkOfQ1BdT5iLkDZEh4/DrQMsSeUQhRfrxU/loCCQPm/SsLQNR+22zBSGcHPPUjNbTsZIwTw69qY7lpHxlQQNtIxUHk5/iqlgqv+03UU+MeYcsSFAwBQFyDU7oWUQk3AK7ADmp0ZXiV0bGBk+9cv40juHniigcKgZe2c1vWMUsGmRpIS0g6kjtQFy5DNsYBlzu6GmanGLi2uI2ADOhU+4IpWIMCnIyBUx2mISOvOM/lQDON8GzSNoxtNwM9s7RNnrjOc1ryEyRNGVwVGc+tYFtJ9h8dXdtEAq3yBs+h68VtXrrBF5Ss2c8mmiSvuZyBsAAHftV47YyS0nVeQKzln3oWJIQdc+lTRXSys6JIjsq5x3OKYhwdpJfkXKgcetSO7SALMTuUg/UVFFM5V2XCsRx2qFpJHILdQOuKGBckXdE5UHGc4rl/Hi77LEYykiFwD2IFdFFcBwEJO5W28HqSKyvFibtMmHH7tuPXGMGoBM5TwLKXjuYUYkkLIAPyNdJqcsrwIIzsPQ+9cJ4PvjYasADwwKEGvRxieOORgvHOK0Q2QoJI9PAkwTtOPyrkH4J9c12c0nmIcLjIwBXFzffc+5rGYR3AGkz8w+tMzSMcVBZ09s261U+1OZxuPPeq1i2bNKe+d7fWtUBEDz/n3pwJzxRRVWQiezbYxlA9iD3qPUGiklhRA4LOHbJ445/pRRVpCKOu2xlvrW5Vyu/gj8a37qNhpFvGXJzcouf8AgQoopgXDK7P5bnJLdfb/ACK3LNW8lWDtkHGKKKmwFm5O+EMOPUGs+7hBsplZjyuePzoopWATwrZx2+mCRAC7kknFaU7AFXA5oop2ASNj54YdWqzcny04AyeaKKVgKNzbi7jQvgFCHU+lWo3aaEnOG6UUU7AMQCWLGMEd6WViY427elFFKwzh/iSZNMm0rVLYqssUmDxyw61pXcglEmAcMQck8jODRRTsIr6igh0uUgt9w1z3hXzW1nBlPzK2D6UUU0FjqjGy7mdt+04FTSjzVRjxuIGBRRSCyOMgvJoPEBiQ4VZCc559K6DX3N1pk+Tj90zZxRRRYlLU8itJNl3C2Mnev88V6xZSMqRDr8vGaKKplk9wMRSzMfmVSQB06Vxdyf3j/X+YzRRXPIRBn5RSk9KKKko3dPObIfQ1OwO4896KKtCP/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Scoliosis may be indicated by differences in the height of the shoulders or scapulae and asymmetry of the waistline, all of which are depicted in the above photograph.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. Susan Scherl.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_0_20495=[""].join("\n");
var outline_f20_0_20495=null;
